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SUMMARY
A range of studies are described examining the responses to blockade of 
the renin angiotensin system with angiotensin converting enzyme inhibition in patients 
with heart failure and normal volunteers. The common theme of the studies is the 
definition of response at low doses of drug and differentiation of effects between agents 
or over time on first administration.
First dose response to ACE Inhibitors in heart failure
(a) Oral doses of placebo, captopril 6.25mg, enalapril 2.5mg and perindopril 2mg were 
given in a randomised double blind parallel group study of 48 elderly patients with stable 
heart failure. Despite diuretic withdrawal considerable falls in supine blood pressure and 
heart rate were noted with captopril and enalapril. Compared to placebo perindopril 
produced no significant fall in pressure. Enalapril and perindopril produced similar 
plasma ACE inhibition. No patient experienced adverse symptoms.
(b) Intravenous doses, by slow (6hr) constant rate infusion, of placebo (saline), 
enalaprilat (1.5mg) or t. 'rindoprilat (lmg) were given in a randomised, double blind, 
parallel group study of 36 elderly patients with stable heart failure. Both diacid ACE 
inhibitors caused falls in blood pressure and similar though greater inhibition of plasma 
ACE activity compared to the oral treatments. Five infusions were terminated on a priori 
criteria because of the degree of blood pressure fall. Termination of infusion effectively 
controlled the blood pressure fall. Two patients on active treatment had asymptomatic 
deterioration in biochemical indices of renal function necessitating withdrawal of 
maintenance ACE inhibitor treatment.
Studies of the response to ACE inhibition in volunteers
(a) The transpulmonaiy extraction of perindoprilat (lmg; by constant rate infusion into a
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peripheral vein over 20minutes) was examined in a novel study in 10 patients undergoing 
diagnostic cardiac catheterisation predominantly for symptoms suggestive of ischaemic 
heart disease. A co-infusion strategy employing concurrent indocyanine green as an 
intravascular marker was used. Concurrent sampling in the ascending aorta and the 
pulmonary trunk failed to show any significant first pass uptake of the drug into the 
pulmonary circulation. Pharmacokinetic models designed to incorporate elements 
describing simple nonlinear kinetics based on "tissue" distribution were not found to be 
applicable. A variety of procedural problems may have been responsible for the failure of 
this study to document tissue distribution.
(b) Protracted low dose constant rate infusion of perindoprilat (lmg) over 1,3 or 6hrs or 
placebo (saline over 31r) was conducted in a single (subject) blinded randomised study in 
10 healthy male volunteers. This predominantly pharmacokinetic study confirmed a 
blood pressure fall despite the low doses employed in normal volunteers. Despite higher 
peak drug concentrations the plasma ACE inhibition profile summarised by the area 
under the curve was greatest following the 6hr infusion where peak drug concentration 
was lowest. Drug concentration time profiles showed a clear sigmoid accumulation 
profile during drug infusion. Pharmacokinetic modelling of individual profiles confirmed 
that from a hierarchy of systems a non linear model with terms to represent tissue and 
plasma binding of drug provided the best fit to the observed data.
(c) A model of activation of the renin angiotensin system was outlined in a double blind 
randomised study of low dose oral enalapril (5mg) in eight healthy salt depleted normal 
volunteers. A system of modest dietary salt restriction (40mmol per day) and diuretic 
therapy (40mg Frusemide BDS) over three prestudy days produced a reliable activation 
of the renin angiotensin system. Baseline and reactive elevation of renin activity was 
recorded in response to enalapril with an associated significant fall in supine and erect 
blood pressure.
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Conclusions
Differential effects on blood pressure are evident between similar ACE 
inhibitors (enalapril and perindopril) but not with their respective diacid metabolites 
despite similar circulating enzyme inhibition in controlled circumstances. This may relate 
to a differential interaction with the tissue based elements of the renin angiotensin 
system. Although the transpulmonary study did not reveal significant extraction of the 
diacid ACE inhibitor perindoprilat into the lungs, the subsequent pharmacokinetic studies 
with low dose infusions of the same drug indicate that an indirect index of the tissue 
based system may be possible. Studies in heart failure patients may be usefully extended 
in volunteers whose renin system is activated using the salt depletion protocol as 
described.
CHAPTER 1
INTRODUCTION
Developments in the drug therapy of disease have proceeded with astounding 
speed in the 20th Century. Puring my undergraduate training in pharmacy in the 1970*s 
it was common to be told that the pace of development had been so rapid, on all fronts, 
that there would undoubtedly be a hiatus in progress during the latter part of the 20th 
century. Perhaps not surprisingly this has not been the case. During this period, at least in 
the realm of cardiovascular drugs, there have been continued developments. There are 
few agents introduced into clinical practice in recent years which might reasonably be 
compared to the group of drugs known as the angiotensin converting enzyme inhibitors.
The origins of the renin angiotensin aldosterone system, one of the key 
physiological systems regulating blood pressure and sodium homeostasis, date back to 
experiments in the laboratory of Dr Robert Tigerstedt at the end of the 19th Century in 
Finland. It took almost 60 years to analyse the functions of this system and develop 
inhibitors. Useful drugs appeared in clinical research studies in the mid to late 1970*s. 
Since that stage their initial use in hypertension has been expanded and refined in general 
medical application with the subsequent development of large series of compounds 
sharing the property of inhibiting the non rate limiting step catalysed by the non specific 
metalloprotease angiotensin converting enzyme (ACE). In last ten years ACE inhibitors 
have continued to develop in their clinical uses. For the first time they provided a therapy 
for the effective management of chronic heart failure capable of making a positive step in 
reducing the symptoms and mortality of this disease. Developments continue with 
extension of the assessment of these drugs into different populations of cardiovascular
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patients, and new insights of the role of the renin angiotensin system in a variety of 
pathological states.
This thesis comprises two sections firstly dealing with ACE inhibitor studies in 
heart failure and subsequently a series of investigations in normal human or patient 
volunteers. This is preceded by a detailed description of ACE inhibitor pharmacology.
An example is made of the properties of the long acting prodrug ACE inhibitor 
perindopril, which is employed in a number of the subsequent studies. In addition the 
renin angiotensin system, particularly the more recent work concentrating on the 
relevance of an extra-plasmatic site mediating drug effects is also described in detail. The 
practical and pharmacological management of heart failure including the role of ACE 
inhibition is also described by way of introduction to the experimental section.
The first series of studies are designed to assess and refine the application of ACE 
inhibitor drugs, more specifically to allow better understanding of the relationship 
between dose, concentration and (predominantly haemodynamic) effects in heart failure 
patients. Particular attention is paid to the response to the introduction of the drugs in 
heart failure where, for a variety of reasons, the endogenous renin angiotensin system is 
activated and a marked haemodynamic response might be anticipated. Despite many 
years of use the exact dose required to produce a given effect, be that chemical, pressure 
or flow related or more importantly a symptomatic benefit in the individual patient has 
remained obscure. This is not unusual in cardiovascular therapy. First dose studies are of 
interest as they allow the lower end of the concentration response relationship to be 
explored. This has been a notable failure in the development of the ACE inhibitor drugs 
whose "effective" doses have fallen after introduction into clinical practice and 
experience. In addition comparative studies, commercially unpopular but
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pharmacologically essential, are described which portray novel findings in these patients.
To complement this series of observations in heart failure are a range of studies in 
the normal human volunteer are presented where control of the variables affecting the 
response can be more precise. Controlled low dose infusion strategies are used in an 
attempt to characterise the use of a pharmacokinetic model as an index of tissue 
distribution of drug at low doses relevant to heart failure therapy, at least during the 
introduction of treatment. An attempt to define the transpulmonary handling of an 
intravenous ACE inhibitor is described. This is again based on the plasma 
pharmacokinetic profile and looking at its potential as an index of drug distribution into 
tissue based sites, of which the lungs has been highlighted as a key area of ACE activity. 
The studies are complemented by a series of preliminary observations involving 
activation of the renin angiotensin system based on controlled salt depletion and the 
subsequent response to low dose ACE inhibition.
21
CHAPTER 2
ANGIOTENSIN CONVERTING ENZYME INHIBITION: PERINDOPRIL
2.1. GENERAL INTRODUCTION
Perindopril is a long-acting non-thiol, prodrug inhibitor of angiotensin converting 
enzyme (ACE). The compound has been undergoing evaluation since the early 1980s 
and is at present available for clinical use in several countries throughout the world 
(Todd & Fitton, 1991). An overview of its chemistry, pharmacodynamic and 
pharmacokinetic properties is provided here for this drug as representative of its class 
and as the subject of a number of the following research studies which form the first part 
of the thesis. As a relatively less popular agent, in terms of its post marketing use, full 
appreciation of the specific advantages or disadvantages of this agent will emerge only 
after widespread, post-marketing surveillance and further clinical research (Editorial, 
1988). Perindopril is available alongside the current agents in this class, captopril 
(Brogen et al, 1988), enalapril (Todd & Heel, 1986; Todd & Goa, 1989), lisinopril 
(Lancaster & Todd, 1988) ramipril (Todd & Brogen, 1989), quinapril (Frank et al,1990), 
cilazapril and fosinopril, all of which are licensed for use in the United Kingdom at the 
time of writing.
2.1.1. Origin and Chemistry
The synthesis of perindopril was first described by Vincent and colleagues (1982) 
from Servier Laboratories. Orally active, potent, long-lasting inhibition of ACE was 
confirmed as the primary pharmacological response. This compound is a third 
generation ACE inhibitor, the perhydroindole 2-carboxylic acid derivative of an N- 
carbethoxybutyl alanine. The diastereoisomer (s,s) perindopril is prepared as a tertiary
22
(S9490-3)
CH3-C H 2-C H 2-HC-NH-CH-CO-N  
COOC2H5
COOH
(S9780)
CH3
c h 3- c h 2- c h 2- h c - n h - c h - c o - n
COOH
COOH
Figure 2.1: Structural formulae of perindopril (S-9490-3) as butylamine salt, 
and perindoprilat (S-9780).
perindoprilat (S9780) (Figure 2.1). The parent molecule resists hydrolysis of the amide 
bond due to the stabilising influence of the bicyclic ring (Drummer et al, 1987).
Metabolism is by esterases in the liver, plasma and possibly also in the gut wall to 
the active diacid perindoprilat. A desprolyl metabolite similar to that noted with 
enalapril (Drummer & Kourtis, 1987a) is not produced but a glucuronide conjugate has 
been identified which cross-reacts with antisera to perindoprilat (Drummer & Kourtis, 
1987b; Drummer et al, 1987; 1988). This conjugate can be excreted or is available for 
conversion back to a form capable of inhibiting ACE. The conjugate per se is 
biologically inactive.
2.1.2. Analysis
Perindopril and perindoprilat can be assayed in plasma and tissue extracts by a 
variety of techniques. \n  enzyme inhibition assay, similar to that employed by Tocco 
and colleagues (1982) for enalapril, has been employed using the inhibition of exogenous 
ACE generation of a chromophobe from a variety of synthetic substrates (see Chapter 5). 
Alternatively, radio- inhibitor binding and displacement principles have been applied 
employing a radio-iodinated tyrosyl derivative of lisinopril, JI-351A (Johnston et al, 
1987). The principles of competitive protein binding are adapted where the substrate is 
the radioligand and the drug and the ACE interaction is time, concentration, pH, chloride 
and zinc dependent (Shapiro & Riordan, 1984; Jackson, Cubela & Johnston, 1986; 
Johnston et al, 1988). Specific and sensitive immunoassay of ACE inhibitors are also 
available (Hichens et al, 1981) but such radioimmunoassay methods for perindopril have 
not been published. Analysis of both perindopril and perindoprilat by combined high 
pressure liquid chromatography and mass spectrometry has been described (Tsaconas et 
al, 1989).
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2.2. PHARMACOLOGICAL PROPERTIES
The interaction of inhibitors of ACE in a variety of physiological and 
pathophysiological states is more complex than initially appreciated. Initially 
characterised in horse plasma by Skeggs and colleagues (1956), ACE is now known to 
be widely distributed throughout many tissues. The specific evidence for this 
differentiation and its implications for the results of treatment with ACE inhibitor drugs 
is considered in the following chapter (see chapter 3). Although ACE has a variety of 
neurohormonal substrates it is generally felt that the predominant effects of enzyme 
inhibition are mediated through a reduction in the generation of angiotensin II from 
angiotensin I. The central effect of this hormone is pressure and volume homeostasis. 
Secondary elevation of renin, angiotensinogen and angiotensin I by negative feedback 
and falls in aldosterone and angiotensin II are observed after acute treatment. Enzyme 
inhibition is known to be competitive for a number of inhibitors (Ondetti & Cushman, 
1982) with at least two binding sites on the enzyme itself (Perich et al,1991). This is also 
likely to be the case for perindopril (Laubie et al, 1984).
It should be noted that recent studies with sensitive and specific assays of 
angiotensin peptides have suggested that persistent ACE inhibition can be accompanied 
by resetting of the renin angiotensin system and the reappearance of angiotensin II in 
plasma, which is not reflected by ACE inhibition determined in vitro (Nussberger et al, 
1988,1989).
2.2.1. Inhibition of ACE and hormonal effects
A. Circulating ACE
Laubie and colleagues (1984) demonstrated ACE inhibition by perindopril, 
attenuation of the pressor dose response curve to angiotensin I infusion and a 
potentiation of the vasodilatation with exogenous bradykinin in a variety of animal
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species. In these studies the in vitro potency of perindoprilat was approximately 1,000 
fold greater than that of the parent compound against serum ACE. Both drug and 
metabolite exhibited competitive antagonism of the enzyme. Intravenous administration 
of perindopril was followed by de-esterification to perindoprilat, which appeared to be 
more efficient in rats and rabbits than in cats, guinea pigs and dogs. This was reflected 
by the ED^q of circulating ACE and in the ID^q of the pressor response to angiotensin I 
in anaesthetised animals (rabbits > rats »  cats »  guinea pig »  dog). Unger and 
associates (1986) using inhibition of rat plasma ACE showed that the curves for 
ramiprilat and perindoprilat were almost identical and both were 50-100 fold more potent 
than enalaprilat or captopril respectively. Using human plasma ACE, Johnston and 
colleagues (1988) found that the rank order of potency of a variety of ACE inhibitors 
including both perindopril and perindoprilat was comparable whether expressed in terms 
of IC50 or by radio-inhibitor displacement. They reaffirmed the approximately 1,000 
fold difference between perindopril and perindoprilat.
It should be noted that the source of circulating plasma ACE has not been clearly 
established (Erdos, 1976). Although lung, kidney and vascular endothelium in culture 
can release large amounts of the enzyme with similar kinetic and inhibitory 
characteristics between different species (Takada et al, 1982; Miyazaki et al, 1984), 
evidence is emerging that this may not be the case for circulating serum or plasma ACE 
(Ibarra-Bubio et al, 1989; Harrigan, Hughes & Meredith, 1989). Thus data on the tissue 
assimilation of specific agents for example perindopril, should probably be assessed in 
human tissue and circulating ACE.
ACE inhibition, as assessed by synthetic substrate in vitro, has repeatedly been 
shown to be poorly correlated to the haemodynamic effects (Waeber et al, 1980; Unger et 
al, 1986). Persistent and unquantified tissue ACE inhibition may be one explanation for 
this phenomenon but Nussberger et al (1989) have shown that the definition of ACE
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inhibition in vivo using sensitive analysis of angiotensin I and angiotensin II may clarify 
the relationship (see section 3.2.1). As yet the effect of perindopril or perindoprilat on 
ACE has only been defined using in vitro techniques. There may be a question mark 
over the reliability of these assessments. The comparative potency of perindopril and 
perindoprilat on the IC^q of human plasma ACE is summarised in Table 1.
The onset of circulating ACE inhibition after oral perindopril is slower than that 
seen with other ACE inhibitors (Brunner, Nussberger & Waeber, 1985) taking 
approximately four hours to achieve greater than 90% inhibition in studies conducted in 
normal volunteers (Bussien et al, 1986; Richer et al, 1987; Lees & Reid, 1987). Bussien 
and colleagues (1986) found that doses of greater than 4 mg provided greater than 70% 
inhibition of plasma ACE after a single dose with a maximum response of 79% 
inhibition after 16 mg. Lees and Reid (1987) found comparable inhibition 24 hours after 
a dose of 8 mg or greater.
Chronic treatment with oral perindopril in doses of 1- 16 mg daily has also been 
reported in normotensive, male volunteers. In two studies the level of ACE inhibition 24 
hours after dosage remained at approximately 60-70% of baseline, dose related, with a 
slow return towards normal in the days after discontinuation. Neither of these studies 
recorded the return to baseline activity during monitoring (Bussien et al, 1986; Lees & 
Reid, 1987).
B. Neurohormonal changes
It would be expected that inhibition of circulating ACE would cause falls in 
angiotensin II and aldosterone with elevation of plasma renin activity and angiotensin I. 
Oral perindopril in acute and chronic settings has been shown to produce these trends 
four hours after oral doses of 4 and 8 mg (Bussien et al, 1986). In this study, although
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Table 2.1: Plasma concentrations (EC^q) of a variety of angiotensin converting 
enzyme inhibitors corresponding to 50% inhibition of maximal ACE activity 
(human plasma) (after Johnston, 1988).
DRUG e c 50(M) DRUG e c 50(M)
Perindopril 0.1 X 10"4 Perindoprilat 0.18 x  10'8
Enalapril 0.24 x  10'4 Enalaprilat 0.25 x  10'8
Ramipril 0.8 x  10'5 Ramiprilat 0.19 x  10‘8
Cilazapril 0.28 x  10‘6 Cilazaprilat 0.8 x  10'9
Lisinopril 0.45 x  10'8
Captopril 0.22 x  10'7
aldosterone was seen four hours post dosing, at 24 hours the hormones had returned to 
baseline values. This is in contrast to the first dose response where angiotensin II and 
aldosterone remained low at 24 hours. Lees and Reid (1987) confirmed dose related 
elevation of plasma renin activity after oral doses of 1-16 mg, however the effects on 
plasma aldosterone were variable. Chronic treatment for 7 days produced further 
elevation of plasma renin activity. Circulating levels of catecholamines were unaltered.
Richer et al (1987) conducted more detailed temporal sampling of plasma renin 
activity and aldosterone and found with doses of 4, 8 and 16 mg that there was a 
progressive elevation of plasma renin activity peaking at 6 hours post dosage though 
once again plasma aldosterone was not significandy altered. These workers suggested 
that this was due to the low baseline values associated with supine sampling.
2.2.2. Haemodynamic Effects
A. Normal Volunteers
The effects of ACE inhibitors on arterial pressure, organ perfusion and blood 
flow in normal volunteers and cardiovascular diseases have been extensively 
investigated. In normal salt replete volunteers the effects of acute inhibition on supine 
and erect blood pressure are controversial. Carefully controlled studies with appropriate 
doses and placebo usually reveal small but significant falls in blood pressure in animals. 
The acute effects of ACE inhibitors are suggested to be mediated in part by reductions in 
angiotensin II and are dependent on the prevailing activation of the circulating renin 
angiotensin system and dietary salt depletion where there is renin activation (Lever, 
1989). However, ACE inhibition will also produce a hypotensive response on long-term 
treatment in low renin states such as is the case in the majority of essential hypertension 
(Brown et al, 1965). This has been taken to reflect modification of the slow pressor 
element of hypertension which may be mediated through renin, angiotensin II or
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aldosterone (Lever, 1986,1989).
In the conscious dog, Laubie et al (1984) demonstrated an inhibition of the 
pressor response to angiotensin I using both intravenous and oral perindopril and 
intravenous perindoprilat in cumulative dosage. Vasodilatation mediated by exogenous 
bradykinin was seen tc be potentiated. Conscious animals did not show a hypotensive 
response until sodium restriction was employed although this was not required in 
anaesthetised animals.
Lees and Reid (1987b,c) observed the response to oral perindopril or intravenous 
perindoprilat in salt replete normal volunteers. They noted a fall in erect systolic blood 
pressure with an oral dose of 16 mg of perindopril but not with lower doses. This was 
maintained over seven days chronic therapy and was present without alterations in heart 
rate. Intravenous perindoprilat given as a bolus of 4 mg caused a fall in erect diastolic 
blood pressure over 8 hours and a similar but not significant trend was noted in erect 
systolic blood pressure. Ajayi et al (1986) studying ten normotensive salt replete 
volunteers found a modest but significant fall in supine systolic and diastolic blood 
pressure when giving 8 mg oral perindopril in a double-blind, crossover assessment of 
autonomic function. There was no effect on heart rate.
In contrast Bideville et al (1987) studied five of 16 healthy, male volunteers 
treated with 8 mg perindopril daily using semi- automatic, ambulatory blood pressure 
monitoring. Neither this treatment nor cilazapril (5mg per day) nor CGS 12824A (10 
mg) produced any consistent effect on blood pressure either acutely or over eight days 
chronic therapy. Similarly Richer et al (1987) in a double-blind, crossover study in six 
healthy volunteers found no effect on blood pressure or heart rate after single doses of 4, 
8 and 16 mg perindopril despite dose dependent augmentation of brachial and carotid 
artery flow for up to ten hours after drug treatment and the observation of appropriate 
neurohormonal changes in circulating ACE, plasma renin activity and aldosterone.
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Dollery and colleagues (1984) have described initial dose finding studies in 
normal volunteers employing individual angiotensin I pressor responses in five subjects. 
Perindopril (2.5, 5 and 10 mg orally) inhibited responses by between 30 - 90%. Maximal 
inhibition of angiotensin II pressor response, set at 25 mmHg for each individual, 
occurred approximately 4-6 hours after treatment with maximal rises of 17.2,9.5 and 4.6 
mmHg with the three doses employed. At 24 hours after a dose of 10 mg a pressor 
response of only 16.6 mmHg was noted, which was associated with persistent ACE 
inhibition and elevation of plasma renin activity.
Boussien et al (1986) assessed the individual pressor response in three subjects to 
intravenous angiotensin I with concurrent oral perindopril in doses of 2 ,4  and 8 mg on 
different days. Only with 8 mg was a consistent attenuation of the pressor responses 
noted within 1.5 hours of dosing. Eight days chronic therapy with 4 mg oral perindopril 
in twelve subjects produced no changes in semi- recumbent blood pressure or heart rate.
B. Essential Hypertension
Although initially restricted to the treatment of severe hypertension where other 
agents had failed, it is now clear that ACE inhibitors are effective in any stage of 
hypertension regardless of the prevailing renin activity (Williams, 1988). Moreover the 
United States Joint National Committee on the detection, evaluation and treatment of 
high blood pressure (Chobanion et al, 1988) recommends that they can be considered as 
first line agents similar in standing to diuretic therapy or beta blockade. In the UK all 
recent ACE inhibitors are licensed for first line use in hypertension.
In experimental hypertension perindopril has been shown to lower blood pressure 
in several strains of spontaneously hypertensive rat (DiNicolantonio & Doyle, 1985; 
Unger et al, 1986) and in experimental Goldblatt 2 kidney 1 clip hypertension (Michel et 
al, 1986). In acute studies with or without salt depletion the response appears to be 
unrelated to pretreatment plasma renin activity or the degree of circulating ACE
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inhibition and is dissociated in onset and duration from the hormonal changes (Di 
Nicolantonio & Doyle, 1985). The initial response to ACE inhibition is thought to be 
mediated mainly by a decreased peripheral vascular resistance in the absence of changes 
in mean arterial pressure. This has been shown in normal, human volunteers by Thiullez 
et al (1988) and Webb and colleagues (1988) using pulsed Doppler techniques and 
forearm venous occlusion plethysmography.
The haemodynamic efficacy of oral perindopril in human essential hypertension 
has been documented by several groups. Lees and Reid (1987d) showed an average 
reduction of arterial pressure from 164/93 on placebo to 142/82 in a group of seven salt 
replete essential hypertensive patients treated with 4 mg perindopril daily for one month 
in a single-blind study. No first dose accentuation of the antihypertensive effect was 
noted and symptomatic hypotension was absent. Blood levels of perindoprilat on 
chronic therapy revealed high peak concentrations but comparable circulating ACE 
inhibition although the latter tended to be less pronounced. Plasma renin activity 
remained elevated on chronic therapy whereas aldosterone was unchanged. These 
patients did not have high renin hypertension.
Luccioni and colleagues (1988) demonstrated a dose- related antihypertensive 
effect of oral perindopril in forty patients with essential hypertension treated in a double­
blind assessment. Doses of 2 ,4  and 8 mg oral perindopril or placebo given once daily 
after a two week placebo run-in produced dose related falls using automatic 
sphygmomanometry.
Morgan and colleagues (1987) in 32 patients with essential hypertension found 
that the falls in erect and supine blood pressure noted after dose titration with 2 - 8  mg of 
oral perindopril given once daily were unrelated to the sodium excretion or the plasma 
renin activity in this group.
Safar and colleagues have studied the effect of perindopril on arteriolar dilatation
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using a pulsed Doppler flow meter in essential hypertension (Asmar et al, 1987; Asmar et 
al, 1988a,b). In 16 patients with essential hypertension defined as diastolic blood 
pressure greater than 100 mmHg, three months treatment with oral perindopril 2 - 8 mg 
per day significantly reduced blood pressure and this was associated with increased 
brachial artery flow, flow velocity and arterial diameter. This was not thought to be due 
to a simple flow dependent dilatation as occlusion produced a greater fall in flow 
velocity in perindopril treated patients with an equivalent fall in arterial diameter. 
Treatment was found to be associated with increased arterial compliance and reduced 
pulse wave velocity. In this same series of patient studies echocardiographic cardiac 
mass was also reduced by perindopril treatment and this beneficial effect persisted after 
discontinuation of therapy despite the return of arterial parameters towards pretreatment 
baseline values. Structural changes were therefore dissociated from simple pressure 
reduction at a level beyond first order windkessel vessels and these clinical studies were 
in support of experimental work by the same group in Goldblatt renovascular 
hypertension (Levy et al, 1988). Not all experimental studies however,support such 
close association between continued antihypertensive effect after perindopril withdrawal 
and the vessel structure (Christensen et al, 1988).
The regression of left ventricular hypertrophy on chronic therapy with 4 - 8 mg 
oral perindopril daily was also found by Grandee et al (1988) in a study of 15 patients 
with essential hypertension. Echocardiographic left ventricular mass was decreased 
without an alteration of left ventricular diastolic diameter or peak systolic shortening 
though diastolic relaxation rate was increased. A cold pressor test was employed to 
assess the response to acute increases in afterload and this was unimpaired by the 
changes mediated by perindopril therapy.
In animal models of hypertension reduction of left ventricular hypertrophy has 
been noted on chronic perindopril treatment by several studies (Barres et al, 1985;
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Cadilhac & Giudicelli, 1986). However Michel et al (1988a) in 1 clip 2 kidney 
renovascular hypertensive rats or deoxycorticosterone salt hypertension failed to show 
reversal of structural changes in the myocardium with chronic perindopril therapy though 
the collagen content was considerably reduced.
West and colleagues (1989) studied eight patients with essential hypertension 
using 24 hour intra-arterial blood pressure monitoring. During six weeks therapy with 8 
mg perindopril daily in a double-blind, placebo controlled, crossover study they noted 
reduction of average hourly blood pressure throughout the 24 hour period with 
maintenance of the normal circadian pattern. Forearm blood flow assessed by venous 
occlusion plethysmography was increased. The haemodynamic response to Valsalva’s 
manoeuvre, tilt, isometric exercise and cold pressor testing was unaffected by perindopril 
but the sino-aortic baroreceptor heart rate reflex was reset within two hours of the first 
dose. This remained altered throughout chronic therapy and the heart rate remained 
unchanged. Chronic therapy with perindopril was associated with a persistent increase 
in parasympathetic tone. Enhanced parasympathetic tone has been found in 
normotensive volunteers in the studies of Ajayi et al (1986) using oral perindopril and has 
been noted with other ACE inhibitors (Sturani et al, 1982; Campbell, et al, 1985; Ajayi et 
al, 1985).
In a study of 21 patients monitored by non-invasive 24 hour ambulatory blood 
pressure recording Asmar and colleagues (1988c) found that 4 - 8 mg of perindopril once 
daily affected systolic pressure greater than diastolic pressure. This conclusion was 
derived from the relationship between systolic and diastolic pressures before and after 
three months therapy. This is also a feature of other ACE inhibitors (Webster et al,
1986).
The place of perindopril as an antihypertensive agent in clinical practice has been 
studied in three multicentre trials of similar design described by Zanchetti and Desche
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(1989) and Lees and colleagues (1989). Oral perindopril (4 mg) was compared to 
captopril 25 mg twice daily (165 patients); atenolol 50 mg (173 patients) or to a diuretic 
regimen of amiloride and hydrochlorthiazide (165 patients) in double-blind, placebo 
controlled studies in mild to moderate essential hypertension. After single blind 
placebo washout, treatment was designed to obtain a diastolic blood pressure less than or 
equal to 90 mmHg. If this was not achieved at monthly review then the daily dose was 
initially doubled and if required subsequent treatment was supplemented by hydro­
chlorthiazide 50 mg (captopril or atenolol comparisons) or atenolol 50 - 100 mg daily 
(diuretic comparison).
In the study comparing perindopril to captopril (Lees et al, 1989) monotherapy 
was equally effective in each group (49% vs 49%) though the overall fall in diastolic 
blood pressure after three months therapy was greater with perindopril (26.9 + 1.9 vs 
18.9±1.9 mmHg). This probably reflects the higher initial pretreatment diastolic blood 
pressure in this group (105.410.8 vs 102.310.6). With dose titration, control was 
achieved more readily with perindopril monotherapy than captopril (75% vs 57%). In 
an extension of this trial Herpin et al (1989) using 24 hour ambulatory monitoring 
suggested that diastolic blood pressure was controlled for a significantly greater part of 
24 hours by perindopril once daily than by captopril twice daily
In the series comparing perindopril to atenolol, after three months therapy the 
reduction in erect systolic but not diastolic blood pressure was greater with perindopril. 
The mean reduction in supine blood pressure (26.5 mmHg) was greater than that 
achieved with atenolol (20.6 mmHg) and in this, as in the diuretic arm of the study, the 
pretreatment blood pressures were equivalent.
Diuretic therapy was compared to perindopril 4 mg daily in the preceding format 
with dosage doubling and the addition of beta blockade as stepped therapy. After three 
months treatment monotherapy was equally effective in the perindopril and diuretic
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treated groups (72% vs 72%) and in total the percentage of patients responding with 
monotherapy or combination was not significantly different between perindopril therapy 
(78%) or diuretic based treatment (84%). Although the reductions in supine blood 
pressure were similar, erect mean blood pressure was reduced to a greater extent by 
diuretic therapy (-31.1 mmHg) and perindopril (-24.6 mmHg).
Backhouse and colleagues (1989) in forty patients with essential hypertension has 
reaffirmed the antihypertensive efficacy of perindopril. With the combination of 
perindopril and a thiazide diuretic a synergistic response was noted in antihypertensive 
effect and in the elevation of plasma renin activity in this trial conducted over one month 
using double-blind therapy.
C. Cardiac Failure
It is now generally accepted that ACE inhibitors are the major adjuncts to diuretic 
therapy in the management of chronic cardiac failure (Packer, 1989). Efficacy has been 
proven in terms of alleviating symptoms increasing exercise capacity and producing a 
significant reduction in long-term mortality (Cleland et al, 1984; Consensus Trial Study 
Group, 1987; Captopril Digoxin Multicentre Research Group, 1988). While efficacy is 
accepted in severe chronic heart failure there is also evidence to support the use of ACEI 
in less serious degrees of cardiac failure (Kleber et al,1992; SOLV'D Investigators 
1991; 1992). These issues are dealt with fully in chapter 4 (section 4.4).
2.2.3. Effects on renal function and renal blood flow
In a double blind study in eleven normotensive volunteers on controlled sodium 
intake Reyes et al (1988) showed that single doses of 4 and 8 mg perindopril produced 
dose dependent increases in 24 hour urinary output and instantaneous renal clearance of 
sodium and chloride without affecting urinary water production. Other solutes were
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unaffected by treatment though urate excretion tended to increase.
Morgan and colleagues (1987) in a study of 32 hypertensive patients without 
renal failure stratified the group in accordance with 24 hour sodium excretion. No effect 
of perindopril treatment (2 - 8 mg daily) was found on glomerular filtration rate, 24 hour 
urinary protein or plasma urea or creatinine with titrated antihypertensive therapy.
In ten patients with hypertensive nephropathy Rondeau et al (1988) reported that 
15 days therapy with oral perindopril did not alter proximal or distal tubular sodium re­
absorption as reflected by renal sodium or lithium clearance.
The effects of ACE inhibition on renal blood flow and sodium handling are 
complex and related in most instances to the modulating effect of angiotensin II on 
vascular resistance at a variety of pre and post glomerular sites (Hollenberg & Williams, 
1988). Renal arteriolar vasoconstriction and reduced renal blood flow are common in 
essential hypertension and thus improved flow with ACE inhibitor therapy is an 
important component of antihypertensive effect. This response has been documented for 
other ACE inhibitors (Mimram et al, 1979; Hollenberg & Williams, 1988).
Experimental studies have been conducted in anaesthetised dogs using local bolus 
injection of perindoprilat into the renal arteries (Schmidt et al, 1989). Increased renal 
blood flow was demonstrated after 48 hours sodium restriction associated with a 
decreased filtration fraction. Renal vascular resistance was reduced in association with 
effects predominantly on the efferent side of the glomerulus, the preferential site of 
action of angiotensin n. Increased fractional elimination of electrolytes was noted due to 
altered sodium and water reabsorption in the proximal tubule secondary to the decrease 
in filtration fraction. In general the effects were much less prominent in sodium replete 
animals as would be expected (Hollenberg & Williams, 1988).
In eight essential hypertensive patients without nephropathy on a standard sodium 
intake Chaignon and colleagues (1988) saw only marginal increases in renal blood flow
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in an open study using four days therapy with perindopril (8 mg). Calculated renal 
vascular resistance fell with initial therapy and remained depressed on day 5.
Glomerular filtration rate was unchanged and filtration fraction decreased significantly 
from 0.27 to 0.25 after four days treatment. An acute and chronic natriuresis was 
evident in this study.
In the last few years a number of studies in mild diabetic nephropathy associated 
with persistent or exercise related microalbuminuria have suggested a beneficial effect of 
converting enzyme inhibition in the absence of hypertension and without a fall in mean 
arterial pressure (Taguma et al, 1985; Marre et al, 1987; Romanelli et al, 1989). These 
observations were recorded in patients with equivalent diabetic control. Similar benefit 
has been recorded in patients with proteinuria due to hypertensive renal disease (Ikeda et 
al, 1989). Preliminary reports have suggested that this beneficial effect on 
microalbuminuria in hypertension complicated by diabetes is also evident on long-term 
perindopril therapy (Brichard et al, 1988). Other studies suggest that this property is at 
least shared by calcium channel blocking drugs (Melbourne Diabetic Nephropathy Study 
Group, 1991)
2.2.4. Cardiac ischaemia and arrhythmia
The investigation of the role of ACE inhibition in ischaemic heart disease and in 
arrhythmia control is a rapidly developing field. Myocardial infarction is known to be 
associated with activation of the renin angiotensin system and linked alterations in 
sodium and potassium balance may generate an arrhythmogenic state (Dargie et al, 1987; 
Michorowski & Ceremuzynski, 1983). Interactions with the sympathetic nervous 
system, myocardial perfusion and possibly antiarrhythmic effects may underlie some of 
the beneficial effects of ACE inhibition in ischaemic heart disease and infarction (Ertl,
1988).
36
Ribuot and Rochette (1987) have presented experimental evidence in ischaemia 
induced arrhythmias which suggests that captopril, enalapril, or perindopril all reduce the 
incidence of arrhythmia and death to an equal extent in comparison with untreated 
control animals. Using a similar model in rats Howes et al (1989,1991) demonstrated 
that chronic perindopril therapy post infarction attenuates the development of 
cardiomegaly seen in control animals. Tissue concentrations of 3,4 
dihydroxyphenylethyiene glycol were also noted to be reduced suggesting an attenuation 
of the chronic increase in cardiac sympathetic activity. Michel et al (1988b) also using 
a rat infarction model, found treatment with perindopril produced a hypotensive 
response, attenuation of the infarct related rise in atrial natriuretic peptide and reduced 
atrial and right ventricular mass. The reduced ventricular mass seen on therapy was 
accompanied by a reversal of infarct related changes in isomyosin profile and a reduction 
in the volume density of collagen. As yet there are no clinical studies assessing the 
effects of perindopril or perindoprilat in human ischaemic heart disease.
2.3. PHARMACOKINETIC PROPERTIES
The pharmacokinetics of ACE inhibitors are non linear and model independent 
methods are the most appropriate techniques to assess this group of drugs (Till et al, 
1984).
2.3.1. Protein binding and tissue distribution
The protein binding of ACE inhibitors is variable between agents and this 
influences the distribution and availability of the drugs to active sites. The binding of 
carbon 14 labelled perindopril and perindoprilat to plasma proteins has been studied 
using membrane dialysis techniques to steady state. The data are summarised in Table
2.2. In general the binding of perindopril is higher than that for perindoprilat, the 
predominant fraction being bound to albumin i n  v i t r o . Limited in vivo studies in
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humans showed a decrease in plasma protein binding with time after administration of 
perindopril which was thought to be related to the metabolic conversion to perindoprilat.
Limited information on the tissue distribution of the drug in experimental animals 
is available. Using tritiated perindopril in tracer doses with our without the addition of a 
10 mg/kg bolus intravenous dose, Borge et al (1987) showed a rapid and extensive 
distribution to the lung within three hours of administration. Distribution to the kidney 
lagged behind that of the lung but was also extensive at 24 hours and in general all 
binding was less marked after larger doses.
3.2. Pharmacokinetics in normal volunteers and essential hypertension
Lees and Reid (1987b) have defined the pharmacokinetics of intravenous 
perindoprilat in eight normotensive volunteers using 1,2 or 4 mg bolus doses (Figure 
2.2). Plasma concentration time profile was fitted best by a three compartment model in 
this study with half lives for the alpha, beta and gamma phases of 0.2±0.04 hours,
1.24±0.2 hours, and 31±17 hours respectively. The respective area under the curve 
(AUC) for the three doses was 206±31 hr/ng/ml, 411±63 hr/ng/ml and 822±125 hr/ng/ml 
giving an estimated clearance value of approximately 4 .9 1/hr.
After similar studies with oral doses of perindopril 4, 8 or 16 mg daily for seven 
days estimated clearance was similar after the first and seventh doses (45.9±13.21/hr vs 
40.9±8.61/hr) as was the volume of distribution (305±12.8 litres vs 311±14.4 litres). 
Time to the peak plasma concentration of perindoprilat was dose dependent, being 
0.410.6 hours after 4 mg, 2.1±0.9 hours after 8 mg and 2.910.6 hours after 16 mg of oral 
perindopril. Again no changes were found in the pharmacokinetics after one week’s 
chronic therapy.
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Figure 2.2: Plasma perindoprilat concentrations following acute bolus intravenous 
administration of 1, 2 and 4 mg perindoprilat (n=8). Data from Lees & Reid (1987b).
Drummer et al, (1987c) studied 24 essential hypertensive patients treated with 2,
4 or 8 mg oral perindopril for four weeks. Acute studies revealed a dose dependent 
increase in plasma perindoprilat with a Tmax of approximately 6.5 hours and peak 
concentrations of 6.7,19 and 58 ng/ml respectively. Four weeks therapy produced 
higher peak concentrations and a significant reduction in the time to peak to 
approximately 3.2 hours. The area under the curve (AUC) at all three doses was 
unchanged by chronic therapy. The glucuronide conjugate of perindopril was readily 
detectable after the first dose in this study but declined rapidly with a half life of 
approximately 2.9 hours. During chronic therapy a smaller amount was found. Urinary 
excretion studies after a single oral dose of 4 mg revealed 2.6% excreted as perindopril, 
6.4% as perindoprilat and 6.5% as the glucuronide which on chronic therapy increased to 
4.2% for the parent drug and 13.2% for the diacid but that excreted as glucuronide was 
reduced. Predictably the urinary recovery for oral perindopril was much less than that 
seen after intravenous treatment found by Lees, Green and Reid (1988) of 70±16% in 
normotensive volunteers studied up to 120 hours.
The excretion of perindopril is characterised by an extended terminal elimination 
phase close to the limit of assay detection. This has been observed with other ACE 
inhibitors (Till et al, 1984; Francis et al, 1987). This phase does not predict the 
accumulation profile during repeated dosing and is thought to relate to saturable protein 
binding to ACE in blood and possibly at tissue sites. Lees et al (1989) have studied their 
previously collected data with intravenous perindoprilat to assess the applicability of a 
non linear model incorporating zero order saturable tissue and plasma ACE binding. On 
comparison to standard 1,2 and 3 compartment models the non linear binding model 
gave the best fit to the observed data.
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2.3.3. Age and other disease states
A. Age
The influence of increased age on the pharmacokinetics of perindopril have been 
studied by Lees, Green and Reid (1988). In a double-blind crossover design using oral 
perindopril (8 mg) with saline intravenously or intravenous perindoprilat (1 mg) with 
oral placebo, the plasma profile and renal elimination was examined in eight healthy 
elderly volunteers in comparison to eight young volunteers. The systemic availability of 
perindopril after oral perindopril was increased in the elderly (35±17% vs 19±7%) 
primarily due to an increased conversion of perindopril to perindoprilat (61 ±20% vs 
32±15%). Renal clearance of the drug estimated from the cumulative urinary recovery 
divided by the AUC from 0 -120 hours was reduced in the elderly in comparison to the 
young (57±25% vs 7Q±16%) although this was not statistically significantly different. 
Increased availability of the drug in this group with oral therapy may require dose 
reduction to prevent excess blood pressure falls. The changes are similar to those 
previously observed with other ACE inhibitors (Lees & Reid, 1987a; Hockings et al, 
1986).
B. Hepatic impairment
Tsai and colleagues (1989) have conducted pharmacokinetic studies in patients 
with hepatic cirrhosis. In eight patients with stable, biopsy proven, predominantly 
alcohol mediated cirrhosis (7/8) oral perindopril (8 mg) or intravenous perindoprilat (2 
mg) was administered in a placebo controlled, double-blind, crossover study. The 
calculated systemic availability of perindoprilat in molar terms after oral perindopril was 
not reduced, indeed it tended to be greater than in similar studies in normal volunteers 
(30±6% vs 19±7%; Lees and Reid, 1989). The patients in this study were middle aged 
(59±9 years) and this was suggested to be a factor in explaining the apparent increase in
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drug availability.
C. Renal impairment and congestive cardiac failure
Lees et al (1988) in their study of the influence of age on the elimination of 
perindopril found that renal clearance of the drug was reduced in proportion to the lower 
creatinine clearance in the elderly group. Previous studies with other ACE inhibitors 
have shown an elevation of serum concentration, decreased excretion and urinary 
re'covery (Lancaster & Todd, 1988; Duchin et al, 1988; Todd & Goa, 1989).
Sennesael and colleagues (1992) studied 23 patients with stable chronc renal 
impairment secondary to hypertension given 2 to 4mg perindopril for 15days. Steady 
state was reached in three days and no decline in renal function was noted. 
Pharmacokinetics of perindopril were unaffected by renal dysfunction, however the renal 
clearance of perindoprilat closely correlated with creatinine clearance. Though the direct 
implications of this for toxicity are unclear, dosage reduction or decreased frequency of 
administration is generally recommended.
Similarly the effects of chronic cardiac failure on the pharmacokinetics of 
perindopril have not yet been defined. Evidence from studies with other ACE inhibitors 
are contradictory in that in some cases pharmacokinetic parameters are altered (Till et al, 
1989; Duchin et al, 1988) whereas in other studies no changes have been observed 
(Dickstein et al, 1987).
4. CLINICAL USE AND SIDE EFFECTS
An adequate description of the side effect profile of any new drug awaits 
widespread clinical use with appropriate and detailed post marketing surveillance. Such 
data is not yet available for perindopril given its limited general release at the time of 
preparation of this review. The adverse reactions to this group of drugs are often
41
divided into those which are class related and those which are seen only with individual 
agents (Williams, 1988; Di Bianco, 1986). Hypotension, renal haemodynamic 
dysfunction, hyperkalaemia, cough and, rarely, angioedema are regarded as present with 
all ACE inhibitors and in general associated with concurrent potassium sparing diuretic 
use, low salt intake, renal artery stenosis, solitary kidney or uncontrolled cardiac failure. 
In this respect patients who would be regarded as at high risk of class related adverse 
reactions include those with collagen vascular disease, renal disease including renal 
artery stenosis (regardless of the serum creatinine) or essential hypertension/refractory 
cardiac failure with a serum creatinine greater than 1.7 mg/dl (1.5 mmoLT^) prior to 
treatment (Rucinska et al, 1989). Non productive cough is an often quoted side effect 
yet has proved difficult to quantify. It has been reported relatively infrequently (2- 4%) 
in clinical trials. However its true incidence in clinical practice may be nearer 10-15%. 
Idiosyncratic dermatological reactions seen with captopril have proven to be dose related 
(Irvin & Viau, 1986) and cross-reactivity between various agents is invariably limited 
when proteinuria, skin rash and taste disturbance are considered (Jackson et al, 1988c).
In the largest clinical studies with perindopril so far published, Zanchetti and 
Desche (1989) recorded patient withdrawal in 14 of 249 patients treated with perindopril 
compared with 18 of 254 patients treated with alternative therapies excluding placebo. 
These figures include non compliance and personal reasons for withdrawal and all 
recorded symptomatic withdrawals were minor and infrequent. A summary of the limited 
side effect data available from this experience is given in Table 2.3.
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Table 2.3: Incidence of side effects in a multicentre trial of oral perindopril in patients 
with essential hypertension (after Zanchetti & Desche, 1989).
SIDE EFFECT NUMBER OF PATIENTS EXPERIENCING SIDE 
EFFECT SUFFICIENT TO CAUSE DRUG 
WITHDRAWAL
PERINDOPRIL CAPTOPRIL ATENOLOL CO-AMILOZIDE
(n=249) (n=83) (n=88) (n=83)
Rash 2 1
Dizziness 1 1 1 2
Headache 1 - 1 -
Flushing 1 - - -
Nausea - 1 1 -
Hypotension - - - 2
Aggravation of 
IHD/CCF
1 1 (MI) - 1 (CCF)
Electrolyte
disturbances
- - “ 1
Overall S/E(%) 3.6 3.6 4.5 4.8
CHAPTER 3
THE TISSUE AND PLASMA BASED RENIN ANGIOTENSIN SYSTEM
Angiotensin converting enzyme (ACE; kininase H; EC 3.4.15.1) is a zinc based 
metalloprotease closely related in structure and function to pancreatic carboxipeptidase 
A. Inhibitors of the ACE enzyme developed from the mechanistically related zinc 
metalloprotease bovine pancreatic carboxypeptidase A (Martin et al,1989). ACE has 
been extensively studied since it was first described by Skeggs and colleagues in horse 
plasma in 1956 (Skeggs et al, 1956). The enzyme is known to circulate in soluble form 
and can also be found anchored by carbohydrate residues to a variety of membrane 
structures. It operates primarily as an exopeptidase but also has recently described 
endopeptidase functions (Ehlers & Riordan, 1989). The molecular structure of the 
enzyme is known to include two identical putative active sites. Probably only one 
functional site is involved in catalysis. This high affinity binding site incorporates a 
single zinc atom providing competitive interaction with a variety of substrates, primarily 
angiotensin I or ACE inhibitors (Shapiro & Riordon, 1984; Strittmatter & Snyder, 1985; 
Martin et al, 1989).
In phylogenetic terms the enzyme is widely distributed among invertebrate and 
vertebrate species as a tissue based system with the addition of a circulating renin 
angiotensin system (RAS) appearing in species more advanced than the chondrichthian 
fish (Nishimura et al, 1973). In general terms the enzyme is non specific interacting 
with a range of peptide substrates in addition to its major role in the generation of 
angiotensin II (AH) from angiotensin I (Al) and to a lesser extent in the degradation of 
bradykinin. Alternative routes for the generation of angiotensin II from angiotensin I 
have been demonstrated both in plasma and tissues (de Silva et al, 1988; Jacobsen et al,
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1988; Johnson & Drummer, 1988; Okamura et al, 1990).
Specific inhibitors of ACE activity were initially purified from the venom of the 
snake Bothrops Jararaca which led to the peptide intravenous ACE inhibitor, teprotide 
(Ondetti et al, 1971) and subsequently to studies with the first oral derivative, captopril, 
in man some years later (Ondetti, Rubin & Cushman, 1977). Since that time numerous 
developments in ACE inhibitor structure have led to the production of prodrug and non 
prodrug molecules, further sulphydril group containing inhibitors, the availability of 
intravenous diacids and a variety of hepatic and renal routes of elimination to the extent 
that recent estimates suggest that some 50 compounds are undergoing various stages of 
clinical development or clinical use (Brunner et al, 1985; Johnson, 1988). One such 
compound, perindopril, has been used as an illustrative example in the preceding chapter.
The purpose of the following review is to highlight the evidence available for the 
existence and functional importance of a tissue based renin angiotensin system and the 
importance, if any, of differential interaction between ACE inhibitors with tissue and 
plasma ACE in a variety of sites.
3.1. DEFINITION OF THE TISSUE RENIN ANGIOTENSIN SYSTEM
Tissue based elements of the renin angiotensin system have been studied for the 
past ten years in an attempt to delineate the contribution of circulating and "tissue fixed" 
systems to biological effects in a range of key organs (Ganten et al, 1983). In general 
terms membrane bound ACE is known to be susceptible to hormone based induction 
which is clearly demonstrable in the maturation of monocyte cells towards macrophages 
and the changes noticed in granulomatous diseases such as sarcoidosis (Friedland et al, 
1978). The enzyme maturation and induction found in these circumstances is 
glucocorticoid dependent and relatively specific (Hinman et al, 1979; Vuk-Pavlovic et al,
1989). Studies in experimental animals have shown that the tissue renin angiotensin
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renin gene expression (Metzger et al, 1988). These and other general controlling factors 
are summarised in Table 3.1.
The evidence regarding the tissue specific distribution of ACE activity and a 
tissue RAS will be considered systematically for the major sites (i.e. vascular, 
pulmonary, cardiac, brain and renal) in the following sections. One tissue which has 
received considerable attention which will not be considered in detail is the ACE activity 
which has been identified in the testis. This isoenzyme of ACE is known to have a 
different peptide structure from either plasma or pulmonary enzyme and has been widely 
demonstrated as inaccessible to the effects of circulating ACE inhibitors in a variety of 
acute animal studies (El-Dorry et al, 1982; Velletri et al, 1985; Jackson et al, 1988; 
Johnston et al, 1989). The role of this enzyme, presumably during developmental 
reproductive biology is as yet unclear.
3.1.1. Vascular renin angiotensin system and ACE activity
The tissue based RAS of the vascular tree has been intensively studied as the 
most logical source mediating the haemodynamic effects of ACE inhibition. A major 
assumption in the majority of experimental work is that studies in large bore conducting 
vessels have relevance to more distal resistance vessel structure and response. All the 
components of the RAS are evident in isolated vascular tissue when studied using the 
techniques of molecular biology in animals (Dzau, 1986). The key elements of renin and 
angiotensinogen have been documented to the level of messenger RNA. The peptides 
can be generated locally or can be taken up from the circulating pool. Due care must be 
taken to exclude artefactual generation or degradation of angiotensins from simple in 
vitro pH changes or non specific protease activity (Swales & Hegerty, 1987; Campbell, 
1985,1987). The production of angiotensin II by synthesis and release into culture 
media has been demonstrated in vitro and in several experimental preparations of isolated
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Table 3.1; Some general factors controlling the renin angiotensin system
Na+/RENIN STATUS
GLUCOCORTICOIDS
ANDROGENS
ACE INHIBITOR THERAPY
and perfused hind limbs without circulating renin or angiotensinogen (Okamura et al, 
1986; Mizuno et al, 1988). In these studies exogenous renin was shown to produce a 
temporal dissociation of an induced pressor response to angiotensin in nephrectomised 
animals whose circulating renin activity was low or absent. Measured arteriovenous 
differences in the clearance of exogenous renin implied tight binding of the enzyme to 
tissue sites with consequent activation of the tissue based renin angiotensin system and 
subsequent angiotensin II production. Similar experiments documented by Oliver and 
Sciacca (1984) demonstrated that the pressor response to angiotensinogen and 
angiotensin I in isolated perfused hindquarters could be ablated by concurrent captopril 
or peptide renin antagonist. In this situation the tissues generated renin activity over and 
above the quantity supplied in the infusate.
Although the accurate determination of angiotensin peptides in plasma and tissue 
are well known to be susceptible to methodological and analytical difficulties (de Silva et 
al, 1988) including the possibility of alternative routes for the hydrolysis of angiotensin I 
(Johnson & Drummer, 1988; Ideishi et al, 1990) careful studies on peptide kinetics have 
given valuable further evidence.
Campbell (1985), considering experimental data on the arteriovenous gradients of 
angiotensin peptides within subjects calculated a substantial production of angiotensin II 
in addition to the inactivation of arterial angiotensin II by tissues as demonstrated in 
classical isolated organ experiments (Ng & Vane, 1968). Using approximations of 40% 
angiotensin I conversion and 65% for the rates of angiotensin I and II inactivation he 
calculated that local production of angiotensin I was responsible for 83% of the total 
venous concentration of angiotensin I and similarly that local production of angiotensin 
II accounted for 68% of the total venous angiotensin n.
These approximations were recently bome out by elegant studies conducted in 
man to define the regional generation of angiotensin I in the renal, antecubital,
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hepatomesenteric and femoral circulations using steady state tracer infusions of 
exogenous peptide and concomitant captopril therapy. Schalekamp and colleagues 
demonstrated that 40-90% of venous angiotensin I in these vascular beds was in fact 
generated by regional production from angiotensinogen (Schalekamp et al, 1989; 
Admiraal et al, 1990). Similar, though less extensive, studies have been documented by 
other groups (Reams et al, 1989).
ACE activity has been demonstrated immunohistochemically on vascular 
endothelium (Ryan et al, 1975; Caldwell et al, 1986) and furthermore the amino acid 
sequence and molecular structure of vascular ACE has been defined by cDNA cloning 
techniques (Alhenc-Gelas et al, 1989). The existence of a tissue based renin angiotensin 
system seems accepted from a number of different viewpoints. However, each element 
in the system of course must be demonstrated to be co-localised and to interact. As was 
suggested above for the case of angiotensin I to angiotensin II processing it has to be 
clear that only one specific enzyme is mediating any extra-vascular processing. This is 
questioned with regard to renin, since a significant fraction of renin-like activity appears 
not to be inhibited by renin specific antibodies in some studies (Rosenthal et al, 1984). 
Whereas co-localisation, specific action and functional interaction have been agreed for 
some tissues in experimental animals this full picture in the vasculature has been 
questioned by some authors (Corvol et al, 1989). A key element must be the degree of 
interaction and interchange of substrates with the circulating endocrine renin angiotensin 
system.
3.1.2. Pulmonary renin angiotensin system and ACE activity
The pulmonary circulation, on the basis of ex vivo pharmacology (Ng & Vane, 
1968), has long been regarded as the most important if not exclusive site for the 
conversion of angiotensin I to angiotensin n  by ACE activity. It has been regarded as the
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major endocrine function of the lungs (Said, 1982). This view has undergone revision 
with the more precise definition of tissue renin angiotensin systems in many other sites. 
Within the lung, ACE activity has been localised on the endothelium of the pulmonary 
vasculature (Ryan et al, 1980; 1985) but is also present on other parenchymal sites and is 
widely recognised as a marker of lung injury (Kelley, 1988; Foresti et al, 1989) or of 
hypoxia (Joderlinic et al, 1988; Oliver et al, 1989).
The anatomy of the pulmonary circulation has allowed this site of tissue ACE 
activity to be studied using elegant single pass kinetic studies in animals which allow the 
definition of the enzyme in vivo (Chen et al, 1984; Catravas & White, 1984; Moalli et al, 
1985; Linehan et al, 1990). Multiple indicator dilution techniques employing time 
paired samples of a relevant indicator and an ACE substrate have been applied to the 
pulmonary circulation (Linehan et al, 1985). The kinetic profile on single 
transpulmonary passage is mapped employing the synthetic substrate tritiated benzoyl- 
phenylalanyl-alanyl proline (^H-BPAP) which is specific substrate for ACE. This 
sophisticated technique has not been applied to the human pulmonary circulation and has 
only been used to define the broad responsiveness to ACE inhibition rather than 
comparing different agents. However Chen et al (1984) showed a markedly attenuated 
lung metabolism of BPAP produced by 6 days of intravenous captopril bolus dosing in 
the face of rapid recovery of plasma ACE activity. The time course of pressor responses 
to angiotensin I after captopril followed the pattern of plasma ACE inhibition, i.e. rapid 
recovery after each dosing, and did not reflect continuing pulmonary tissue ACE 
inhibition between dosing. Of great importance was the fact that the mean hypotensive 
response followed neither the pattern of plasma ACE inhibition nor pressor response to 
exogenous angiotensin I but the pattern of persistent pulmonary ACE inhibition. This 
finding is qualitatively similar to the patterns observed in both ex vivo and in vitro 
studies of the temporal course of pulmonary ACE inhibition after a variety of ACE
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inhibitors (Cohen & Kurz, 1982; Sakaguchi et al, 1988; 1989; Welsch et al, 1989).
As with other sites direct comparative studies on the reactivity of pulmonary ACE 
to different ACE inhibitors are complex in that equipotent doses should be administered 
preferably by intravenous injection or infusion. Unger et al (1985) demonstrated a 
slower recovery of pulmonary ACE after single dose ramipril than after enalapril in 
experimental animals. Relevant information on human tissue ACE, particularly at 
steady state dosing with ACE inhibitors, is not available. Further experimental studies 
show that induction of pulmonary ACE occurs on chronic ACE inhibitor therapy 
(Fyhrquist et al, 1982). Such enzyme induction is a general biochemical principle and 
may be relevant to the mediation of responses as considered later in the thesis.
In contrast to other circulations there are limited data on the transpulmonary 
conversion of angiotensin I in man. It may be that this is predominantly related to 
vascular endothelial ACE and its interaction with the circulating renin angiotensin 
system. However like other circulations it is complicated by the tissue generation and 
metabolism of peptides, previously described peptide assay problems and difficulties in 
differentiating between the tissue and plasma elements. A novel study by Neilly and 
colleagues (1987) demonstrated a wide range of transpulmonary angiotensin II formation 
rates in a rather heterogeneous population of cardiac and respiratory patients with cor 
pulmonale. The latter group of hypoxic patients showed no changes in transpulmonary 
angiotensin II formation during oxygen supplementation. This is perhaps somewhat 
surprising given the documented sensitivity of the enzyme to hypoxia and ion balance in 
vitro (Skoglof et al,1990).
3.1.3. Cardiac renin angiotensin system and ACE activity
As the central organ of the cardiovascular system the heart has been of particular
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myotropic actions of angiotensin II (Koch-Weser, 1964) and its indirect neurogenic 
facilitation of the sympathetic tone (Xiang et al, 1985). A summary of the actions of 
angiotensin II on the heart is given in Table 3.2.
As with other tissues the key elements of the renin angiotensin system have been 
demonstrated using molecular biology and once more the co-localisation and functional 
significance of the findings is controversial (Mebazaa et al, 1989; Dzau, 1988). Studies 
of the localisation of angiotensin n, its specific receptors and generation of the peptide 
have shown that the right sided cardiac chambers and the right atrium in particular are 
ksy sites for angiotensin II production (Lindpainter et al, 1987; Rosenthal et al, 1987). 
Persistent detection and generation of angiotensin II can be seen in the heart following 
ablation of the circulating renin angiotensin system by bilateral nephrectomy (Mebazaa 
et al, 1989).
ACE activity is readily demonstrable in the heart with the similar increased 
activity in right sided chambers, especially the atrium, that is found with angiotensin 
peptide (Johnson et al, 1989). It is suggested that the majority of the enzyme is found in 
association with the vasculature and that only a small component is associated with 
myocardium. There is a high concentration on the surfaces of the cardiac valves. No 
ACE activity is found i . \  association with the conducting system or in the region of the 
inter-ventricular septum (Saito et al, 1987; Yamada et al, 1989). There is some evidence 
to suggest that the molecular weight (Polsky-Cykin & Fanburg, 1979), carbohydrate 
content, primary (Iwata et al, 1982) and tertiary structure (Polsky-Cykin & Fanburg, 
1979; Velletri et al, 1985) are different for cardiac with respect to soluble plasma ACE. 
Certain in vitro physicochemical properties of ACE isolated from the human heart 
similarly differ from that isolated from other tissues (Sakharov et al, 1987). There is no 
data to suggest that these laboratory findings are of functional significance.
ACE inhibitors have not been frequently used to define the specificity of the
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Table 3.2 : Actions of Angiotensin II on the heart
- Vascular constriction
- Inotropic effects
- Mitogenic effects
- Myocardial conduction
direct
indirect - (autonomic tone)
- (prostaglandin synthesis)
- (kinin potentiation)
direct
indirect - (sympathetic facilitation)
potentiation of myocyte growth 
fibrosis
? secondary to - structural changes
- altered vasomotor tone/ 
ischaemia
interaction with cardiac tissue ACE but Fabris and colleagues (1989) have done a small 
experimental study in rat tissue. They were able to confirm concentration dependent 
binding in which the relative binding affinity of a range of ACE inhibitors was higher in 
right than left sided myocardial ACE. A similar rank order of potency was found for six 
ACE inhibitors of differing lipophilicity but the differences in ligand binding properties 
were not reflected in a small examination of the temporal degree of ACE inhibition to the 
compound quinapril. These authors therefore felt that the altered binding affinity 
between atrial and ventricular ACE was not of functional importance. They did not 
compare the temporal binding characteristics of the full range of the ACE inhibitors 
employed.
The functional importance of the renin angiotensin system to the heart is 
supported by clinical and experimental studies showing that ACE inhibitor therapy can 
reduce infarct size (Ertl et al, 1982), inhibit the progressive ventricular dilatation 
following experimental and clinical myocardial infarction (Pfeffer et al, 1985,1988,
1992; SOLVD 1991,1992a) and have an important role to play in limiting ventricular 
fibrosis and remodelling ventricular hypertrophy from a variety of causes (Yoshimura et 
al, 1989; Swynghedauw, 1989; Michel et al, 1988). Most recently it has become clear 
that ACEI therapy can reduce the incidence of reinfarction in chronic heart failure 
patients whose initial cardiac damage originated in an index infarction (SOLVD 1992b)
As in the lung there are a number of separate issues in relation to the role of the renin 
angiotensin system in the modulation of coronary vasomotor tone during normal 
perfusion or ischaemia which will not be considered in detail here (Ertl, 1988; Van Gilst 
et al, 1988; Gasic et al, 1990; Packer,1992).
Evidence to suggest interactions of tissue ACE with the conducting system is 
controversial and based more on indications of putative antiarrhythmic activity with 
some ACE inhibitors but not with others (Van Gilst et al, 1986; Westlin & Mullane, 1988;
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Ferrari et al,1992). The relevance of the tissue based renin angiotensin system to this 
phenomenon is unclear but there is experimental evidence confirming alterations in 
ventricular hypertrophy with ACE inhibitor therapy are associated with beneficial 
changes in electrophysiological conduction (Thollon et al, 1989).
3.1.4. Brain renin angiotensin system and ACE activity
A brain renin angiotensin system has been identified in a number of species and 
has important functions in stimulating thirst to increase extracellular fluid volume 
(Ganong, 1984). Angiotensin converting enzyme has been specifically localised in the 
central nervous system (Strittmatter et al, 1985) and its relationship to angiotensin 
receptors defined (Chai et al, 1986; Allen et al, 1988). The inhibition of central ACE 
activity may be an important point in generating the chronic haemodynamic response to 
ACE inhibition as is suggested by the hypotensive response to intra-cerebroventricular 
ACE inhibitors in animals with experimental hypertension where there is no peripheral 
ACE inhibition (Phillips & Kimura, 1986; Sakaguchi et al, 1988). Brain ACE is active 
in vivo as is demonstrated by the inhibition of the pressor response to intra- 
cerebroventricular angiotensin I but not to angiotensin II in the presence of concurrent 
intraventricular ACE inhibitor treatment. Studies of the penetration of ACE inhibitors 
beyond the blood brain barrier have revealed a concentration dependent phenomenon. 
Although the circumventricular organs lying outwith the blood brain barrier are readily 
inhibited by circulating ACE inhibitors excessive "pharmacological" doses are required 
to penetrate deeper structures such as the basal ganglia in acute studies and indeed some 
agents do not penetrate in the doses chosen (Sakaguchi et al, 1988). Again the issue of 
relative potency and the doses chosen in such studies is of critical importance. The 
significance of these acute studies to chronic therapy in man is unclear.
Although these animal studies involved the circumventricular organs which do
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not have a major role in human central vasomotor control the tissue angiotensin system is 
also evident in areas of the ventrolateral medulla in post mortem human specimens (Chai 
et al, 1990). These areas are more closely associated with blood pressure control (Allen 
et al, 1988). Animal studies with respect to this region of the brainstem indicate that the 
angiotensin system may modulate the control of vasomotor outflow (Chevillard & 
Saavedra, 1982; Andreatta et al, 1988).
3.1.5. Renal renin angiotensin system and ACE activity
Tissue based elements of the renin angiotensin system are of central importance 
in the kidneys due to the role of this organ in normal fluid and electrolyte balance and in 
the pathological genesis and perpetuation of hypertension (Klahr, 1989) and chronic 
cardiac failure (Stanton & Bremner, 1986). The origin of the circulating renin 
angiotensin system within the kidney is well established. However, a local paracrine 
and autocrine function for tissue generated angiotensin II is now supported by increasing 
evidence. As with the other organs there is certainly an element of renal ACE related to 
vascular endothelium. However the enzyme can also be identified on the tubular cells 
and intercellular membranes.
As with the other sites renin, angiotensinogen and ACE have been identified 
using the techniques of molecular biology in fetal renal tissue and it has been suggested 
that these tissue based elements have a role in controlling organ development (Moumier 
et al, 1987). As with the other tissues the local functional significance of these 
observations is still a matter of debate.
ACE is associated primarily with the proximal tubular cell in man but is also 
present in more distal structures in other species (Takada et al, 1982a). Experimental 
work in isolated nephrons by Marchetti et al (1987) suggests that there may be a 
gradation of activity from proximal to more distal segments of the tubule. However these
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animal studies must be set in the context of interspecies differences which have been 
shown 1) in i n  v i t r o  characteristics of kidney ACE (Takada et al, 1982b), 2) in the total 
content and distribution of the enzyme (Morin et al, 1989) and 3) with the known 
presence of other non specific tubular peptidases.
The biochemical structure of kidney ACE is again suggested to be altered with 
respect to carbohydrate content from the circulating soluble enzyme. However the 
authors who described these changes declared them to be irrelevant to functional activity 
and regarded the immunoreactivity of renal ACE as identical to that in the lung (Alhenc- 
Gelas et al, 1983).
Interestingly the temporal inhibition of renal ACE activity following ACE 
inhibitors tends to follow the pattern set by aortic vascular ACE which recovers more 
rapidly than that extracted from the lung (Sakaguchi et al, 1988; Jackson et al, 1988).
As with other tissues renal ACE inhibition is markedly dissociated from the profile of 
plasma ACE inhibition (Unger et al, 1985). Intercomparison between agents is again 
complicated by variable potency and the use of potentially non equivalent doses. Even 
so, different patterns of inhibition in renal cortical ACE have been demonstrated between 
agents for example in the studies of Chevillard and colleagues using enalapril and 
trandolapril (Chevillard et al, 1989).
The generation of angiotensin II within the renal circulation has a potent local 
vasoconstrictor effect particularly affecting the postglomerular intravascular pressure 
which controls glomerular filtration and hydrostatic pressure. The effect of changes in 
circulating angiotensin II are therefore most evident in sodium deplete states and in the 
presence of renal artery stenosis (Navar & Rosivall, 1984). From studies in the isolated 
rat kidney it has been suggested that the relatively reduced quantity of ACE available 
may allow ACE to take on the role as the rate limiting step in angiotensin II formation 
(Misumi et al, 1989) which is not the case in other sites (Erdos, 1975). Studies of the
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regional extraction of angiotensin I across the renal circulation give estimates in the 
region of 80%. Local generation of angiotensin I results in only a marginal 
arteriovenous gradient (Schalekamp et al, 1989; Admiraal et al, 1990).
The effects of ACE inhibitor therapy are predominantly focused on the 
haemodynamic effects, on renal function and certainly on the possibility of detrimental 
effects on kidneys affected by renal artery stenosis (Bumier et al, 1989). The beneficial 
effects of ACE inhibitor therapy in kidneys affected by diabetic hyperfiltration (Taguma 
et al, 1985; Marre et al, 1987; Romanelli et al, 1989) or hypertensive nephropathy (Ikeda 
et al, 1989) are equally felt to be based primarily on haemodynamic alterations (Raij et 
al, 1989). The interaction between overall blood flow, regional intrarenal flow and 
glomerulotubular pressures are complex and there is still considerable debate as to the 
relative importance of tissue based endothelial or tubular ACE in generating positive or 
negative responses to ACE inhibitors in various renal diseases. This is reflected in the 
continuing clinical debate over the net efficacy of ACE inhibitor treatment in progressive 
renal insufficiency (Keane et al, 1989).
3.2. ACE INHIBITORS AND TISSUE ACE INHIBITION
3.2.1. Analytical aspects
The definition of ACE activity in plasma and in tissue extracts is associated with 
well defined problems of methodology. The majority of analyses in clinical use are 
based on the generation of a chromophobe from a variety of peptide substrates for the 
quantitative description of peptide hydrolysis (Piquilloud et al, 1970; Cushman & 
Cheung, 1971; Ryan et al, 1977). Alternatively ACE activity has been expressed 
employing competitive binding inhibition of a radiolabelled tyrosyl derivative of 
enalaprilat (^I-M K 351A) which has the advantage of describing either ACE activity, 
by competitive displacement, or the concentration of any given ACE inhibitor (Fyhrquist
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et al, 1984; Jackson et al, 1986; Johnson et al, 1987).
The results achieved with different chromophobes have been criticised by some 
workers who believe that inhibition of the renin angiotensin system either in plasma or 
tissue must be related directly to local or circulating ratios of angiotensin II to 
angiotensin I (Biollaz et al, 1982; Nussberger et al, 1988,1989). This is not easily 
achieved. The cross reactivity of angiotensin peptides, and there are a variety of more or 
less bioactive breakdown products, hexapeptides, heptapeptides etc, causing an 
overestimation of key effector substance, Angll octapeptide. This can only be 
circumvented by incorporating preliminary separation of peptides with high pressure 
liquid chromatography and subsequent sensitive angiotensin II octapeptide 
radioimmunoassay. This is a particularly time consuming and difficult analysis which is 
expensive to perform. There is disagreement whether or not even the effects of different 
ACE inhibitors can be compared even using the same chromophobe assay to detect ACE 
activity (Bumier et al, 1989).
In vitro studies of serum ACE activity as defined using chromophobe techniques 
have demonstrated significant differences in the kinetic and inhibitory constants to 
captopril between species. In addition the level of circulating enzyme is well described 
as being variable between species (Ibarra-Rubio et al, 1989). Thus comparisons of 
plasma and tissue ACE deduced from animal experimentation using various 
methodologies should be treated with caution.
3.2.2. Acute vs chronic ACE inhibitor treatment
A large volume of published work studying serum and tissue ACE is based on 
experimental and clinical studies in which drug therapy is given either on a single dose 
basis or on short term administration lasting days or at the most a few weeks. There is 
little doubt that the acute and chronic responses of the renin angiotensin system to ACE 
inhibitor therapy differ considerably. There is an interaction between the analytical
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technique used to define plasma ACE and the definition of the changes on chronic 
therapy. Studies in normal volunteers have shown reactive hyper-reninaemia which is 
associated with the re-appearance of bioactive angiotensin II octapeptide despite 
maximal ACE inhibition when defined by chromophobe techniques (Mooser et al, 1990). 
Such hormonal changes are of considerable importance in the definition of 
haemodynamic responses in that some authors suggest that both renin and by implication 
angiotensin II entirely explain the response to ACE inhibitors (Case et al, 1977). In 
effect responses to ACE inhibitors, for example in hypertension, can be defined on the 
basis of renal perfusion and local renin production in the kidney (Cody, 1984; Buhler, 
1986; Laragh, 1989). These theories do not explain the re-emergence of circulating 
angiotensin II and a continuing and developing response to ACE inhibition with chronic 
treatment nor evidence of responses to ACE inhibitors in low renin states (Chatteijee & 
Opie, 1987).
3.2.3. Kininase II inhibition
In terms of alternative substrates for ACE the major interest in haemodynamic 
and stuctural effects mediated by ACE inhibiton lies in the local potentiation of 
bradykinin mediated by kininase E/ACE inhibition. Mammalian ACE can more 
efficiently degrade bradykinin (Km = 8 x 10"^  M) than activate angiotensin I (Km = 3.3 
x 10“5 M) (Ryan, 1983) and it has been suggested that the secondary association of ACE 
with the renin angiotensin system seen from phylogenetic studies supports the 
importance of kinins as the major substrate for ACE (Lipke & Olson, 1988).
There is some evidence from experiments in anaesthetised animals that the acute 
hypotensive effects of captopril can be partially reversed by competitive antagonists of 
bradykinin in excess of the pressor effect caused by the infusion of the kinin antagonist 
alone (Seino et al, 1989). The antihypertensive effect of chronic ramipril therapy in SHR
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rats can be partially reversed by the addition of a bardykinin antagonist (Bao et al,1992). 
A remarkable series of studies by Linz and colleagues has suggested that kinin 
antagonism can block the anti hypertrophic response seen following low dose ACE 
inhibition in rats who have left ventricular hypertrophy induced by surgical aortic 
constriction (Linz et al,1992). This series has also demonstrated a remarkable 
concentration dependency in that the anti hypertrophic effects were evident at doses of 
the ACE inhibitor which were devoid of haemodynamic effect (Linz et al,1989).
In addition localised studies on human forearm vascular tone by Benjamin and 
colleagues showed that without generalised ACE inhibition or haemodynamic changes, 
infusion of the ACE inhibitor enalaprilat has local effects whose onset and extent are 
mediated through angiotensin II but possibly also through bradykinin (Benjamin et al, 
1989). This and similar studies showing potentiation of a range of bradykinin mediated 
effects such as intradermal wheals (Femer et al, 1989) or increased forearm blood flow in 
response to intra-arterial bradykinin (Kiowski et al, 1982) have been used to suggest that 
this effect might explain the hypotensive effects of ACE inhibitors in low renin states 
(Swartz et al, 1979). The key element of course is the nature of the interaction: whether 
this is direct, as suggested by the workers above, or is in fact simply an indirect 
phenomenon. Nonetheless kinins are emerging as a strong candidate for future research 
as mediators of some ACE inhibitor effects (Kiowski et al,1992).
3.2.4. Tissue distribution of ACE inhibitors
The matter of physicochemical differences between ACE isolated from different 
organs and from different species has partly been addressed in preceding sections.
Tissue and plasma ACE are likely to originate from one gene product but the possibility 
of a variety of isoenzymes responsible for variable properties is acknowledged 
(Strittmatter et al, 1985; Bernstein et al, 1988). Recently there has been much speculation
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as to the functional significance of variations in ACE genotype in defining increased 
cardiovascular risk in a non-obese population of patients with myocardial infarction who 
had an otherwise low rating of "conventional" cardiovascular risk factors (Cambien et 
al',1992). Structural differences are highlighted particularly for the testicular enzyme 
(Iwata et al, 1982; Velletri, 1985) but the again the functional significance of this site and 
its differing structure remain unclear from ex vivo studies (Jackson et al, 1988).
The distribution of the drug between the plasma compartment and the tissue sites 
whether they are endothelial, epithelial or in deeper structures must be a concentration 
dependent equilibrium. This depends upon the quantitative availability of binding sites 
in the plasma and tissue and a range of factors related to the structure of the ACE 
inhibitor and the tissue enzyme such that interaction can occur. These factors are 
outlined in Table 3.3. The majority of comparative data on different ACE inhibitor 
profiles for tissue ACE inhibition have necessarily been gathered in animals using short 
term or acute doses of drugs. A large body of work has come from the group at the 
University of Melbourne (Johnston et al, 1988,1989) using temporal ex vivo radioligand 
binding studies of tissue ACE. Whether simple tissue bioavailability or true differing 
tissue interactions with the enzyme are responsible for differential regional effects 
between ACE inhibitors is unclear. As the physicochemical properties of the ACE 
inhibitor also provide the more general pharmacokinetic properties of the drugs the 
interaction between plasma concentration time profiles and tissue binding has achieved 
considerable interest especially as there are marked differences in the conventional 
pharmacokinetic profiles between agents (Kubo & Cody, 1985; Belz et al, 1988).
3.2.5. Pharmacokinetics and pharmacodynamics of ACE inhibitors and tissue ACE
Circulating plasma ACE inhibition, regardless of the technique of determination,
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Table 3.3: Factors influencing the tissue distribution of ACE inhibitors
PLASMA CONCENTRATION (ESTER/DIACID) 
LIPOPHILICITY
RELATIVE PLASMA/TISSUE BINDING SITES
ESTER/DIACID INTERCONVERSION 
(PLASMA/TISSUE)
MEMBRANE BARRIERS 
(BLOOD/BRAIN/TESTIS)
ELIMINATION
is thought to correlate closely with simultaneous plasma drug concentrations without any 
significant hysteresis in this biochemical effect of the drug (Ajayi et al, 1987; Francis et 
al, 1987). However, theoretically this relationship should obey the laws of mass action 
and a non linear saturable binding phenomenon should be observed. In many instances 
the accumulation of drug is such that the very earliest phases of drug accumulation and 
ACE inhibition are not well described even in oral dosing studies (Francis et al, 1987). 
Similar non linear relationships have been described where in vivo ACE inhibition is 
defined using angiotensin peptide ratios (Biollaz et al, 1982) although the exact 
description of the observed data is a matter of debate (Kelman et al, 1983). Preliminary 
studies using low dose intravenous infusions of ACE inhibitors have suggested that a 
sigmoid drug accumulation profile in venous plasma is evident. This is best described by 
non linear saturable binding in which the model incorporates terms indicative of the 
proportions of drug bound to both plasma and tissue ACE (Lees et al, 1989). These 
studies have attempted to include statistical validation of the "goodness of fit" of the 
model but require further definition of the validity of the parameters generated. These 
parameters may give an alternative means of describing human tissue ACE inhibition i n  
v i v o .
The clinically important relationship centres upon that relating drug concentration 
to haemodynamic effect. Thus although ACE inhibition has been frequently compared 
to haemodynamic effects in a large number of normal and pathological states with a 
range of age groups and renin status, rarely if ever has drug concentration been 
quantitatively applied to individual subjects in the general terms of drug concentration 
effect modelling (Holford & Sheiner, 1981; Donnelly et al, 1989). In terms of acute 
hypotensive responses to ACE inhibitors or renin inhibition, temporal dissociation from 
circulating ACE activity or drug concentrations is well documented in a variety of animal 
models (Waeber et al, 1980; Boomsma et al, 1981; Blaine et al, 1984; Unger et al, 1986;
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Kamei et al, 1989). The interpretation of this basic observation is at the heart of the 
complex and previously discussed points regarding definition of plasma ACE inhibition, 
peptide analysis and interaction with alternative vasoactive substrates are clearly 
pertinent. Although the existence and importance of tissue ACE are frequently cited as 
the explanation for this failure to correlate observations with response it should be noted 
that there are a number of single dose animal studies which suggest a close correlation 
between ACE inhibition and blood pressure fall (Sweet et al, 1981; Jackson et al, 1984). 
Studies with alternative means of blocking the renin angiotensin system such as specific 
renin inhibitors or angiotensin receptor antagonists (see chapter 8) are as yet too limited 
and do not define the temporal excursion of angiotensin II in sufficient detail to explain 
the discrepancy although again there is limited evidence of a direct relationship (Szelke
| et al, 1985).
| In quantitative terms the discrepancy between drug concentration and
I
| haemodynamic effect is described over time a prosteresis (anticlockwise hysteresis)
I
j where the haemodynamic response lags behind drug concentration (Belz et al, 1989).
[ This is common to a number of vasoactive agents (Donnelly et al, 1989). The suggestion
that the delay is due to the equilibration of drug into key tissue sites and interaction with 
tissue ACE is tempting. Kirch and colleagues (1988) found that the shape of the blood 
pressure to ACE inhibition curve for cilazapril in hypertension was retained after 2 
weeks therapy with a more rapid initial response to dosing and some reduction in the area
| of hysteresis. They suggested therefore that the eventual degree of haemodynamicJ
| effect was well described after the initial dose but that the duration of the effect was
|
; underestimated.!
i
I
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3.2.6. Activated renin angiotensin system in heart failure
In explaining the haemodynamic effects of inhibiting the renin angiotensin 
system it has been suggested that the fluid and sodium status and changes in the 
activation of the circulating renin angiotensin system combine to define completely the 
extent of the first dose response to an ACE inhibitor (Dzau, 1989). For example, in 
renovascular hypertension it is suggested that where there is no increase in extra-cellular 
volume nor sodium loss then there is in effect no acute blood pressure response to ACE 
inhibitor treatment. This is not a universal experience and marked hypotension is 
documented in this setting (Hodsman et al, 1983). The role of diuretic mediated 
natriuresis and volume depletion and secondary hyper-reninaemia are of significance. 
Equally in renovascular hypertension there is some evidence to suggest tissue based 
vascular ACE is the unquantified element in describing this haemodynamic response 
(Okamura et al, 1986).
Hyper-reninaemia was first suggested to play a role in the vasoconstriction of the 
chronic cardiac failure syndrome in the mid 1940s (Merrill et al, 1946). In addition to 
the circulating system there is clearly scope for quantitative alterations in the tissue 
elements of the renin angiotensin system in response to chronic changes such as occur in 
hypertension (Lever, 1989) and in cardiac failure (Anand et al, 1989). Animal studies 
support the activation of the tissue based renin angiotensin system at a number of levels 
in experimental heart failure (Fabris et al,1990; Hirsch et al,1991,1992). Both tissue and 
circulating systems are liable to be influenced by prior or concomitant drug therapy 
known to act directly or indirectly with the renin angiotensin system, diuretic therapy in 
particular (Bayliss et al, 1987).
The renin angiotensin system is centrally involved in the response to heart failure 
as one of the primary homeostatic systems controlling cardiovascular function. These are 
relevant to the pathology of heart failure in generating peripheral regional
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vasoconstriction acting via the pressor peptide Angll. Activation is mediated by the fall in 
renal perfusion during heart failure activating baroreceptor mediated renin release. The 
sensitivity of various vascular beds to angiotensin II varies (Motwani & Struthers,1992) 
and this affects the response to activation of the system in heart failure. Fluid and 
electrolyte balance is also altered resulting in potassium loss, sodium and water retention 
intrinsic to the heart failure syndrome. This gives rise to the fluid overload at least 
partially responsible for the symptoms of heart failure (Schrier,1988). Management with 
diuretic drugs in patients with heart failure and a variety of other vasodilator agents also 
acts as a stimulus to the renin angiotensin systems (Doig et al,1992).
In chronic cardiac failure the first dose response to ACE inhibition has been 
associated with marked hypotension usually catalogued in small series or in isolated case 
reports (see Table 3.4). The exact incidence and severity of these events is unclear yet 
strategies of dose reduction, hospitalisation for initiation of therapy, and an initial choice 
of short acting ACE inhibitors appear to be common in clinical practice when this has 
been audited (McMurray et al, 1989). It is as yet unclear whether these episodes reflect 
a distribution of individual responsiveness, whether they are agent or dose related, or 
whether they simply reflect vagally mediated reflex hypotension which is common with a 
number of hypotensive drugs (Semple et al, 1988). The belief in an idiosyncratic first 
dose response which is not dose related has emerged to the extent that some groups 
employ small "test doses" prior to treatment although the rationale for these is unclear 
(Rademaker et al, 1986). As has been suggested for renovascular hypertension, hyper- 
reninaemia has been employed whether related to disease or diuretic therapy as the whole 
explanation for the magnitude of first dose response (Cody, 1984; Packer et al, 1985; 
Kubo et al, 1987; Dzau, 1989). However individual patterns of the response, where 
presented in detail, frequently show a sudden collapse in blood pressure (Cleland et al, 
1985; Lantz et al, 1984) rather than any more rapid decline than expected and the
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Table 3.4: Reports of hypotension following ACE inhibition
Report n N YHA Diuretic 
Grade
Agent Dose
Acampora et al (1989) 1 n Enalaprilat 0.625mg(IV)
Ader et al (1980) 10(2) III-IV + Captopril 25 mg
Cleland et al (1984) 10 m -iv  + Captopril 6.25mg
Cleland et al (1985) 26 II-IV +/- Enalapril 5/ lOmg
Kramer et al (1982) 15 II-IV + Captopril 25 mg
La Barre et al (1982) 1 IV ? Captopril 6.25mg
Lantz et al (1984) 16 hi ? Captopril 12.5/6.25mg
Mujais et al (1984) 10 III-IV + Captopril 25 mg
Packer et al (1983) 7 IV + Captopril 25 mg
has never been documented and indeed only very recently has a placebo controlled trial 
of the initial response to ACE inhibitor therapy in chronic cardiac failure been published 
(Herrlin et al, 1990). The importance of placebo control to any scientific study is as true 
for heart failure as any other area of therapeutics (Packer,1990).
Although ACE inhibitors are available as intravenous formulations (Kubo et al, 
1985; Homung & Hillis, 1987; Semple et al, 1987; De Marco et al, 1987; Walinsky et al, 
1987) and have been suggested to be valuable in the management of severe acute heart 
failure (Rademaker et al, 1986; Flynn et al, 1988) they have not been studied in detail 
with respect to the concentration effect relationship of their first dose response.
Although this pattern of haemodynamic response to ACE inhibitors may provide 
further valuable insights into the balance between circulating and tissue ACE activity in 
generation of a response it should be noted that where studied this response apparently 
does not reflect a likelihood of overall clinical benefit from chronic therapy with ACE 
inhibitors in heart failure (Massie et al, 1984; Packer et al, 1985). Patterns of 
symptomatic response in individual patients appear to be variable and certainly emerge 
over 6-8 weeks of continuous therapy (Packer et al, 1983). Unfortunately many studies 
concentrate on acute short term central haemodynamic changes which have little 
relevance to long term efficacy (Lipkin & Poole Wilson, 1985; Packer, 1988).
Moreover such invasive studies involve well documented placebo changes in pressures 
related to cardiac catherisation and as stated above placebo therapy is rarely documented 
(Massie et al, 1984; Packer et al, 1985; Siemienczuk et al, 1986; Gibbs et al, 1989).
Chronic therapy with ACE inhibitors has been demonstrated in large numbers of 
patients to reduce the morbidity and mortality of chronic cardiac failure. However many 
if not all of these studies incorporate concomitant diuretic and digitalis therapy (Cleland 
et al, 1984,1985; Consensus Study Group, 1987; Giles et al, 1989; Gheorghiade et al, 
1989; Cohn et al,1991; SOLVD,1991,1992a,b). It is clear that beneficial effects produced
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by such combination treatment may not be entirely related to haemodynamic changes. 
Alternatives include amelioration of the chronic electrolyte abnormalities of the 
syndrome (Cleland et al, 1987) or attenuation of primary or secondary neurohormonal 
changes induced by diuretic therapy (Bayliss et al, 1987). These may be a major cause of 
mortality, an important mechanism of action of ACE inhibitors and possibly a reason for 
differences in efficacy among ACE inhibitors (Packer et al, 1986a,1987a,1987b).
The significance of initial hypotensive effects for patients is unclear although 
cerebral and renal hypoperfusion have been documented with transient dysfunction 
(Rajogopalan et al,1984; Mujais et al, 1984). Similarly in many patients with cardiac 
failure secondary to ischaemic cardiomyopathy or coronary artery disease transient 
episodes of significant systemic hypotension might be expected to decompensate 
coronary perfusion and cause silent myocardial ischaemia. There is little definitive 
evidence in this important area although Gibbs et al (1989) found individuals with 
chronic stable angina pectoris who tolerated enalapril therapy poorly when assessed by 
electrocardiographic changes to exercise. Similarly, a retrospective analysis of previously 
published data have also suggested an aggravation of myocardial ischaemia, with 
subjective and objective indices, in heart failure patients who have active chest pain 
during controlled studies of ACE inhibition (Cleland et al,1992). The direct effects of 
ACE inhibitors on coronary perfusion are complex. Whereas some authors have 
suggested a "coronary steal" phenomenon diverting blood away from the ischaemic areas 
(Ertl, 1988) others conclude the opposite (Gasic et al, 1990). In balance the exact role of 
ACE inhibition in the ischaemic myocardium is as yet unclear. It is essential that the 
selected populations who recieve overall benefit should not be confused to the extent that 
ACE inhibition becomes a ubiquitous treatment for "heart disease"!. There is a worrying 
trend towards this assumption in recent published commentary about these drugs.
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CHAPTER 4
CHRONIC HEART FAILURE AND ITS THERAPY
4.1. BACKGROUND AND INTRODUCTION
The characteristic symptoms of cardiac failure are lethargy, limitation of exercise 
capacity, breathlessness on progressively less exertion or at rest, and fluid retention and 
oedema (Poole-Wilson,1988). The exact relationship of the clinical signs and symptoms 
of heart failure to underlying central or peripheral perfusion, primary or secondary 
neurohormonal responses and tissue oxygenation and substrate or electrolyte metabolism 
is unclear (Massie,1988;Editorial,1989). What is abundantly obvious is the relentless 
morbidity and mortality of this sequence of events (Sutton, 1990;Kannel et 
al,1988;Schocken et al,1992). This is manifest as a cycle of episodes of fluid overload 
and pulmonary oedema requiring hospital admission with progressive reduction in 
mobility. Furthermore and possibly of differing origin is the high prevalence of sudden 
cardiac death in this patient group which is often attributed to the presence of life 
threatening arrhythmias (Cleland et al,1987).
Estimates of overall mortality for heart failure are complex as clinical diagnosis is 
fraught with problems despite the simplicity and common nature of the complaint 
(Wheldon et al,1993). Symptoms are relatively non-specific particularly where there is 
coincident pulmonary disease. Clinical signs (Remes et al,1991;Ghali et al,1991) and 
radiological features (Chakko et al,1991) are open to misinterpretation. Aetiology and 
subclassification of predisposing illness are rarely stratified eg sex, diabetes, 
hypertension, cardiomyopathies of varying types, non-stenotic valvular heart disease, 
myocardial ischaemia and/or post myocardial infarction. These may have variable 
outcomes and differing prognoses (Packer, 1988). Despite these caveats and the potential
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for wrong diagnoses and misclassification the mortality of severe heart failure in 
community terms is comparable, and in individual instances greater than, other terminal 
illnesses such as common neoplasms (Kannel,1989).
Somewhat distinct from this group but also relevant in terms of discussing the 
place of ACE inhibitor therapy and ventricular dysfunction are the population of patients 
with minimally symptomatic or asymptomatic cardiac dysfunction evident only during 
quantitative stress testing or non invasive monitoring of cardiac function for example 
using echocardiography (Yusef et al,1990).
Another relatively asymptomatic group of patients who have come under scrutiny 
as a target for ACE inhibitor treatment are those patients with recent myocardial 
infarction who have the "potential" for progressive ventricular dysfunction.
4.2. GENERAL THERAPEUTIC STRATEGIES
All patients with heart failure are managed within a strategy of graded exercise. 
This is somewhat of a reversal of previous general policies of bed rest and exercise 
limitation (Drexler,1992). The change is clearly based on well controlled clinical trials 
published in recent years (Coats et al,1990).
4.3. DRUG TREATMENTS
4.3.1. DIURETICS, FLUID BALANCE AND SODIUM STATUS
General management of the patient with heart failure is primarily based on 
control of fluid balance, in the first instance by combination of dietary sodium and fluid 
intake restriction. All patients with will require the use of diuretic drugs and in the 
majority this will imply the use of more potent loop acting agents in order to achieve 
adequate diuresis and natriuresis. A small proportion will be adequately controlled on 
less potent (in diuretic terms) thiazide agents. In more severe fluid imbalance
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combination therapy may be required using aldosterone antagonists or ultimately both 
thiazide and loop acting drugs together which is a particularly potent natriuretic and 
diuretic regimen (Dargie,1989). It is clear from clinical observational studies that optimal 
fluid balance and diuretic administration can be achieved by simple clinical assessment 
and drug titration in accordance with reproducible and accurate measurement of body 
weight (Anand et al, 1989b). There is general agreement that monotherapy with ACE 
inhibitor drugs is not an adequate treatment, regardless of the degree of myocardial 
dysfunction, in symptomatic patients (Cowley et al,1986;Richardson et al, 1987;Anand et 
al',1990)
4.3.2 VASODILATORS
For the most part vasodilator therapy in heart failure is based on the simple 
relationship between central cardiac filling pressures and cardiac output. With cardiac 
failure of whatever cause the optimal pressure-output relationship at rest and/or during 
exercise is disrupted. In the process of trying to sustain optimal perfusion the 
neurohormonal modulators of cardiac function, peripheral blood flow and autonomic 
tone (such as catecholamines, angiotensin, natriuretic factors, vasopressin etc) generate a 
peripheral vasoconstriction inappropriate for optimal organ perfusion and function. The 
responses initially designed to maintain homeostasis ultimately perpetuate the syndrome 
generating sodium and fluid retention. A variety of vasodilator drugs have been tested in 
attempts to break this cycle. Some act primarily on the arteriolar system, some the 
venous system, some affect both to a variable degree and others have accessory 
properties such as positive inotropic activity (table 4.1.).
Examples of these agents will be considered in turn. In real terms not only 
individual activity is important. Most vasodilators will, in practice, be used with other 
drugs. Heart failure treatment is one of the few areas of clinical therapeutics where
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Table 4.1 Vasodilator therapy for heart failure
A: Arterial vasodilators
(i) a  j adrenoceptor antagonists e.g. prazosin, trimazosin, 
doxazosin
(ii) Calcium channel blocking drugs e.g. dihydropyridines, 
nifedipine etc; diltiazem
(iii) Dopaminergic agents, e.g. dopexamine, ibopamine, 
fenoldopam (SKF 82526)
B: Mixed acting vasodilators
Flosequinan (BTS 49465); hydralazine; pimobendan (UDCG 115 BS)
C: Venous vasodilators
Nitrates; Nicorandil
D: Inotropic drugs with vasodilator activity
Phosphodiesterase III inhibitors: e.g. Milrinone; Enoximone
(MDL 17043); Piroximone (MDL 19205)
Vasodilator drugs have obvious haemodynamic endpoints and in principle are 
expected to alter central cardiac haemodynamics. This is the first activity which tends to 
be documented for new and existing agents to suggest efficacy in heart failure. 
Unfortunately central haemodynamic changes have little relevance to clinical 
symptomsin chronic heart failure patients and do not reliably predict whether these will 
be improved by treatment (Chattergee, 1989; Franciosa et al, 1981). Furthermore, 
haemodynamic studies, although relatively easy to perform in the cardiac catheterisation 
laboratory, are notoriously difficult to interpret. Placebo treatment is frequently omitted 
from studies. The placebo response in heart failure mimics a vasodilator drug 
(Packer,1990a). Supine haemodynamics are less relevant than the response to exercise 
although it is the former which are usually documented. Everyday activities such as 
feeding have well described "vasodilator" effects (Herrlin et al,1990). These are often 
specifically excluded from study and therefore the true response in practice remains 
unknown. The incidence of acute myocardial ischaemia/infarction and the 
decompensation of CCF follows a well described diurnal pattern with a peak onset of 
events during night-time (Muller et al,1989). Effective treatment should cover this 
nocturnal phase yet this is rarely studied with respect to haemodynamic drug responses 
(Giles, 1991). Open, sequential or stepped dose pilot studies in small numbers of patients 
are of limited value but seem to be common relative to double-blind placebo controlled 
designs. This is a particular problem in heart failure (Lipkin et al,1985). Of prime 
importance, although some studies do support the relationship between certain central 
haemodynamic parameters and the length of survival, mortality studies with vasodilator 
treatments are rare with notable exceptions.
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A. Arterial vasodilators
Predominantly arteriolar dilatation has been studied with alpha j antagonists 
(prazosin, trimazosin) calcium channel blocking drugs (dihydropyridine drugs, eg, 
nimodipine, nifedipine etc or diltiazem) or prostacyclin analogues. Studies largely 
document the effects of acute treatment on reducing cardiac filling pressures specifically 
right atrial pressure, pulmonary capillary wedge pressure and reductions in calculated 
systemic vascular resistance and arterial pressure. These studies are relevant to the 
management of acute heart failure, for example, during acute myocardial infarction. In 
chronic cardiac failure persistent haemodynamic effects have not always been evident. 
This is particularly relevant to alpha blockade (Bayliss et al,1985; Kirlin et al,1985). 
Prostacyclin derivatives, with no oral bioavailability, have not been tested on repeated 
administration.
The use of calcium channel blocking drugs in chronic heart failure has been 
described as a matter of concern (Editorial, 1991; Packer,1990b). Although persistent 
changes in haemodynamic parameters can be documented in some studies, the failure of 
these drugs to increase exercise tolerance in small randomised, double-blind studies (Tan 
et al,1987) and evidence of clinical deterioration with increased hospital admission 
during treatment (Dunselman et al,1990; Jezek et al,1990) has led to a reappraisal of their 
value. Diltiazem shares these deleterious effects (Goldstein et al,1991). There is little to 
distinguish any calcium antagonist suggested to have less negative inotropic properties. 
Despite these results conflicting reports based on the haemodynamic efficacy of calcium 
antagonists in heart failure continue to occur (Reicher-Reiss & Barasch,1991; Thomas et 
al,1989).
Drugs acting to stimulate arterial vasodilatation through vascular dopamine 
receptors have been studied in heart failure. These agents have complicated dose and 
concentration dependent pharmacology and some such as ibopamine also act as alpha j
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and beta2 adrenoceptor agonists (Marchetti,1990). The most frequently studied agent in 
this class is ibopamine. Evidence of clinical efficacy with this group of agents is limited 
to demonstrations of vasodilatation on central haemodynamic studies. However, there 
are studies which show a symptomatic improvement with ibopamine (Barbino et al,1991) 
based on clinical assessment of heart failure. Diuretic effects of this group of drugs have 
been highlighted as an additional beneficial property. The diuresis is at best modest 
(Baumann et al,1990; Wehling et al,1990) and quantitatively unlikely to be relevant to 
the management of heart failure. As with some other drugs even in acute studies partial 
haemodynamic tolerance has been shown to occur during fenoldopam infusion within 24 
hours (Munger et al,1990).
B. "Balanced" vasodilators
Mixed arterial and venous dilatation is produced by a variety of drugs dependent 
on dosage. The most recent agent studied with this predominant mode of action is 
flosequinan. This has the characteristic haemodynamic profile (Reigger et al,1990; 
Markus & Cowley, 1991) and has been suggested to improve exercise parameters (Silke 
et al,1992, Elbom et al,1990). It is felt that the venous dilatation is relevant to the mode 
of action of this drug and a degree of positive inotropic activity is also suspected (Corin 
et al,1991). The place of this drug in treatment is unclear but early studies based on 
improved exercise capacity are promising.
C. Venous "offloading"
Oral nitrate therapy has long been a part of heart failure treatment. For the most 
part this is felt to act by venous dilatation and reduced right heart pressure. However, it 
has become apparent that high doses of nitrates are required in the treatment of heart 
failure and selective venodilatation is unlikely to be relevant (Cohn,1985). Tolerance to
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haemodynamic effects is readily produced unless a nitrate free interval is present (Sharpe 
et al,1987; Elkayam et al,1991; Jordan et al,1985) although there is some interesting if 
flawed evidence that combinations of nitrovasodilators and ACE inhibitors might 
ameliorate this problem (Katz et al,1991;Mehra et al,1992). Alternative routes of 
administration such as transdermal preparations (Jordan et al,1985) or different structures 
such as nicorandil (Galie et al,1990) probably have little to offer over oral nitrate. A 
recent study employing seven day therapy with a range of ACE inhibitors in normal 
volunteers using forearm venous plethysmography to assess the response to a low dose 
transdermal nitrate patch has suggested that nitrate tolerance might be avoided with this 
combination (Katz et al,1991). With the established role of ACE inhibitors in treatment 
this finding merits further study in heart failure. Fluid imbalance or sub-optimal diuretic 
therapy may also be a factor in nitrate tolerance in heart failure (Varriale et al,1991).
D. Vasodilator drugs with inotropic properties
A final group of agents with a component of vasodilator activity in addition to 
more direct positive inotropic properties has been extensively studied in heart failure. 
Based largely on favourable changes in the acute haemodynamic profile, a series of 
orally active, selective, inhibitors of phosphodiesterase III; eg enoximone, milrinone and 
piroximone, have been developed. Despite the favourable changes recorded in cardiac 
pressures, even in the early stages of clinical study, concern was expressed about a lack 
of symptomatic benefit and increased prevalence of arrhythmias in treated patients 
(Rubin et al,1985). Well designed studies have failed to document changes in exercise 
capacity and have confirmed an increase in mortality on longer term treatment with these 
drugs (Uretsky et al,1990; Packer et al,1991). Although this class of treatment appears to 
have little future in population terms for the management of chronic heart failure they 
may still prove useful in acute heart failure and exceptionally in individual patients in the
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longer term (Chattergee,1989).
E. Vasodilators and mortality in heart failure
Due to the undoubted need for combinations of drugs in the treatment of heart 
failure it is interesting to note that the best evidence for symptomatic efficacy and 
reduced mortality through vasodilator therapy comes from a combination regimen. The 
two multicentre Veterans Administration Cooperative studies examined large numbers of 
patients receiving hydralazine (300 mg/day) and isosorbide dinitrate (160mg/day) in a 
double blind randomised study compared to prazosin or placebo in the first study (Cohn 
et al,1986) or to the ACE inhibitor, enalapril, in the second study (Cohn et al,1991). 
Although of borderline statistical significance (not significant statistically speaking but 
regarded as clinically significant), the first study showed a reduction in mortality (%) 
with hydralazine/ISDN (25.6) compared to placebo (34.3) or prazosin (34.1) at 2 years. 
Although the second study revealed significantly greater benefits in terms of reduced 
mortality for the patients receiving the ACE inhibitor enalapril over the vasodilator 
combination, it was felt that the pattern of mortality differed between the treatments. The 
incidence of sudden death was particularly affected by enalapril and the combination of 
vasodilator treatment with ACEI treatment could provide a greater mortality reduction. 
The success of the hydralazine/isosorbide dinitrate therapy in both Veterans 
Administration studies is clear. It appears to be dose dependent for both agents and the 
role each of each component in the overall response remains unclear (Remme,1989).
F. Development areas of vasodilator therapy
The scope for further improvements in the response and use of vasodilator 
treatments in heart failure is considerable. Although many invasive studies of acute 
pressure changes in small numbers of patients do not seem to reliably identify those
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treatments which will have an impact on symptoms and mortality, they do indicate drugs 
which should prove efficacious at least in acute heart failure. Furthermore on an 
individual patient basis the pattern of aetiology of heart failure, long neglected as a 
prognostic or therapeutic indicator, may be employed with haemodynamic response in 
attempts to select sub-populations who will benefit from treatments at least on a 
symptomatic basis. What needs to be used in combination with this are simple methods 
for controlled assessment of response which are readily applied to individual subjects 
(Guyatt et al,1986). As the Veterans Administration Heart Failure investigators suggest 
the future undoubtedly revolves around developing better combinations of vasodilators, 
exploring the efficacy of high dose nitrates and hydralazine and the power of 
combinations involving other vasodilators, diuretics, digoxin, ACE inhibition and 
antiarrhythmic drugs.
4.3.3 ACE INHIBITION IN HEART FAILURE
The theoretical basis for the use of angiotensin converting enzyme inhibitors 
(ACEI) in the management of congestive cardiac failure is blockade of the 
neuroendocrine activation which accompanies heart failure and in response to the 
management of fluid overload with diuretic drugs (Packer, 1988). The primary effector 
peptide of the renin angiotensin system (RAS), Angiotensin n  (AngH), has detrimental 
effects on cardiac structure (Tan et al,1991; Pfeffer et al,1991), perfusion (Ertl,1988) and 
overall function (Moclrzuki et al,1992). There are additional deleterious effects on renal 
function, overall electrolyte balance and peripheral skeletal muscle perfusion. Ultimately 
the neurohormonal reflexes, primarily those involving the renin angiotensin system but 
with important contributions from the sympathetic nervous system (Francis, 1989) and 
other humoral factors such as natriuretic peptides (Uretsky et al,1990) ,initially designed 
to maintain peripheral organ perfusion, become deleterious (Packer,1992).
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Blockade of the renin angiotensin system by ACE inhibitors has been shown 
unequivocally to have beneficial effects on the key end points in heart failure. These are 
overall patient mortality, whether related to decompensation of heart failure to a terminal 
state of fluid imbalance and organ failure or sudden cardiac death (CONSENSUS Trial 
Study Group, 1987;SOLVD investigators, 1991;1992). In addition frequency of hospital 
admission, an excellent indicator of impact on morbidity and general quality of life, is 
also significantly reduced in real terms by ACE inhibitor therapy (Cohn et al,1991). 
Although exercise capacity and the related parameters of oxygenation, symptoms of 
dyspnoea, or heart failure classification are very difficult parameters to stratify and 
interpret in controlled therapeutic trials (Poole-Wilson, 1989) in general terms there is a 
considerable body of data to attest to the efficacy of ACE inhibitor therapy on such 
"symptom based" parameters in patients with heart failure (Cleland et al,1984;Creager et 
al,1985). With this data available drug treatment of individual patients should include an 
ACE inhibitor as a cornerstone of treatment along with diuretic therapy 
(Braunwald, 1991 ;Editorial, 1992).
4.4 PHARMACOLOGY OF ACE INHIBITION IN HEART FAILURE: THE 
EXAMPLE OF PERINDOPRIL
4.4.1. Experimental studies - general principles
In experimental animals the syndrome of heart failure is simulated by a variety of 
techniques. Either volume or fluid overload of the heart can be created by a variety of 
surgical techniques eg, aortic or pulmonary banding or ligation, or valve rupture. Failure 
of the ventricles can be induced by a variety of pacing techniques (Dibner-Dunlap & 
Thames, 1990). Direct injury to cardiac muscle can be created eg by cryo-injury (Lefer et 
al, 1986),ligation of coronary arteries (Howes et al,1991) or microsphere occlusion of
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coronary arteries (Gorodetskaya et al,1990). A toxic cardiomyopathy can be induced by a 
variety of agents, the most commonly used being the cytotoxic antibiotic, doxorubicin 
(Amolda et al,1985;Wanless et al,1987). A range of genetically based cardiomyopathies 
are available (Hirakata et al,1990; Haleen et al,1991). Although each of these models has 
its own limitations (Smith & Nuttall,1985) in general low output models with a chronic 
course which generate the appropriate neurohormonal responses to those seen in man are 
preferred. Pharmacological treatments can be employed in an attempt to mimic the 
autonomic dysfunction common in heart failure (Hof et al,1992). In the main the animals 
studies do not receive any additional therapy such as diuretic drugs which are intrinsic to 
the management of human heart failure. Such models have been used to characterise the 
pharmacology of perindopril and perindoprilat.
4.4.2. Hormonal effects
Experimental studies have shown that the renin angiotensin system is an essential 
component to the response to heart failure resulting in a peripheral vasoconstriction 
affecting perfusion of the kidneys and skeletal muscle beds. The former responds by 
initiating fluid and sodium retention (Anand et al,1989) and the latter may be involved in 
the generation of further reductions in exercise capacity typical of heart failure (Myers & 
Froelicher,1991). Perindopril has been shown to effectively provide blockade of the 
renin angiotensin system resulting in ACE inhibition, reactive elevation in renin, 
reduction in infarction related rises in natriuretic factor but little effect on plasma 
aldosterone (Michel et al,1988).
Experimental myocardial infarction and heart failure are associated with 
activation of the sympathetic nervous system at a variety of levels primarily due to 
increased secretion and occurring in association with receptor down regulation (Abraham 
et al,1990;Bristow et al,1989). Activity of the sympathetic nervous system as portrayed
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in elevated serum catecholamines has been defined as a sensitive indicator of poor 
prognosis in heart failure (Cohn et al,1984). In experimental animals Howes and co­
workers demonstrated that perindopril treatment whether introduced early or late after 
experimental infarction produced complete attenuation of infarction related augmentation 
in sympathetic activity as indicated by the ratio of dihydroxyphenylethylene glycol to 
noradrenaline (Howes et al, 1991).
4.4.3. Vascular structure
The effect of perindopril in reversing the vasculopathy associated with 
experimental hypertension has been documented in detail (Levy et al,1991). Altered 
vascular structure and reactivity are features of the response to heart failure and deficits 
in blood flow during exercise may at least play a partial role in the generation of fatigue 
in heart failure patients (Drexler et al,1988). It is clear that altered muscle structure and 
metabolism are common in heart failure and these effects may interact with flow 
abnormalities or even dominate the peripheral generation of symptoms (Arnold et 
al,1990;Buller et al,1991; Massie et al,1987)
4.4.4. Cardiac hypertrophy/infarction and remodelling
During all its clinical phases from the asymptomatic stage through to terminal 
pump failure the myocardium during heart failure undergoes a complex process of 
adaptation. This involves concurrent thinning, regional dilatation and expansion and 
compensatory hypertrophy of the ventricular walls, altered myocardial structure and 
composition (Swynghedauw,1989; Pfeffer et al,1991). The renin angiotensin system is at 
least a major element, if not the major element controlling these responses to myocardial 
damage and/or heart failure (Katz, 1990;Weber et al,1992).
As has been recorded for other ACE inhibitors perindopril effectively blocks or
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reverses the process of ventricular dilatation and increased heart size following 
experimental myocardial infarction (Howes et al,1991). Sensitive studies by Michel and 
colleagues demonstrated a trend towards normalisation of the ventricular myosin 
isoenzyme profile and collagen content following experimental infarction in rats treated 
with perindopril (Michel et al,1988).
Electrophysiological abnormalities are common in all patients with heart failure 
and sudden cardiac death, often attributed to the onset of a lethal arrhythmia, is a 
common mode of death for patients with this disease (Cleland et al,1987). Experimental 
models have been employed to examine this aspect of heart failure pathology only 
infrequently (Doherty & Cobbe,1990). Thollon and colleagues (1989) examined the 
effect of perindopril therapy on the electrophysiological consequences of myocardial 
infarction. They observed increased action potential lengthening in association with 
cardiac remodelling after infarction. Perindopril therapy prevented the development of 
cardiomegaly and attenuated the increase in action potential duration significantly. Direct 
effects of perindoprilat on the inward calcium current of isolated porcine ventricular 
myocytes has also been demonstrated which acts to inhibit the action of noradrenaline 
(Enous et al,1992). These findings suggest potential anti-arrhythmic effects of 
perindopril treatment relevant to heart failure. A small acute study in a peri-infarction 
model in pigs failed to demonstrate significant abnormalities despite a significant 
reduction in mortality in the perindopril treated group (Tobe et al,1992)
4.4.5. Tissue renin angiotensin systems
Although human heart failure is widely regarded as being accompanied by an 
activation of the renin angiotensin system much confusion is caused by the concurrent 
use of diuretic therapy. In untreated heart failure there may only be small elevation in 
circulating renin in keeping with the increased intravascular fluid volume (Anand et
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al,1989). However in experimental models of low output heart failure activation is 
demonstrable at the level of the tissue based system (Hirsch et al,1991,1992; Schkunert 
et al,1990;Fabris et al,1990). In addition it is clear that other non converting enzyme 
dependent pathways for the local generation of Angll are also activated in heart failure 
(Urata et al,1990).
4.4.6. Mortality
Clearly one of the most significant levels of efficacy in heart failure treatment 
must be the effect on mortality. Experimental studies in rats treated with captopril after 
myocardial infarction clearly show reductions in long term mortality with ACE inhibitor 
treatment (Pfeffer et al,1985). Short term studies with perindopril in similar models of 
left ventricular infarction in rats show no appreciable difference between sham operated 
placebo treated controls and perindopril (Michel et al,1988). This is largely due to the 
duration of study than any real suggestion of anything other than a class related activity. 
In longer term studies with a similar long acting ACE inhibitor, quinapril, hamsters with 
a genetic cardiomyopathy showed a decreased mortality compared to placebo controls 
(Haleen et al,1991). Similar results have been documented with enalapril (Sweet et 
al,1987). A relatively small study examining the effect of intravenous perindoprilat 
(0.06mg/kg) on experimental myocardial infarction in pigs showed a significant 
reduction in the death rate 7 of 12 controls compared with 2 of 12 treated animals over 
the 2 weeks following coronary occlusion (Tobe et al,1992).
In the context of experimental studies the reasons given for the observed 
reductions in mortality tend to focus on myocardial changes. Altered myocardial 
structure is often cited as a major factor. Specifically the reduction in myocardial fibrosis 
following infarction demonstrated clearly by Michel and colleagues (1988) using 
perindopril is felt to be a central element in the concept of "cardioprotection" manifest as
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improved cardiac haemodynamics and coronary perfusion, attenuated progression of 
myocardial failure and inhibition of acute events such as the tendency towards 
arrhythmia and sudden cardiac death (Gavras & Gavras,1991). While theoretically 
appealing the concept originates in animal observations and the treatments employed do 
not always mimic the clinical situation (McMurray et al,1991). This remains an exciting 
area for further definition of the mechanism of action of ACE inhibitor treatment. 
Experimental studies tend to examine the contribution of one of the above mechanisms in 
isolation and tend not to give an integrated answer to the mechanism of action in man.
4.5. CLINICAL STUDIES
4.5.1 PHARMACOKINETICS
A. GENERAL
It is important to remember that the duration of action of ACE inhibitors has 
important functional implications. The incidence of a variety of cardiovascular 
emergencies follows a well described periodicity. The majority of events, and this 
includes the onset of acute cardiac decompensation, peak in the late evening or early 
hours of the morning (Cugini et al,1990;Muller et al,1989). This has important 
implications for drug therapy and it is a notable omission that many heart failure 
treatments are not studied for efficacy at the peak hours of onset of the disease, namely in 
the middle of the night (Giles,1990). This has recently been a focus of attention in the 
description of the efficacy of anti-hypertensive drugs .
The pharmacokinetics of perindopril in heart failure are affected by some simple 
principles applicable to most drugs used in this condition (Table 4.2).
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Table 4.2: General effects of heart failure on the pharmacokinetics of cardiovascular
drugs
ABSORPTION
FIRST PASS METABOLISM
VOLUME OF DISTRIBUTION 
ELIMINATION
reduced blood flow to gut and muscle
reduced hepatic blood flow
reduced hepatic metabolism
interstitial fluid accumulation (little impact)
interaction with alterations in volume of
distribution, associated renal/hepatic dysfunction
moderate to severe heart failure, continued on their normal diuretic regimen but off 
vasodilators for 48 hours, the time to peak perindopril concentration (2 hours) was only 
slightly prolonged compared with that expected in healthy age matched controls 
receiving a single 4mg oral dose. This was thought to be due to a delay in drug 
absorption. The peak plasma concentration of perindopril was higher (112.6±12.7ng/ml) 
and apparent half life (3.54±0.46hr) prolonged. Perindoprilat appearance was delayed 
(8.22±0.85hr) as was ACE inhibition in plasma. Calculated elimination constants are 
similar to healthy controls but their definition hinges largely on the sensitivity of the 
assay system employed. The peak plasma ACE inhibition remained unaltered.
B. AGE
People who have heart failure are in the main elderly. The condition has a high 
prevalence in those above the age of 65 years. It is responsible for nearly 10% of all 
acute hospital admissions in this age group (McMurray & McDevitt,1990). Elderly 
patients may be particularly susceptible to the haemodynamic effects of these drugs 
(Reid, 1987). Considering age alone there is clear evidence of reductions in the clearance 
of perindopril. Lees and colleagues showed that the mean AUC for a single oral dose of 
8mg perindopril was increased from 119.7 ng/ml/hr to 295.3 ng/ml/hr comparing young 
and elderly normal volunteers. This may be related to a reduction in renal clearance of 
perindoprilat but the relationship is not direct. This is similar to the findings for other 
prodrug ACE inhibitors (Hockings et al,1986).
Gilgenkrantz and Flammang (1987) studied 33 heart failure patients (35-77 years) 
over three months perindopril therapy in the dose range from l-4mg once daily. Model 
independent pharmacokinetic parameters increased in a dose related manner both for 
perindopril and perindoprilat (see table 4.3).
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Table 4.3: Pharmacokinetics of perindpril in heart failure patients, data on file from 
study PKH 07.02, Gilgenkrantz and Flammang,1991; Servier Europe Courbevoie, 
France.
Population tm ax Cmax AUC t* ,2
<h) (ng.ml-1) (ng.m l-l.h) (h)
Heart failure 1.85 ± 0.39 112.55 ± 12.67 577.01 ± 111.46 3.54 ± 0.46
patients (0.5 -  4.0) (28.7 -  172.1) 93.3 > 1261.9) (1.3 -  6.0)
(n=  10)
Healthy subjects 1.0** 73.27* 168.90* 0.89*
(0.5 /  3.0) 19.74 /  126.79 (38.77 /  298.94) (0.31 /  1.47)
(n = 66) (n = 66) (n = 66) (n = 54)
* mean (95% confidence limits) 
median (extreme experimental values)
three month treatment interval. The increment in perindoprilat AUC of approximately 1.5 
is typical of that seen with other ACE inhibitors and heart failure does not significantly 
alter this phenomenon in comparison to normal individuals or patients with hypertension.
Reduction in the total body clearance of perindopril and perindoprilat occurs in 
elderly patients with heart failure as seen by the higher plasma concentrations again in 
comparison to reference data from normal volunteers or patients with hypertension.
C. RENAL IMPAIRMENT
Renal responses are central to the development of heart failure. Through a variety 
of mechanisms renal impairment is a common feature of many patients (Ritz & 
Fliser,1991;Naschitz et al,1990). As the major route of elimination of perindopril is by 
metabolism, largely hepatic, and that of perindoprilat is excretion by the kidneys as 
expected renal impairment affects the pharmacokinetics of perindoprilat rather than 
perindopril. In stable chronic renal impairment there is a direct positive correlation 
between cumulative clearance of perindoprilat and creatinine (Verpooten et 
al,1991;Sennesael et al,1992; see figure 4.1).
This results in elevation of maximal plasma perindoprilat concentrations and 
AUC in proportion to the degree of renal impairment. Terminal elimination half life, 
which reflects in part distribution of the drug to tissue compartments (Lees et al,1989), is 
unaltered by renal failure. Proportionally a reduction in perindopril dosage is required 
where renal function is impaired.
D. HEPATIC IMPAIRMENT
Liver dysfunction is a feature of heart failure. In the majority of instances this is a 
reflection of hepatic congestion which can be in part corrected by appropriate diuretic
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Figure 4.2 The relationship between cumulative renal clearance of perindoprilat 
(CL^and creatinine clearance (CL^r) (data from Sennesael et al,1992)
unclear. The de-esterification of prodrug ACE inhibitors is a diffuse process occurring in 
a variety of sites. However the majority of this step is conducted in the liver (Larmour et 
al,1985). Studies by Tsai (Tsai et al,1989) and Thiollet (Thiollet et al, 1992) have 
examined clearance of perindopril and its metabolites in patients with established 
cirrhosis. Both these investigators suggested increases in the AUC for perindopril, 
roughly doubled (eg 602 ± 294 ng/ml/hr vs 266 ± 70 ng/ml/hr), but similar values for 
perindoprilat (eg 134 ± 139 ng/ml/hr vs 120 ± 29 ng/ml/hr) to those found in normal 
volunteers (Devissaguet et al,1990).
On the assumption that perindoprilat is the entity which generates the metabolic 
effects of treatment it was concluded that no dosage alteration was necessary. Similar 
observations have been made using other prodrug ACE inhibitors (Ohnishi et al,1989). 
Comparable studies are not available in heart failure but liver dysfunction per se does not 
appear to pose specific risks of drug accumulation requiring alterations in daily dose.
E. FOOD
Food has an important effect on drug bioavailability. In the context of heart 
failure responses and ACE inhibitor drugs this is doubly important as a meal will in 
addition have independent effects on blood pressure. The haemodynamic effects 
resemble the effect of vasodilator drug treatment and effectively enhance or overestimate 
the effects of ACE inhibitor treatment (Herrlin et al,1990).
Generally the bioavailability of captopril and its haemodynamic effect are 
reduced and delayed respectively by concommitant food (Singhvi et al,1982;Mantyla et 
al,1984). This does not appear to be relevant to longer acting drugs such as enalapril 
(Swanson et al,1984). In twelve healthy volunteers Lecocq and colleagues (1990) found 
reductions in the bioavailability of perindoprilat and its fractional urinary excretion 
associated with reductions in the metabolism of perindopril to perindoprilat. Perindopril
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disposition was unaltered in this single dose study in which 4mg perindopril was studied. 
Plasma ACE activity was affected by the altered perindoprilat profile (Table 4.4).
The reduced interconversion of perindopril to perindoprilat was not due to altered 
total absorption as total urinary excretion remained unaltered.
4.5.2 PHARMACODYNAMICS
A. Hormonal effects
The effects of heart failure on the renin angiotensin system alone are difficult to 
address. In most instances patient studies are complicated by concurrent treatments 
which directly or indirectly affect the system. The most common example is diuretic 
therapy (Bayliss et al,1986), but any vasodilator treatment will also activate the renin 
angiotensin system (Dcig et al,1992). Rare studies in untreated severe heart failure 
indicate elevated renin activity but on a variable and unpredictable basis (Anand et 
al,1990). With the technical limitations of most common renin activity measurements 
this probably underestimates the extent of the elevation of renin in these circumstances 
(Plouin et al,1990).
Induction of the renin angiotensin system in human heart failure has been 
suggested to occur on chronic treatment with ACE inhibitors in man (O’Neill et al,1992). 
This may relate to the disease process per se in addition to being an effect of the drug 
treatment itself. In general the blockade of the renin angiotensin system is felt to be 
central to the efficacy of the drugs despite their non specific profile. The direct 
relationship to beneficial effects on symptoms or in reducing mortality is not yet clear. In 
the same respect the optimal dosage employed within the range of drugs available is also 
unclear both in terms of symptomatic relief and reducing mortality.
In an open study of 10 patients with moderate(5) and severe(5) heart failure
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Table 4.4.: Pharmacokinetic parameters of perindoprilat following oral perindopril 
(4mg) in the fasted and fed states (data from Lecocq et al,1990).
F a s t e d F e d  p  V a l u e
Cr^ x (ng • ml"') 4.7 ±  1.6 3.6 ± 1 . 5  NS
t™, (hr) 3.6 ±  2.2 3.9 ±  2.5 NS
AUC(O-t) 52 ±  22 29 ±  17 p  <  0.05
(ng • hr • ml*')
tv2 10.9(8.3-31.1)* 12.0-14.2** —
F, (% dose) 19 ±  7 13 ±  4 p  <  0.01
CLr (ml • min-1) 171 ±  70 177 ±  70 NS
Relative amount of biotransforma­ 0.65 ±  0.42tion (AUCfed/AUCfaMed)
•Median (range); n =  6** range; n ~  2.
Data are mean values ±  SD.
C rux. Peak serum concentration; tm,,. time to reach maximum concentration; 
AUC(O-t), area under the serum concentration-versus-time curve; tv2, half-life; 
Ft , fractional urinary excretion; CL*, renal clearance; NS, not significant.
significantly greater and more prolonged than that observed in healthy normal volunteers 
Thuillez and colleagues (1990) showed that a single dose of perindopril 4mg, after 24hr 
diuretic withdrawal in sodium restricted state, produced approximately 70% inhibition of 
plasma ACE (Figure 4.2). There was an associated rise in plasma renin and fall in 
aldosterone (Lees & Reid 1987a,b). In summary Perindopril produces rapid onset of dose 
dependent inhibition of plasma ACE of a protracted nature with appropriate changes in 
renin and aldosterone (Table 4.5).
B. Cardiac Haemodynamics
Central cardiac haemodynamic studies are conducted in order to define the initial 
status of agents used in the treatment of heart failure. They serve as indicators of 
compounds which are likely to prove valuable in the management of acute heart failure 
through beneficial alterations in the Frank-Starling relationship defining cardiac output in 
relation to initial LVEDP and cardiac work. They may be valuable in the selection of 
therapy for individual patients with severe heart failure who have a poor prognosis 
despite multiple therapies (Chatteijee, 1989;Uretsky & Hua,1991).
Such studies are not efficient predictors of individual symptomatic responses to 
long term therapy in chronic heart failure. Some significance has been attributed to the 
pulmonary vascular response as a therapeutic predictor of response to long term ACE 
inhibitor therapy in individual patients (Packer et al,1985). This is surprising given the 
known resistance of the pulmonary circulation to the haemodynamic effects of Angll (de 
Bono et al,1966). Patients may have acute responses compatible with haemodynamic 
improvements which are either not sustained on chronic therapy or are not translated to 
functional benefits in terms of exercise studies.
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Figure 4.2: Effects of oral perindopril (4mg) on plasma converting enzyme activity 
(PCEA), renin activity (PRA) and aldosterone (PA) in heart failure patients (data from 
Thuillez et al,1990)
Table 4.5: Inhibition of ACE following acute and chronic dosing with perindopril in 
a range of unpublished reports in heart failure patients (data on file from expert 
report, Dargie,1990)
ACE
inhibition
CP 04.04 
acute
CP 04.01 
acute
CP04.02 
acute 
2 m g
(n m 12)
CP04.03 
acute 
4 m g
(n »  10)
CP04.G5/2 
chronic 
4 m g
(n =  11)
PKH 06.02 
chronic 
4 m g
(n *  12)
1 m g
(n *  11)
2 m g
( n ~ S )
2 m g  
(n ** 6)
4 m g
(n ~ 6 )
Peak
inhibition
4 4 %  
at 4 h
7 1 %  
at 12 h
53%
at6ir
79% 
at 6 h
63% 
at 12 h
72% 
at 12 h
86% 
at 4 h
89% 
at 5 h
Inhibition 
at 24 h
34% 59% 50% 59% 45% 56% 57% 67%
heart cardiac catheterisation with pressure monitoring and cardiac output determinations 
by thermodilution techniques. None of these studies has a placebo control. Interpretation 
is therefore difficult in the light of a well characterised placebo effect of instrumentation 
(Packer, 1990), spontaneous improvements in cardiac function (Francis et al,1990), and 
diurnal variation in the haemodynamic aspects of the disease (Caruana et al,1988) and 
the response to treatment. However changes can be described with respect to baseline 
values.
Thuillez and colleagues (1990) demonstrated a significant and long lasting fall in 
systemic vascular resistance (-18%), right atrial pressure (-60%), and mean capillary 
wedge pressure (-28%) following perindopril 4mg in 10 patients with moderate to severe 
heart failure. There was an associated rise in cardiac index (+12%). Anguenot and 
colleagues (1987) saw delayed falls in systemic vascular resistance and mean pulmonary 
artery pressure at 24hrs compared to 12hrs in 14 patients with severe refractory heart 
failure. These are in keeping with the expected profile of vasodilatation expected to 
occur with acute ACE inhibition.
C. Regional blood flow
Thuillez and colleagues (1990) in their invasive study also observed the regional 
vascular responses to perindopril in heart failure patients. The regional sensitivity of the 
circulation to Angll is well described (Motwani and Struthers,1992). ACE inhibition 
because it affects systems other than Angll generation would be expected to produce a 
pattern slightly different from simple Angll withdrawal and would be modified by the 
disease process itself.
Thuillez found that in addition to the central haemodynamic changes described 
above there was a marked increase in brachial (+130%) and renal (+34%) blood flow. 
The falls in forearm and renal vascular resistance appeared to be related to the basal
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circulating plasma noradrenaline concentrations rather than renin. As expected the 
vasodilatation was inhomogeneous in different vascular beds. In keeping with the 
insensitivity of the pulmonary circulation pulmonary arterial resistance was virtually 
unaltered.
These alterations in regional blood flow may be important in determining the 
beneficial effects of treatment on exercise symptoms originating in the poorly perfused 
skeletal muscle vascular beds (Cohen-Solal,1989). There appears to be a gradual increase 
in' skeletal muscle flow with long term ACE inhibition (Drexler et al,1988;Drexler,1992). 
Although there is not a marked initial increase in flow the key element may be intra 
muscular redistribution of flow mediated by the blockade of the localised renin 
angiotensin system.
D. Blood pressure and first dose response
Where there is felt to be activation of the renin angiotensin system and a 
circulation dependent on Angll pressor tone, acute ACE inhibition has occasionally been 
associated with marked and symptomatic falls in blood pressure. The nature of this 
phenomenon is unclear but most individuals assume a direct relationship with the 
circulating or localised contribution of Angll to vascular tone. Concern has arisen as to 
the functional significance of such falls in blood pressure in heart failure patients where 
there is frequently concurrent renovascular, cerebrovascular or coronary vascular disease. 
Attention has been focused by anecdotal case reports (Cleland et al,1985;Lantz et 
al,1988;La Barre et al,1982) and small series of patients where detrimental effects 
particularly on renal function have been documented in renovascular hypertension and 
heart failure (Hodsman et al,1983;Mujais et al,1984). The incidence of the problem and 
its overall clinical importance in the light of the potential benefits of ACE inhibitor 
therapy (Editorial, 1992) are unclear and controlled studies are lacking. The phenomenon
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is seen with many cardiovascular agents (Semple et al,1988) or placebo and may 
represent effects on arterial, venous tone and autonomic function (Capewell & 
Capewell,1991).
The lack of initial haemodynamic response does not, as expected (Massie et 
al,1984) have implications for beneficial increases in exercise tolerance (see section 
4.2.5). Longer term therapy with 2 or 4mg perindopril once daily was similarly not 
associated with significant falls in blood pressure (Bounhoure et al,1989). For this drug 
at least symptomatic improvement can occur without overt reductions in mean arterial 
pressure. This is, at present, a unique feature among the ACE inhibitors available for the 
treatment of heart failure.
E. Exercise Capacity
This is one of the key areas of documenting the beneficial effects of drug 
treatment in heart failure. This appears to have little to do with the acute effects of drugs 
on blood pressure or cardiac haemodynamics (Packer et al,1985;Massie et al,1984). Like 
haemodynamic studies placebo control, training effects and structured assessment are 
essential (Lipkin & Poole-Wilson,1985).
Kirlin and colleagues (Kirlin et al,1988) have suggested that the hormonal effects 
of ACE inhibitor drugs are affected by exercise. They found that a dose dependency was 
evident only following exercise which was not evident at rest. In their study the focus 
was concentrated around the short duration of effects on hormones found with the short 
acting drug captopril and the long acting drug, lisinopril. The authors conclude that full 
blockade of the system was important and that this may not always occur during exercise 
on chronic dosing despite similar resting levels of inhibition. Using hormonal responses 
(reactive rise in renin or falls in aldosterone) this was not achieved adequately. Although 
lisinopril is not a prodrug the profile of inhibition seen with perindopril most closely
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resembles this pattern.
Bounhoure and colleagues studied the effects of perindopril treatment (2 or 4mg 
daily) or matched placebo in a double blind parallel group design on clinical symptoms 
and exercise parameters (Bounhoure et al,1989). Patients received three months therapy. 
Little change was noted in blood pressure or heart rate. Placebo treatment was associated 
with initial reductions in symptom scores, NYHA classification and exercise time at 1 
month. This is a common feature of most controlled studies, but as expected this was not 
sustained at the three month assessment. In contrast perindopril treatment produced 
significantly greater and sustained improvement in all these parameters at both 1 and 
three months of active treatment (Table 4.6). In addition there was also a small but 
statistically significant fall in cardiac size as reflected in cardiothoracic ratio. These 
results are in keeping with the emergence of efficacy in the 6-8weeks following the 
initiation of ACE inhibitor treatment (Massie et al, 1984,Packer et al,1983)
It is clear that the dose of perindopril appropriate for the management of heart 
failure (2-4mg daily) is below that normally employed in the management of 
hypertension with this agent (Lees et al,1989).
4.6 SAFETY AND TOLERABELITY
Perindopril has been studied during long term treatment in relatively small 
numbers of heart failure patients in order to observe its record of safety and tolerability. 
In controlled studies there have been no major reports of significant biochemical or 
haematological adverse events. In particular there were no significant changes in 
biochemical indices of renal function although as expected a small but statistically 
significant rise in serum potassium can be documented.
Treatment withdrawal from controlled studies as expected shows a significant 
incidence of death and progression of heart failure (Table 4.7). Matched placebo data are
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Table 4.6: Exercise response to oral perindopril table 5 study C 04.01/2
Before
treatment
After 3 months 
treatment
Excercise test duration (sec)
Bicvcle -  placebo (n =  36) 563.6 (25.9 ) 594.4 (33.8 )
-  perindopril (n =  36) 493.8 (23.6) 619.4 (28.2 )
Treadmill- placebo (n =  16) 530.3 (49.4 ) 544.7 ( 70.4 )
-  perindopril (n =  18) 597.6 (50.0) 778.4 (60.1)
NYHA class
-  placebo (n =  56) II = 38 I = 9
III = 18 II = 32
III = 12
IV = 3
-  perindopril (n = 56) II = 30 I = 12
III = 26 II = 37
III = 7
IV = 0
Heart failure score
-  placebo (n =  55) 4.5 (0.3) 3.7 (0.4 )
-  perindopril (n =  56) 5.5 (0 .4) 2.4 (0.3 )
Table 4.7: Summary of treatment withdrawals in heart failure patients during a range of 
clinical trials of oral perindopril therapy (data on file from Dargie,1990).
Study 
C 04.01/2 Study 
C 04.02 
(n  — 3 2 0 )
Study 
CP 04.05/2 
( n  « 15)
Study 
PKH 06.02
(n  m  1 2 )S 9490
(n  - 6 1 )
placebo
(n  *= 6 4 )
Total no. of 
withdrawals
Reasons
5 7 75 5 0
Death 0 1 10 4 0
Adverse event 2 4 38 1 0
Worsening of 
heart failure
1 0 9 0 0
Poor compliance 0 1 1 0 0
Loss to follow-up 2 1 7 0 0
Other 0 0 10 0 0
not available for comparative purposes.
Generalised adverse events reported in the safety studies cover the usual range of 
non-specific symptoms (Table 4.8). There is little to distinguish the pattern of symptoms 
from those generally attributable to the class effects of ACE inhibitor treatment.
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Table 4.8: Adverse symptoms reported (total number and percentage) during clinical 
studies with oral perindopril in heart failure patients (data on file, Dargie,1990)
Symptom
C 04.01/2 
3 months
C 04.02 
up to 30 
months
PKH 
06.02 
1 month
S 9490
(n * 6 1 )
placebo 
(n * 6 4 )
S 9490
(n * 3 2 0 )
S 9490
(n *  12)
n % n % n % n %
Cardiorespiratory
• anginal pain 8 2.5
• orthostatic discomfort 6 1.9
- dizziness 2 3.3 3 4.7 13 4.1 2 17
- palpitations 1 1.6 0 0.0 5 1.6
- heavy legs 1 1.6 0 0.0 1 0.3
- oedema of lower limbs 1 1.6 1 1.6 2 0.6
- cough 2 3.3 0 0.0 32 10.0 1 8.0
- atypical chest pain 1 1.6 0 0.0 2 0.6 1 8.0
- dyspnoea 2 0.6 2 17
CNS and behaviour
- mood and/or sleep 1 1.6 1 1.6 4.1 1.3
disturbances
- tremor 0 0.0 1 1.6
• concentration and 0 0.0 1 1.6
coordination disturbances
ENT and opthaimology
. tinnitus 1 1.6 1 1.6 1 0.3
- runny nose 0 0.0 1 1.6 1 0.3
• lamination I 1.6 0.0
Digestive system
. taste disturbance 0 0.0 1 1.6
. dry mouth 1 1.6 0.0 1 0.3
- diarrhoea 3 4.9 1 1.6 7 2.2 1 8.0
- nausea 1 1.6 0.0 6 1.9
- vomiting 0 0.0 1 1.6 1 0.3
- epigastric pain 5 8.2 2 3.1 7 2.2
- abdominal pain 1 1.6 0 0 3 0.9
Locomotor system
. joint pains 1 1.6 3 4.7 3 0.9
- muscular cramps 3 4.9 0 0 5 1.6 1 8.0
General symptoms
• tiredness 4 6.6 2 3.1
- headache 2 3.3 2 3.1 8 2.5 1 8.0
- sweating 2 3.3 1 1.6 4 1.3
• hot flushes 0 0.0 1 1.6 3 0.9
- cutaneous signs 1 1.6 1 1.6 10 3.1
- anorexia 1 1.6 0 0.0 3 0.9
- 13 4.1 1 8.0
• angioneurotic oedema I 0.3
STUDIES ON ANGIOTENSIN CONVERTING ENZYME INHIBITION
CHAPTER 5: GENERAL RECURRENT METHODS
5.1. Patient and Volunteer Studies
5.1.1. Blood Pressure and heart rate measurement
During all clinical studies, whether in patients or normal volunteers, the technique 
of blood pressure and heart rate measurement was uniform. Data was recorded using an 
established (Johnson & Kerr,1985) semi-automatic device (Sentron, Bard, Sunderland 
UK), maintained and calibrated at regular intervals by the hospital Clinical Physics 
Department. This machine operates on an ocsillometric technique for indirect blood 
pressure and direct heart rate measurement. All subjects had supine blood pressure 
measurements recorded in triplicate after at least 30 minutes supine rest.
During the heart failure studies (Chapter 6) blood pressure was recorded 
continuously at 2 minute intervals to establish the baseline pressure, for safety reasons 
and to establish a trend analysis. In addition triplicate blood pressure measurements were 
meaned and constituted the data set used to compare drug effects.
Where relevant erect blood pressures were determined in triplicate at 1,2 and 
5mins and meaned to constitute the data point.
5.1.2. Protocol and Patient Consent
All studies involving patients or human volunteers in clinical projects were the 
subject of detailed pre study protocols laid out in a standard format for the relevant local 
Research and Ethical committee. In all cases each protocol was reviewed and granted 
clearance prior to the conduct of the study with only minor modifications.
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All human subjects whether patient or normal volunteers were screened in terms 
of their clinical history and physical examination as suitable for inclusion in the 
particular study by myself. An information sheet as to the aims and details of the 
procedures involved in any given study was provided and written and informed consent 
to participated was subsequently obtained.
5.2. Analytical Methods
5.2.1. ACE activity
The determination of angiotensin converting enzyme (ACE) activity was based 
on the method of Chiknas (1979). This method is based on the measurement of the 
formation of hippuric acid from the synthetic tripeptide substrate Hippuryl-Histidine- 
Leucine (Hip-His-Leu). By quantifying the amount of hippuric acid formed by the 
action of ACE on Hip-His-Leu an indirect index of ACE activity can be calculated. One 
unit of ACE activity (1 EU/1) is that which produces 1 mole hippuric acid per minute at 
37°C under controlled reaction conditions i n  v i t r o .
SOLUTIONS
100 mM potassium phosphate buffer pH 8.3 (substrate buffer)
5.705 g of K2HPO4 and 4.375 g NaCl were dissolved in 250 ml distilled water. 
1.361 g of KH2PO4 was dissolved in 100 ml distilled water. The monopotassium salt 
was then added to the dipotassium salt until the pH reached 8.3.
5 mM Hip-His-Leu (substrate)
21.48 mg Hip-His-Leu was dissolved in 10 ml assay buffer. This was freshly 
made for each assay since there is a gradual degradation of the substrate to hippuric acid, 
the reaction product.
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Internal standard
20.4 mg phthalic acid was dissolved in 20 ml methanol and made up to 100 ml 
with distilled water. The solution was then diluted 1:2:5 with distilled water to give the 
working solution (0.41 mmol/1).
Hippuric acid standards
179.2 mg of hippuric acid was added to 100 ml of distilled water, 2 ml of which 
was taken and made up to 20 ml with drug free plasma (5 mmol/1). A standard 
calibration line of hippuric acid over the range 0.05 to 1.0 mmol/1 was prepared.
Mobile phase
5.44 g KH2PO4 (HPLC grade) was dissolved in 1.51 distilled water and the pH 
adjusted to 4.0 with orthophosphoric acid. The volume was made up to 2.01 with 
distilled water, 140 ml discarded and replaced with 140 ml methanol. The mobile phase 
was filtered through a 0.8 micron aqueous filter and finally degassed by bubbling helium 
through for a minimum of 10 minutes.
ANALYTICAL PROCEDURE 
Procedure for standards
Into 4 ml polypropylene tubes in duplicate were placed;
a) 200 ul substrate buffer.
b) 50 ul 50%HCL (v/v). Vortex briefly.
c) 20 ul standard plasma.
d) 50 ul internal standard solution. Vortex briefly.
e) 50 mg (approximately) NaCl. Vortex briefly.
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f) 1 ml ethyl acetate. Vortex for 15 seconds.
g) Centrifuge at 2000 rpm for 5 minutes.
h) Remove 500 ul of the organic layer to a clean 4 ml. polypropylene tube and 
concentrate under air/N2 at 37°C.
i) When dry add 100 ul of mobile phase and vortex briefly, 
j) Inject 20 ul onto HPLC system.
Procedure for unknown samples
Into 4 ml polypropylene tubes in duplicate were placed:
a) 200 ul 5 mmol Hip-His-Leu in substrate buffer.
b) 20 ul unknown plasma sample. The reaction was started 
by vortexing briefly.
c) Samples were incubated in a water bath at 37°C for 
30 minutes.
d) Reaction stopped by the addition of 50 ul 50% HC1 
and vortexing.
e) Procedure as from step d) in procedure for Standards.
Quality control data
The minimum limit of quantitation was 0.2 EU/1. Using a quality control sample 
supplied by Sigma Chemicals the accuracy of the method was 104% whilst 10 replicate 
analyses of this 18 EU/1 standard revealed intra- and inter-assay variability to be 2.0 and 
3.3% respectively.
5.2.2. Drug concentration measurements
Drug concentrations of ester and diacid ACE inhibitors were analysed using the
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standardised inhibition assay described by Tocco and colleagues (1982) and later 
modified by Francis (Francis et al,1987). It is based on the above assay for angiotensin 
converting enzyme using Hip-His-Leu as substrate and generated hippurate detected by 
HPLC to quantify the presence of inhibitor. The source of high activity plasma ACE is 
rabbit plasma. Drug concentrations are determined against known standard curves. Ester 
prodrug ACE inhibitor concentrations can be determined by alkaline degradation of an 
aliquot in addition to the determination of free diacid. Simple subtraction of diacid from 
total substrate inhibition allows the definition of both ester and diacid from a plasma 
sample where both are present.
This assay is applicable to all prodrug ACE inhibitors and was used extensively 
for perindopril, perindoprilat; and enalapril, enalaprilat in the studies reported here. The 
minimum limit of quantitation was 0.5 mg/ml. Using quality control samples revealed 
intra- and inter-assay variability to be in the region of 3.5 and 6% respectively for both 
prodrugs and diacid metabolites.
5.2.3. Plasma renin activity
Plasma renin activity was determined by quantification of the rate of angiotensin I 
formation using exogenous sheep angiotensinogen added to plasma samples. Angiotensin 
I was measured by a sensitive and specific RIA with a detection limit (in terms of renin 
activity) of 0.1 ngAI/ml/hr and an inter assay coefficient of variation of 7% (Derkx et 
al.1979)
5.2.4. Plasma aldosterone
Plasma aldosterone was kindly measured in the steroid laboratory of Dr Robert 
Fraser of the MRC Blood Pressure Unit at the Western Infirmary. An established RIA 
was employed based on a commercial kit (Aldosterone MAIA, Biodata, SPA, Italy).
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Intra and inter assay coefficients of variation were 2.5 and 4.6% respectively.
5.2.5. Plasma angiotensin II
Plasma angiotensin II was kindly measured in the laboratory of Dr JJ Morton of 
the MRC Blood Pressure Unit at the Western Infirmary using the current technique of his 
own published radioimmunoassay system (Morton & Webb, 1985). Coefficients of 
variation are 5% and 7.8% respectively for intra and inter assay comparisons. The limit 
of detection of the assay is 0.5 pg/ml.
5.2.6. Plasma catecholamines
Plasma concentrations of noradrenaline and adrenaline were measured using a 
technique based on HPLC analysis of alumina extracted plasma. Samples collected and 
frozen (-70°C) after collection were processed following washing in acid washed 
alumina. They were eluted from alumina after washing with perchloric acid. Samples 
were separated on a reversed phase Spherisorb column after preliminary separation. 
Quantification was by concurrent internal standards and detection was based on an 
electrochemical signal system using a silver electrode (Howes et al,1985). The limits of 
detection for noradrenaline and adrenaline were O.lnmol/L respectively. Inter and intra­
assay coefficients of variation were 8% and 3% respectively at the time of analysis.
5.3. Statistical Methods
Blood pressure and heart rate recordings were taken in triplicate at each recording 
time (section 5.1). The mean of these three recordings, rounded to the nearest whole 
digit, was used for the statistical analysis. Where relevant mean arterial 
pressure was calculated from systolic and diastolic pressure using the formula MAP = 
DBP + (SDP - DBP)/3. All blood pressure data are expressed in mmHg and all heart rate
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data in beats per minute. Absolute or baseline corrected values of heart rate, mean arterial 
pressure and systolic or diastolic pressures were subjected to repeated measures analyses 
of variance using the statistical package, RUMMAGE on an ICL 3988 mainframe 
computer. The model included two fixed factors (time, with variable levels and treatment 
with variable levels) and one random factor (patients, with 8-12 levels dependent on the 
individual study). Treatment time interactions were estimated using Bonferroni 
correction for repeated comparisons, based on the premise that the only comparisons of 
interest were those between treatments at any given time point, i.e. individual times 
within each treatment were not compared.
Where the pre-treatment values for heart rate, mean arterial pressure or rate 
pressure product were significantly different between treatment groups, the data were 
baseline corrected by subtracting the pre-treatment value from all subsequent values 
before being subjected to statistical analysis. Statistical significance is assumed if p<0.05 
was achieved.
Angiotensin converting enzyme inhibition was calculated from the formula:
% inhibition = 100 x (1-ACE/pre-treatment ACE).
The graphical representation of all data is based on mean values for each 
treatment group at a given time point with the error bars representing one standard 
deviation of the mean. All graphs show times following dosing on a linear scale with 
the 24-hour or later recordings shown separately on the far right.
Demographic data and baseline sodium creatinine and renin values etc were 
compared amongst the treatment groups using a Freidman one way analysis of variance.
In chapter 6 the New York Heart Association Classification of Heart Failure Severity 
was compared amongst the treatment groups using an analysis of variance by ranks 
(Kruskal-Wallis) The effect of treatment on serum creatinine and other biochemical
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indices was assessed by comparing for the four treatment groups the difference between 
post-treatment and pre-treatment values, using one way analysis of variance.
Specific techniques applied only in certain sections are described at the 
appropriate point.
CHAPTER 6
ANGIOTENSIN CONVERTING ENZYME INHIBITION IN HEART FAILURE
6.1 STUDIES WITH ORAL PRODRUG ESTER ACE INHIBITORS
This section set out to compare three oral agents in an observational study using 
standard clinical practice for introducing ACE inhibitors in heart failure. A non- 
invasive, double blind, randomised, placebo-controlled, parallel group study was 
conducted in elderly patients with stable chronic heart failure. The two standard ACE 
inhibitor in U.K. practice, captopril (6.25 mg) and enalapril (2.5 mg) were to be 
compared with each other and with the more recent long acting prodrug ACE inhibitor, 
perindopril (2 mg). These drugs were compared with placebo therapy in their 
recommended low starting doses for heart failure on a background of diuretic withdrawal 
and hospital supervision. The haemodynamic and neurohormonal responses of these 
drugs or placebo and the drug accumulation profiles were the main features to be studied.
6.1.1. PATIENTS AND METHODS
An observational study was conducted in unselected patients (n=48) (59 - 86 
years; 31:17, M:F) admitted to hospital for initiation of ACE inhibitor treatment as 
adjunctive therapy for the management of heart failure. Patients were symptomatic on 
diuretic therapy (> 80 mg frusemide or equivalent daily) and none had significant fluid 
imbalance. All had stable renal function and normal serum sodium status (Na > 135 
mmol) prior to treatment. The diagnosis was confirmed by symptomatic enquiry, clinical 
history, physical, radiological and electrocardiographic examination prior to treatment. 
The diagnosis had initially been established by a member of the consultant staff. The 
majority had impaired left ventricular function documented by echocardiographic
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examination or left ventriculography. All had NYHA symptoms Grades II - IV, the 
majority were grade in, symptomatic on minimal exertion. The clinical details of the 
four patient groups are given in Table 6.1.
Diuretic therapy was withdrawn under supervision for at least 24 hours prior to 
ACE inhibitor treatment and in the majority this was for 48 hours. All concomitant 
vasoactive drugs such as calcium antagonists or nitrate preparations were withheld on the 
day of treatment and until after monitoring was completed at 24 hours. Digoxin, where 
prescribed, was continued. On the morning of treatment (~ 0730 hours) a heparinised 
peripheral venous cannula was inserted for blood sampling and the patients rested 
undisturbed, semi-supine in bed while baseline blood pressure was recorded semi- 
automatically at 2 minute intervals for at least 30 minutes (Sentron, Bard, Sunderland, 
U.K.). Oral treatments (captopril 6.25 mg, enalapril 2.5 mg, perindopril 2 mg, lactose 
placebo) were administered double blind in their standard formulations within a white 
hard gelatin capsule prepared in accord with a randomisation schedule held by the 
Department of Pharmacy. All patients received their normal meals throughout the study. 
They were kept supine from the start of the study till 10 hours after dosing. Patients 
were allowed up after this but were supine for at least 45 minutes prior to sampling and 
blood pressure measurement at 24 hours. Following supervised oral administration 
blood pressure was recorded supine at 2 minute intervals with supplemental triplicate 
determinations at set observation points when blood samples were also drawn for the 
determination of drug concentration, ACE activity and plasma renin activity.
At 24 hours following dosing, blood pressure, drug concentrations, hormones, 
routine biochemistry and haematology were determined after a period of supine rest.
The nature of therapy was then obtained from the pharmacist to allow appropriate further 
treatment with an oral ACE inhibitor and re-instatement of diuretics and vasodilators. 
Patients who had received placebo continued on diuretic withdrawal and received oral
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Table 6.1: Demographic data of study patients
PLACEBO C APTOPRIL ENAL APRIL PERINDOPRIL
(n=12) (n=12) (n=12) (n=12)
Male/Female (n) 11:1 8:4 6:6 6:6
Age (MeantlSD) 68.2±5.7 67.8±5.6 65.9±7.3 69.2 + 7.9
NYHA Class
II 3 6 4 3
III 9 5 8 9
IV 1
Aetiology of Heart Failure 
Ischaemic heart 6 7
disease
Alcohol related 1
cardiomyopathy (CM)
Dilated CM 1
Valvular disease - 1
Combinations 4 4
Atrial fibrillation 2 2 3
captopril 6.25 mg as open therapy under normal nursing observation in hospital. These 
patients were not included in any subsequent active treatment group.
6.1.2 RESULTS
A. General
Each of the parallel groups contained patients of a similar age distribution,
NYHA class, pretreatment serum sodium, creatinine and plasma renin activity (Table 
6.2). No patient enrolled in the study experienced significant symptoms during the 
study day or in the preceding period of diuretic withdrawal prior to treatment. All left 
hospital after initiation of therapy adjustment of diuretic dosage and other drugs without 
ill effect. No treatment group showed a significant alteration in serum sodium, 
potassium, urea or creatinine 24 hours after study. In all cases there was the expected 
small fall in haemoglobin associated with venesection which was well tolerated. The 
individual changes in pre- and post-treatment laboratory indices are given in Table 6.3.
The pretreatment baseline blood pressure and heart rate values were not equal 
between the groups. Baseline mean arterial pressure (MAP) was significantly higher (p 
< 0.05) in the group who received enalapril (106.4±11.6 mmHg) than those who received 
captopril (98.4±10.8), perindopril (98.2±11.0) or placebo (100.3±12.8). In addition the 
baseline supine heart rate was significantly lower (p < 0.05) in the group who were 
treated with captopril (75.9±9.8 bts/min) than those who received enalapril (83.3±15.9), 
perindopril (77. 1± 10.4) or placebo (81. 1± 12.8). For these reasons the temporal pattern 
of response is described as the change from individual baseline pressures and heart rate 
rather than absolute values. Baseline values are meaned from the 2minute recordings 
recorded during the pretreatment period of 30-60 minutes rest.
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Table 6.2:Summary of comparisons of pre and post treatment laboratory data, age 
and NYHA class between treatment groups
PLACEBO CAPTOPRIL ENALAPRIL PERINDOPRIL ANOVA P=
Age -68.2±5.7 67.8±5.6 65.9±7.3 69.2±7.9 0.677
Na+ 138.9±2.5 141.2±3.4 140.3±2.7 140.8±2.4 0.220
ANa+ -0.2±2.8 +0.1±2.3 -0.5±2.1 +0.3±1.2 0.794
K+ 4.1±0.6 4.2±0.3 4.2±0.6 3.9±0.6 0.407
AK+ +0.02±0.6 -0.15±0.4 +0.05±0.6 +0.08±0.4 0.684
Urea 8.5±5.9 6.3±1.7 7.2±2.5 8.6±3.2 0.380
AUrea -1.4±4.0 -0.1±1.1 -0.4±1.3 -0.4±1.8 0.570
Creat 107±15 98±22 102±29 122±36 0.150
ACreat-0.6±19 -4.0±12 -8.2±16 -6.6±15 0.651
Hb 14.4±1.3 13.5±1.4 14.0±1.2 13.8±1.1 0.408
AHb -1.2±0.6 -i.2±0.5 -1.8±0.5 -1.2±0.5 0.016
NYHA Class
26.7 21.3 24.0 26.0 0.681
(Average rank) (Kruskal-Wallis)
B.Haemodynamic effects 
Heart rate
Only minor changes in heart rate were seen with any treatment, the greatest being a fall 
of 10.8 beats per minute 8 hours after dosing with enalapril. No reflex tachycardia was 
encountered with any treatment. The mean heart rate difference from baseline was -2.62 
beats per minute for the placebo group, -2.96 beats per minute for the captopril group, -6.77 
beats per minute for the enalapril group and -1.06 beats per minute for the perindopril group (P 
= 0.034). The mean heart rate was,therefore, lower for the enalapril group than all other groups 
and was higher in the perindopril group than in the captopril group. From the analysis of 
variance, the probability of a treatment time interaction was P < 0.001. Heart rate differences at 
individual time points were mainly apparent for the enalapril group. The heart rate in the 
enalapril group was lower than placebo from 1 hour to 8 hours after dosing. It was lower than 
the captopril group from 20 minutes until 24 hours after dosing and lower than the perindopril 
group from 20 minutes until 24 hours after dosing (Figure 6.1).
Mean arterial pressure
Mean arterial pressure fell by 10 mmHg from baseline, 4.5 hours after placebo. One and 
a half hours after captopril, mean arterial pressure had fallen by 17.7 mmHg from baseline. The 
fall in MAP after enalapril did not occur until 5 hours post-dosing and reached -23.2 mmHg. The 
lowest blood pressure after perindopril was seen 7.5 hours after dosing at -8.9 mmHg, which 
was higher than the placebo value at that time, and with a similar difference from placebo at 24 
hours post-dosing. Analysis of Variance on the baseline corrected mean arterial pressure data 
revealed a significant mean effect of treatment (P = 0.022) and significant treatment time 
interaction (P < 0.001). The mean values for the 28 recordings in each treatment group were as 
follows:-
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Figure 6.1: The baseline corrected mean effect (±1SD) of oral placebo (□), captopril 6.25mg 
(•), enalapril 2.5mg (o),or perindopril 2mg (■) on supine heart rate in patients with chronic 
cardiac failure.
j
Captopril - 8.82 mmHg 
Enalapril -11.68 mmHg 
Perindopril - 4.08 mmHg
Thus, the mean figures for captopril and enalapril were lower than for placebo or 
perindopril and the mean figure for enalapril was lower than that for captopril.
The comparisons at individual time points revealed the following:- The mean arterial 
pressure following captopril was lower than that after placebo from 40 minutes until 3 hours 
after dosing. Mean arterial pressure after enalapril was lower from 2.5 hours until 10 hours 
after dosing. The mean arterial pressure after captopril was lower than after perindopril from 15 
minutes until 4 hours after dosing and was lower after captopril than enalapril from 50 minutes 
until 105 minutes after dosing. This reversed from 4 hours after dosing, however, with mean 
arterial pressure then being lower after enalapril than after captopril and this difference persisted 
until 10 hours after dosing. The mean arterial pressure after enalapril was lower than that after 
perindopril at 50 minutes and from 3 hours until 10 hours after dosing (Figure 6.2).
C. Drug concentration data and plasma hormonal responses
Sample collection procedures in a double blind study did not allow for the special 
preparations required in order to undertake collections for determination of captopril drug levels 
or measurement of ACE activity in these specimens.
Drug Concentrations
The pharmacokinetic profiles for enalapril and perindopril groups are illustrated in 
Figure 6.3. Concentrations of both parent ester and active diacid metabolite were higher for 
enalapril than perindopril. The mean (± 1 SD) time to peak ester concentrations (tmax) were 
1.95 (±0.7) hrs for enalapril and 1.74 (±0.7) hrs for perindopril. The mean time to peak for
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Figure 6.2: The baseline corrected mean effect (±1SD) of oral placebo (□), captopril 6.25 mg 
( • ) ,  enalapril 2.5 mg (o), or perindopril 2 mg (■) on supine mean arterial pressure in patients 
with chronic cardiac failure.
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Figure 6.3: Mean serum concentrations (±1SD) of perindopril (□) and perindoprilat (■) (a) or 
enalapril (o) and enalaprilat ( • )  (b) following oral therapy in patients with chronic cardiac 
failure.
was the difference in tmax for either ester (p = 0.684) or diacid (p = 0.229) significantly 
different between the treatment groups (Kruskal-Wallis ANOVA). Generally speaking both 
treatments were associated with prolonged plateau concentrations of the active diacid.
ACE Inhibition
The analysis of variance for angiotensin converting enzyme inhibition confirmed 
a significant main effec t of treatment between the enalapril and perindopril groups (P = 0.002) 
and significant treatment time interaction for these groups (P < 0.001).
Plasma ACE activity was significantly reduced in both perindopril and enalapril groups 
with respect to placebo (Figure 6.4). Maximal ACE inhibition was similar for both active 
treatment groups (enalapril 63%; perindopril 68%) at 8 hours post-dosing. The onset of 
inhibition was earlier with perindopril. Inhibition was significantly greater between 50 mins 
and 3 hours after perindopril compared to enalapril. ACE inhibition was also significantly 
greater at 24 hours post-dosing after perindopril.
From the ANOVA the mean ACE inhibition over the 28 recording times for perindopril 
was 30% and for enalapril was 23%. There were differences between the two treatments at 
individual recording times from 50 minutes until 3 hours and also at 24 hours. In each case, 
perindopril showed the greater inhibition of ACE.
Plasma Renin activity
Pretreatment plasma renin activity (geometric mean, 95% confidence limits) after 24-48 
hf diuretic withdrawal was similar in all groups (p = 0.183, one way ANOVA); captopril group 
(1.1; 0.2, 3.8 Al/ml/hr) compared with placebo (3.2; 0.5,11.7), enalapril (1.7; 0.5,44.7) and 
perindopril (2.5; 0.2,11.9). There was no significant difference (p = 0.222 Kruskal Wallis 
ANOVA) in the prestudy dose of diuretic drugs between those patients who received captopril
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Figure 6.4: Plasma ACE inhibition (% baseline activity EU/ml, mean±lSD) following placebo 
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Figure 6.5: Plasma renin activity following oral placebo (□), captopril ( • ) , enalapril (o) or 
perindopril (■): geometric mean values are illustrated.
All three active treatments produced elevations in PRA. The early rise associated with 
captopril was not marked which related to the initial sampling point at 2hrs after dosing. Later 
rises were associated with enalapril and perindopril (Figure 6.5).
6.2 STUDIES WITH INTRAVENOUS DIACID ACE INHIBITORS
In this section a comparison was made of the diacid metabolites enalaprilat and 
perindoprilat administered by intravenous infusion in a non-invasive, double blind, randomised, 
placebo-controlled, parallel group study in elderly patients with stable heart failure. 
Perindoprilat (1 mg) and enalaprilat (1.5 mg) were given in total doses which broadly 
approximated, on the basis of prior bioavailability, to the oral doses of perindopril (2 mg) and 
enalapril (2.5 mg) used in our parallel oral studies (see section 6.1). Both active drugs and 
placebo (saline) were prepared in normal saline (30 ml) and infused at a constant rate of 5 ml/hr 
over 6 hours. The haemodynamic and neurohormonal responses of these drugs or placebo and 
the drug accumulation profiles were the main features to be studied.
6.2.1 PATIENTS AND METHODS
This study was conducted in patients (n=36) (60-87 years; 24:12, M:F) admitted to 
hospital for initiation of ACE inhibitor as adjunctive therapy for the management of heart 
failure. The placebo group was common to section 6.1. Patients were selected in an identical 
fashion to the section on oral ACE inhibitor treatments. As before all symptomatic on diuretic 
therapy (> 80 mg ffusemide or equivalent daily) and none had significant fluid imbalance. The 
clinical details of the three patient groups are given in Table 6.3; 6.4; & 6.5.
All diuretic therapy was again withdrawn under supervision for at least 24 hours prior to 
ACE inhibitor treatment and in the majority this was for 48 hours. All concomitant vasoactive
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Table 6.3: PATIENT DEMOGRAPHY - PLACEBO THERAPY
STUDY SUBJT AGE SEX AETIOLOGY NYHA CARDIAC DURATION
NO. INITL CLASS RHYTHM OF INFUSION
i JM 69 M H/ACM III AF 6 HOURS
4 EW 60 M IHD III s 6 HOURS
5 DR 76 M ACM m s 6 HOURS
11 GH 67 M H/MD n-m s 6 HOURS
17 JB 74 M IHD/MR hi AF 6 HOURS
22 AJ 74 M IHD h i s 6 HOURS
37 TM 74 M IHD m s 6 HOURS
41 JG 64 M IHD hi s 6 HOURS
55 DR 61 M H/IHD hi s 6 HOURS
62 WB 67 M IHD ii s 6 HOURS
66 JW 71 F DCM m s 6 HOURS
27 AM 61 M IHD ii s 6 HOURS
IHD - Ischaemic heart disease 
H - Hypertensive heart disease
ACM - Alcohol related cardiomyopathy 
DCM - Dilated cardiomyopathy 
MR - Mitral regurgitation 
S - Sinus rhythm
AF - Atrial fibrillation
Table 6.4:PATIENT DEMOGRAPHY - ENALAPRILAT 1.5 mg
STUDY
NO.
SUB JT AGE 
INITL
SEX AETIOLOGY NYHA CARDIAC 
CLASSRHYTHM
DURATION DOSE 
INFUSION (mg)
13 EMcM72 F DCM III AF 6 HOURS 1.5
15 MMcD71 F IHD/H III AF 6 HOURS 1.5
19 AB 74 F IHD III S 6 HOURS 1.5
23 JD 60 M DCM HI S 6 HOURS 1.5
28 PW 73 M ACM III S 2 HOURS 0.5
32 MF 76 F IHD III S 2 HOURS 0.5
39 CT 60 M ACM/MR II AF 6 HOURS 1.5
40 MM 77 F MR III AF 6 HOURS 1.5
46 JM 77 F CP III S 3 HOURS 0.75
59 JG 70 M IHD/H HI S 4 HOURS 1.0
63 JB 66 M IHD II S 6 HOURS 1.5
70 AK 63 M DCM/MR III S 5 HOURS 1.5
MEAN4.8 1.2
±SD  1.6 0.4
IHD - Ischaemic heart disease 
H - Hypertensive heart disease
ACM - Alcohol related cardiomyopathy 
DCM - Dilated cardiomyopathy 
MR - Mitral regurgitation 
S - Sinus rhythm
AF - Atrial fibrillation
CP - Cor Pulmonale
Table 6.5:PATIENT DEMOGRAPHY - PERINDOPRILAT 1 mg
STUDY SUBJTAGE SEX AETIOLOGY NYHA CARDIAC DURATION DOSE
NO. INITL CLASSRHYTHM INFUSION (mg)
16 RW 64 M DCM III s 6 HOURS 1
20 AW 84 F IHD II AF 2.5 HOURS 0.42
26 MM 87 F IHD III AF 6 HOURS 1
30 IB 62 F IHD III AF 6 HOURS 1
34 JK 65 M IHD n S 6 HOURS 1
35 HT 68 M IHD n S 5 HOURS 0.83
43 JK 64 M IHD/H II S 6 HOURS 1
45 JL 71 F CP III S 5 HOURS 0.83
47 JM 63 M IHD/CP m S 5 HOURS 0.83
52 LMcC 60 F DCM III S 4 HOURS 0.67
65 TD 71 M DCM/IHD II S 6 HOURS 1
72 JG 73 M DCM/IHD/MRIII S/FVPC 6 HOURS 1
MEAN 5.3 0.88
±SD  1.1 0.18
IHD - Ischaemic heart disease 
H - Hypertensive heart disease 
ACM - Alcohol related cardiomyopathy 
DCM - Dilated cardiomyopathy 
MR - Mitral regurgitation 
S - Sinus rhythm
AF - Atrial fibrillation
CP - Cor Pulmonale
FVPC - Frequent premature ventricular complexes
drugs were withheld on the day of treatment and until after monitoring was completed at 
24 hours.
On the morning of treatment (~ 0730 hours) two heparinised peripheral venous 
cannulae were inserted for blood sampling and infusion purposes in contralateral 
antecubital fossae. The patient then rested undisturbed, semi-supine in bed while 
baseline blood pressure was recorded semi-automatically at 2 minute intervals for at least 
30-60 minutes (Sentron, Bard, Sunderland, U.K.).Infusions (saline placebo, enalaprilat 
1.5 mg; perindoprilat 1 mg) were administered double blind in accord a randomisation 
schedule held by the Department of Pharmacy. All patients received their normal meals 
throughout the study. They were kept supine from the start of the study till 10 hours 
after the start of infusion.
The protocol allowed early termination of the infusion under double blind 
conditions while the observations of blood pressure and sampling strategy continued, on 
the basis of a blood pressure fall to 70% of the MAP established during the baseline 
determinations prior to the start of infusion (2 minute recordings over 30-60minutes).
This step was included in the protocol in order to limit potentially damaging falls in 
blood pressure. In addition it allowed us to test whether low dose constant rate infusion 
of a diacid ACE inhibitor was a readily controllable means of drug administration.
Patients were allowed up after the initial 10 hour observations but were supine for 
at least 45 minutes prior to sampling and blood pressure measurement at 24 hours. As 
before following initiation of the infusion blood pressure was recorded supine at 2 
minute intervals with supplemental triplicate determinations at set observation points 
when blood samples were also drawn for the determination of drug concentration, ACE 
activity and plasma renin activity.
At 24 hours following dosing, blood pressure, drug concentrations, hormones, 
routine biochemistry and haematology were determined after a period of supine rest.
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Again treatment coding was then obtained from the pharmacist to allow appropriate further 
management with an oral ACE inhibitor etc. Patients who had received placebo 
continued on diuretic withdrawal and received oral captopril 6.25 mg as open therapy 
and were not subsequently included in any other study group.
6.2.2 RESULTS
A. General
The three randomised parallel groups had comparable demographic profiles in 
terms of patient age, clinical severity of heart failure (by NYHA grading), pre-treatment 
diuretic dosage and plasma renin activity. The pre-study laboratory tests of serum 
electrolytes were similarly equally balanced (Table 6.6). Laboratory indices were not 
significantly influenced by acute ACE inhibitor with the exception of haemoglobin 
concentration (Table 6.6). The small fall documented in all three groups was similar (p 
= 0.930) and is attributable to the blood sampling protocol employed in this and previous 
studies.
All patients tolerated therapy well and no symptoms were reported. Two patients 
receiving active therapy (1, perindoprilat; 1, enalaprilat) showed transient elevation of 
serum urea and creatinine values (at 24 hrs) following therapy indicative of a decline in 
renal function. This pattern required discontinuation of maintenance oral enalapril (5 
mg b.d.s.). Only moderate biochemical changes occurred and these rapidly reversed on 
discontinuation of oral ACE inhibitor therapy (Figures 6.6 and 6.7). Both patients 
remained asymptomatic throughout.
B. Haemodynamic effects
The group mean absolute blood pressure and heart rate values prior to therapy are 
illustrated in Table 6.7. These were not significantly different from each other (p >
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Table 6.6: Comparison of demographic and laboratory parameters for the three 
treatment groups
PLACEBO ENALAPRILAT PERINDOPRILAT P = 
(ANO
Age (yrs) 68±6 7016 6916 0.822
PRA (geom mean) 3.9 2.3 2.2 0.681
Frusemide
(mg/day)
110±61 100141 83130 0.493
Na+
( mmol . l )
138.9±2.4 140.612.3 140.313.9 0.582
ANa+
(mmol.l")
-0.312.6 -0.912.8 +0.012.7 0.718
K + i (mmol.l")
4.110.6 4.010.4 4.310.4 0.363
AK+
(mmol.l" )
0.010.6 0.010.4 -0.210.2 0.604
Urea
(mmol.l’U
8.515.6 8.212.8 8.013.3 0.958
AUrea
(mmol.r*)
-1.413.8 -0.312.1 -1.212.0 0.661
Creatinine 
(|unol.l )
106.7114 108.3127 101.3124 0.750
ACreatinine
(p.mol.1"1)
-0.6118 8.2157.9 1.3113.9 0.836
Hb
(g/dl)
14.411.2 13.712 13.711.9 0.576
AHb
(g/dl)
-1.310.5 -1.210.7 -1.310.8 0.004
NYHA Class
(Average Rank) 19 20.5 16 0.390
(Kruskal-Wallis)
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Figure 6.6: Individual pattern of renal biochemistry in subject JL (study no 45) receiving 
perindoprilat infusion (lmg over 6hrs) and subsequent oral enalapril (5mg bds).
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Table 6.7: Absolute starting values (group mean + 1SD) in each of the three 
randomised parallel groups (n=12).
GROUP HEART RATE 
(bpm)
SYSTOLIC
(mmHg)
DIASTOLIC
(mmHg)
MEAN ARTERIAL 
PRESSURE (mmHg)
Placebo 81.0±13 139.6±18 80.6±13 100.3±13
Enalaprilat 74.3±8 124.5±30 76.9±11 99.1±14
Perindoprilat 78.5±14 128.4±14 72.1±11 89.1±10
ANOVA, p = NS; Placebo vs Enalaprilat vs Perindoprilat all parameters.
0.05). However, as both active treatment groups tended to have lower starting blood 
pressures than the placebo and in view of the initial pattern of blood pressure changes 
results are illustrated as changes from the values established as baseline as in the 
previous section.
Heart rate
In absolute terms heart rate was significantly less in the enalaprilat group than in 
Table 6.6: Summary of statistical comparisons of demographic and laboratory data 
between groupsthe placebo group from 40 min - 8 hr (excepting 50 min and 4 hrs) and at 24 hrs. 
perindoprilat treated group had a lower absolute heart rate than placebo between 6.5 -> 8 
hrs and at 3 and 4.5 hrs. There were no significant differences between enalaprilat and 
perindoprilat. The overall magnitude of the changes was small and comparable to our 
previous observations with low dose oral enalapril. There were no significant 
differences between either active group or placebo when the results were corrected to 
baseline pretreatment values (Figure 6.8).
Blood pressure
No placebo infusions were terminated. In each of the active treatment groups 
five infusions were terminated prior to the intended completion of dosing at 6 hrs: in the 
enalaprilat group at 2,2, 3 ,4  and 5 hrs; and in the perindoprilat group at 2 .5 ,4 ,5 , 5 and 
5 hrs. The mean total dose of enalaprilat was therefore 1.2±0.4 mg and for perindoprilat 
was 0.88±0.18 mg. The mean responses beyond 2 hrs therefore do not reflect continuing 
infusion in all cases.
Baseline corrected blood pressure values also revealed an early transient rise in 
BP in both active treatment groups. This was significantly greater than placebo in the 
perindoprilat group at the 10 and 20 min time points (Figure 6.9).
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Figure 6.8: Mean baseline corrected change in heart rate (±1SD) following intravenous 
placebo (□), enalaprilat 1.5mg (o) or perindoprilat lmg (•) in patients with chronic 
cardiac failure.
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Figure 6.9: Mean baseline corrected change in supine systolic blood pressure (±1 SD) 
following intravenous placebo (□), enalaprilat 1.5mg (•) or perindoprilat lmg (•) in 
patients with chronic cardiac failure.
Table 6.8: Individual maximal change from baseline of mean arterial pressure with time
recorded and duration of infusion in each of the three treatment groups.
PLACEBO ENALAPRILAT PERINDOPRILAT
Case MAP Time Infusion MAP Time Infusion MAP Time Infusion
(mmHg)(hr) (hr) (mmHg)(hr) (hr) (mmHg)(hr) (hr)
1 -4 0.33 6 -15 0.67 6 -9 4 6
2 -16 4.5 6 -23 3.5 6 -29 2.5 2.5
3 -8 6 6 -15 5.5 6 -30 5 5
4 -27 5.5 6 -19 4.5 6 -29 4.5 6
5 -17 4 6 -21 2 2 -47 4.5 2.5
6 -8 0.33 6 -19 2.5 2 -18 2.5 6
7 -10 2 6 -33 6 6 -11 4.5 6
8 -16 4 6 -38 2.5 6 -25 4 6
9 -12 4.5 6 -30 3.5 3 -29 4.5 5
10 -32 5 6 -45 5 4 -23 4.5 4
11 -10 7.5 6 -25 4.5 6 -15 4.5 6
12 -24 0.08 6 -40 4.5 5 -27 6 6
During subsequent infusion blood pressure fell in both active treatment groups 
(Figure 6.9). This was statistically significant for the enalaprilat group between 1.75 - 
6.5 hrs (excepting 4 hrs) and for perindoprilat (4hrs) for SBP compared to placebo 
(Figure 6.9). A similar pattern was observed for DBP in the enalaprilat group (2.5, 3,
3.5,4.5, 5.5, 7 hr) and the perindoprilat group (5.5 hr) compared to placebo.
The mean maximum recorded fall in SBP from baseline was -27±8 mmHg for 
placebo, -38.8±11 for enalaprilat and -34.9±12 for perindoprilat (p = 0.046).
The relationship between individual maximal recorded fall in MAP, the 
corresponding time, and the duration of infusion for all three treatment groups is 
illustrated in Table 6.8. The maximal mean fall in MAP was -10.4 mmHg at 6 hours 
during placebo infusion, -22.3 mmHg at 5 hours during enalaprilat infusion and -18.6 
mmHg at 4.5 hours during perindoprilat infusion. Early termination of infusion 
successfully controlled the blood pressure fall. The minimum MAP always followed 
cessation of treatment by at most 15-30 minutes.
C. Drug concentration data and plasma hormonal responses 
Drug concentrations
Drug concentrations of enalaprilat and perindoprilat are illustrated in figure 6.10. 
They include the data from the infusions discontinued prior to 6 hours. The mean time 
to peak for enalaprilat concentrations was 4.8±1.6 hr and for perindoprilat was 5.3±1.1 hr 
and as expected the drug concentrations were in each case maximal at the end of the 
individual infusions. Both treatments were associated with a sigmoid shaped drug 
concentration profile during infusion which has previously been reported (Lees et al, 
1989). A sigmoid accumulation is apparent during constant rate infusion. This phase, 
before 2 hours is unaffected by discontinuation of drug infusions (always >2 hours).
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Table 6.8: Individual maximal change from baseline of mean arterial pressure with time
recorded and duration of infusion in each of the three treatment groups.
PLACEBO ENALAPRILAT PERINDOPRILAT
Case MAP Time Infusion MAP Time Infusion MAP Time Infusion
(mmHg)(hr) (hr) (mmHg)(hr) (hr) (mmHg)(hr) (hr)
1 -4 0.33 6 -15 0.67 6 -9 4 6
2 -16 4.5 6 -23 3.5 6 -29 2.5 2.5
3 -8 6 6 -15 5.5 6 -30 5 5
4 -27 5.5 6 -19 4.5 6 -29 4.5 6
5 -17 4 6 -21 2 2 -47 4.5 2.5
6 -8 0.33 6 -19 2.5 2 -18 2.5 6
7 -10 2 6 -33 6 6 -11 4.5 6
8 -16 4 6 -38 2.5 6 -25 4 6
9 ' -12 4.5 6 -30 3.5 3 -29 4.5 5
10 -32 5 6 -45 5 4 -23 4.5 4
11 -10 7.5 6 -25 4.5 6 -15 4.5 6
12 -24 0.08 6 -40 4.5 5 -27 6 6
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Figure 6.10: Serum drug concentrations (±1SD) following intravenous enalaprilat 1.5mg 
(O) or perindoprilat lmg (•) in patients with chronic cardiac failure.
Plasma ACE inhibition
The profile of plasma ACE inhibition for both active treatments was similar 
showing a rapid onset and sustained plateau of inhibition (Figure 6.11). The mean 
maximal %  inhibition of plasma ACE activity was significantly higher (p = 0.004) for the 
perindoprilat group (91.7±3%) compared to the enalaprilat group (86.5±4%). Mean 
maximal ACE inhibition across the whole group was achieved at 4.5±1.3 hrs in the 
perindoprilat group and 5.0±1.2 hrs in the enalaprilat group.
Plasma Renin Activity
Plasma renin activity was significantly elevated by both active treatments 
compared with placebo (Figure 6.12) and remained elevated after discontinuation of 
infusion.
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Figure 6.11: Plasma ACE inhibition (±1 SD) following intravenous placebo (□), 
enalaprilat 1.5mg (O) or perindoprilat lmg (•) in patients with chronic cardiac failure.
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Figure 6.12: Plasma renin activity (±1 SD) following intravenous placebo (□), 
enalaprilat 1.5mg (O) or perindoprilat lmg (•) in patients with chronic cardiac failure.
6.3.1 ORAL ACE INHIBITION IN CHRONIC HEART FAILURE
This study revealed significant differences in the responses to the recommended 
low doses of ACE inhibitors in elderly patients with stable heart failure in the commonly 
employed clinical setting of temporary diuretic withdrawal. The use of a placebo 
controlled randomised parallel group design in this study has permitted comparisons of 
drug effects. It is important to evaluate haemodynamic responses in these patients in the 
light of a placebo treated group to control for diurnal changes and feeding patterns 
(Packer et al,1985a). A parallel group design was chosen to avoid a carryover effect due 
to the protracted elimination phase associated with some ACE inhibitors (Belz et 
al,1988) and to avoid delay in the initiation of active therapy.
The first dose hypotensive response to ACE inhibitors in heart failure has 
received much attention in case reports and small series (see chapters 3 & 4). The 
mechanism and significance of the response in clinical practice remains obscure. The 
relationship of blood pressure fall to previous or concurrent diuretic therapy, the dose or 
type of ACE inhibitor employed and the importance of a spectrum of individual patient 
responses is poorly defined. A comparison was made of the degree and pattern of blood 
pressure response in the group of patients who could be considered to be at greatest risk 
of developing a hypotensive response. These are elderly, diuretic treated subjects with 
moderate to severe heart failure.
Despite employing the standard low doses of both captopril and enalapril both 
these drugs showed falls in blood pressure consistent with previous reports. If, as some 
workers suggest, the first dose blood pressure response is related to the prevailing 
activation of the renin angiotensin system, as predicted by circulating renin activity 
(Packer et al,1985b), it might be suggested that these observations would underestimate 
the general degree of response in the captopril treated group. Nevertheless we
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documented predictable and significant supine blood pressure falls regardless of diuretic 
withdrawal and relatively (but not significantly) lower renin activity in this group.
There is limited experience with lower oral doses of captopril e.g. 1 mg (Warren et 
al,1986) but formulation is compromised by chemical instability (Colucci et al,1989). 
Patterns of test dosing with captopril have been suggested but the individual relevance of 
this strategy to subsequent responses to higher doses of the same or different agents has 
not been documented. However there is some data to suggest that in fact the dose 
reduction of captopril at least between 6.25mg and 25mg makes little difference to the 
overall blood pressure response (McClay et al,1992). The design of this study was far 
from optimal but this study at least questions the validity of empirical dose reduction 
without observational and comparative data. The selection of captopril on the empirical 
basis that if symptomatic hypotension and hypoperfusion were to occur its duration 
would at least be limited in comparison to longer active drugs dose at least appears 
logical (Reid, 1987). The observations with respect to the comparison between low dose 
captopril and enalapril confirm this pattern. In this section treatment with neither 
captopril nor enalapril caused symptoms or adverse changes in renal biochemistry.
In contrast, low dose perindopril was not associated with any change in blood 
pressure or heart rate. This was despite comparable plasma ACE inhibition which was if 
anything more protracted after perindopril than after enalapril. This may therefore 
reflect an important and clinically relevant agent specific difference in response between 
ACE inhibitors. The comparison was performed in patients who remained supine in a 
controlled hospital setting. The ambulatory blood pressure response would be expected 
to follow a similar pattern.
At the doses selected a similar differential response is observed with respect to 
heart rate. Altered autonomic tone and baroreceptor reflexes in heart failure patients are 
well known (Porter et al,1990) as are the anti-adrenergic or parasympathomimetic
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properties of captopril (Campbell et al,1985), enalapril (Boni et al,1990) and perindopril 
(Ajayi et al,1986). This study was the first occasion in which a small but significant 
slowing of basal heart rate in the supine posture after low dose enalapril has been 
demonstrated with an appropriate placebo control group. This effect on heart rate was 
seen only briefly with captopril and not seen at all with perindopril therapy.
One of the mechanisms proposed to be responsible for the fall in blood pressure 
in a proportion of heart failure patients treated with ACE inhibitors is activation of the 
Bezhold-Jarisch reflex with vagally mediated hypotension and bradycardia (Mark,1983). 
In the current study one patient had a marked fall in blood pressure and associated 
bradycardia yet remained asymptomatic immediately following dosing with placebo 
(Figure 6.13). He subsequently tolerated open captopril therapy outwith the study on the 
following day without complications. His placebo response was not excluded from the 
analysis. This reflex mechanism may be relevant in a few reported cases of hypotension 
following ACE inhibitors in heart failure patients. The Bezhold-Jarisch reflex clearly 
has little relevance to specific ACE inhibitors, agent selection or general management 
policies designed to avoid hypotension in heart failure as it is unpredictable and related 
neither to dose nor to individual drugs (Mark, 1983).
This acute study documented similar plasma ACE inhibition with both enalapril 
and perindopril yet divergent blood pressure responses. One explanation may involve 
differences in penetration and interaction with the tissue renin angiotensin systems.
With both enalapril and perindopril the net interaction with tissue and plasma ACE will 
be a product of the parent ester, a weak but lipid soluble ACE inhibitor and the more 
potent but polar diacid metabolite. The potency ratios and polarity of ester and diacid 
vary substantially between different compounds despite similar basic structures (see
2.3.1.) and there is limited in vitro evidence that the interaction is significant at least with
113
H
ea
rt
 
ra
te 
(b
ea
ts
/m
in
) 
Bl
oo
d 
pr
es
su
re
 
(m
m
H
g)
P l ace bo  t h e r a p y  
140- |
120 -
100 -
80-
60*
40 -
80-
60-
40-
20 -
- 4 0 40 60 80-2 0
T i m e  (min)
Figure 6.13: Individual blood pressure and heart rate profile of patient (study no.27) on 
double blind placebo therapy.
of each of these components would also be expected to vary and contribute further to 
potential differences in the pattern of tissue ACE inhibition. In the same fashion the 
tissue conversion of inactive ester to the active diacid as a local phenomenonmay also 
play a role in defining differential activity. As chronic therapy involves the attainment of 
an equilibrium the most likely setting in which potential differences would be apparent 
would be the first dose response.
The reactive rise in renin or aforementioned problems in documenting ACE 
inhibition with substrate based assays are unlikely to be relevant to the acute responses 
described in heart failure patients in this study. In addition they would be inadequate to 
explain the qualitative difference in blood pressure response between enalapril and 
perindopril.
The acute haemodynamic responses to ACE inhibitor drugs in patients with 
chronic heart failure are not markers of symptomatic benefit and conversely smaller 
blood pressure falls can be associated with benefit (Massie et al,1984). In general terms 
improvements in exercise duration and symptoms appear to require 6-8 weeks of therapy 
and alternative mechanisms may be important in reducing mortality (Packer et al,1987). 
As perindopril has been shown to provide symptomatic improvement in chronic cardiac 
failure (Bounhoure et al,1989), similar to other ACE inhibitors, the lack of an initial 
blood pressure fall does not appear to be an indication of a lack of long-term efficacy in 
heart failure at least with respect to exercise capacity. Reductions in mortality have not 
been shown with this drug and this may not be pertinent at these low doses. In addition, 
in acute heart failure oral perindopril is unlikely to share the haemodynamic benefits 
which have been demonstrated with other ACE inhibitor (Flynn et al,1988).
These results have general relevance since the patient population was not highly 
selected and since it included primarily the ’high risk’ groups of the elderly, diuretic 
pretreated, severe heart failure patients. Any manoeuvre which reduces the risk of
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hypotensive responses in these patients may have clinical and possibly resource 
implications although it has been stated on several occasions that the blood pressure 
responses per se are of poorly defined importance. The patient population studied, dose 
and agent employed and the adequate definition of haemodynamic and biochemical 
responses are important and the accurate descriptions provided in this study gave a 
hitherto unknown differentiation between similar agents.
6.3.2. INTRAVENOUS ACE INHIBITION IN CHRONIC HEART FAILURE
This section was designed to extend and complement the oral dosing study. The 
two intravenous diacid ACE inhibitor used produced broadly similar patterns of response 
when administered in low doses by constant rate infusion. The present intravenous 
protocol involving double blind discontinuation of therapy dependent on BP response 
worked well in practice and allowed effective control of the haemodynamic responses in 
these patients. It is a significant improvement upon bolus dose strategies employed in 
other studies with much higher doses of enalaprilat (Kubo et al, 1985; de Marco et al, 
1987; Homung and Hillis, 1987; Walinsky et al, 1987; Taylor et al, 1989) or other ACE 
inhibitors (Rademaker et al, 1986; Dickstein et al, 1987; Volpini et al, 1989; Ahmad et 
al, 1990). Blood pressure responses were intentionally limited by this manoeuvre and 
the low doses employed demonstrated in all cases a more or less smooth controlled blood 
pressure fall. No instance of sudden hypotension and bradycardia (or tachycardia) was 
noted in any patient receiving active therapy. Individual dose titration and optimisation 
of the blood pressure response may be valuable early after myocardial infarction (Nabel 
et al, 1991).
The study demonstrated a hitherto unreported early, transient pressor response to 
very small quantities of ACE inhibitor under the conditions of study. With the doses 
selected this was more clearly observed with perindoprilat. The same trend was apparent
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with enalaprilat but this did not prove statistically significant. The origin of this 
response is unknown. It occurred after very low doses of drug (25-50 |ig perindoprilat) 
during onset of plasma ACE inhibition. It preceded the onset of a controlled blood 
pressure fall during continued constant rate infusion. Clearly the response may be 
spurious and may only reflect the difference between parallel groups of patients. 
Nonetheless it was cleady evident during the data collection phase. It may reflect a 
transient partitioning effect on plasma and tissue based ACE and a further example of 
effects seen at doses of ACE inhibitor too low to affect blood pressure (eg Linz et al, 
1992; Motwani & Struthers,1992).
Drug may be inhibiting plasma ACE prior to concentration dependent diffusion 
into tissue sites. During the lag phase prior to tissue uptake and thus prior to blockade 
of the RAS in tissue sites excess plasma generated Ang I may transiently mediate a BP 
rise through conversion by tissue ACE. As diacid concentrations rise this may 
overcome the molecules’ lack of lipid solubility to gain access to tissue ACE sites and so 
inhibit Ang II mediated vasoconstriction.
This response has not been reported in previous studies. This could largely be 
because they have not employed the low dose protocol used in the present observations 
or have involved inadequate controls, infrequent blood pressure monitoring or bolus drug 
administration. As previous studies have not recorded BP until 30 mins post dosing 
clearly they would have missed this transient response. Similarly it is unclear if this 
response is agent related; or a feature only of patients with heart failure. Both drugs 
tended to show the pattern yet it was significant only after perindoprilat. Tissue ACE 
levels are known to be increased in heart failure from experimental observations (Hirsch 
et'al,1991,1992; Fabris et al, 1990). The total angiotensin II generating activity may not 
be entirely related to angiotensin converting enzyme or susceptible to angiotensin 
converting enzyme inhibitor drugs (Urata et al, 1990). Increased tissue based enzyme
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activity, if present in human chronic cardiac failure, may be pertinent to the transient 
elevation of blood pressure which we have observed.
The clinical use of angiotensin converting enzyme inhibitors has gradually 
evolved. Lower doses are now favoured yet surprisingly few studies have adequately 
examined haemodynamic or biochemical effects after these lower doses. The total dose 
administered and the rate of drug administration probably determine the observed 
dynamic response. Slow intravenous initiation of the angiotensin converting enzyme 
inhibitors is potentially useful in patients who may be at risk of excessive falls in blood 
pressure. Specifically this might be safer in patients with acute heart failure treated with 
diuretics around the period of myocardial infarction.
6.3.3. INTEGRATED FINDINGS OF HEART FAILURE STUDIES
These studies demonstrate under controlled observation a qualitatively different 
pattern of BP response between ACE inhibitors of similar chemical structure and 
metabolism. In the oral study the ester prodrug enalapril, given in low doses (2.5 mg) 
produced significant and long lasting falls in blood pressure and heart rate whereas 
perindopril (2 mg) caused no significant change from placebo. These responses were 
recorded despite comparable plasma ACE inhibition. In a similar randomly assigned 
group of patients with broadly comparable plasma ACE inhibition, the diacid metabolites 
of both drugs given alone reduce blood pressure.
The perindoprilat concentrations achieved after intravenous administration were 
higher than those previously achieved after oral perindopril. The contrasting effects of 
perindopril and perindoprilat may simply be confounded by differences in effective dose. 
Alternatively, the hitherto disregarded prodrug ester (perindopril) which appears first in 
the systemic circulation prior to the generation of significant quantities of the active 
diacid metabolite (perindoprilat) may influence the blood pressure response to perindopril.
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After oral treatment with perindopril it may be that the lipophilic ester, with its weak 
angiotensin converting enzyme inhibiting properties, may undergo rapid tissue 
distribution and interaction with the tissue based angiotensin generating system. From 
in vitro work it appears that perindopril, the parent compound, may reduce inhibition of 
angiotensin converting enzyme by perindoprilat, the metabolite (Harrigan et al, 1989). 
Any interaction between the parent compound and metabolite would be seen primarily 
after the initial dose, it would be expected to be dose and concentration dependent, and it 
could produce effects which would vary among tissues dependent on the distribution of 
each element to different sites.
In general terms the clinical pharmacology of ACE inhibitors in a variety of 
settings has been plagued by a lack of information about the lower end of the dose 
response curve. It was a specific aim of this series of studies to address this issue and it 
has allowed differential and hitherto unreported responses to be demonstrated.
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CHAPTER 7
STUDIES OF ANGIOTENSIN CONVERTING ENZYME INHIBITION IN 
NORMAL AND PATIENT VOLUNTEERS
7.1 TRANSPULMONARY PHARMACOKINETICS OF PERINDOPRILAT IN 
MAN.
The pulmonary circulation has traditionally been associated with the generation 
of angiotensin II from angiotensin I by the action of ACE. For many years it was felt 
that circulating All was the product of pulmonary ACE activity and that this was in turn 
a major endocrine function of the lungs (Ng and Vane, 1968; Said, 1982).
In theory uptake of drug to tissue sites should alter the plasma concentration time 
profile of ACE inhibitors. Non linear pharmacokinetic models are known to describe 
ACE inhibitor disposition better than conventional techniques (Francis et al, 1987; Lees 
et al, 1989). Parameters describing such a profile for an ACE inhibitor could indirectly 
give an index of tissue ACE activity and inhibition.
This study was designed to examine the transpulmonary extraction of the 
intravenous diacid ACE inhibitor perindoprilat (see Chapter 2). As the pulmonary 
circulation is theoretically a rich source of ACE activity this central site might be 
expected to provide a good definition of tissue uptake and altered pharmacokinetic 
profile of an ACE inhibitor.
7.1.1. PATIENTS AND METHODS
A. Patients
The study was conducted in an open design in ten male patients undergoing 
diagnostic cardiac catheterisation for the investigation of chest pain. The demographic 
details of the study population are given in Table 7.1. All patients had stable clinical
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Patients were selected such that they had no clinical, biochemical nor radiological 
evidence of cardiac failure and had not received diuretic therapy in the 2 months prior to 
study.
B. Procedure
All patients underwent routine diagnostic left ventriculography and coronary 
arteriography by the Judkins technique using non ionic contrast media (Iopamidol; 
Niopam 370, Merck U.K.) between 1030 and 1230 hours. After completion of this 
procedure a Coumand catheter was placed in the central venous circulation also by a 
femoral approach. Right heart pressures through to the pulmonary capillary wedge 
pressure, and the on-line pressure from the descending aorta, were recorded at baseline 
and the right heart catheter was then withdrawn to the main pulmonary artery for 
continuous pressure measurement and blood sampling. Aortic pressures were recorded 
throughout. A peripheral vein on the dorsum of the hand was cannulated for drug 
infusion. The surface electrocardiogram was monitored throughout the study. 
Immediately prior to infusion the infusate was prepared in sterile saline to contain 1 mg 
perindoprilat, 0.5 mg/kg indocyanine green and 10 ml purified plasma protein solution in 
a total volume of 20 ml which was infused at a constant rate of 100 (il/min over 20 
minutes. A Braun perfusor pump (Perfusor Secura E, Braun, Melsungen, FRG) was used 
with the infusate primed and running for 2-5 minutes prior to connection to the patient at 
the start of the infusion. The co-infusion of indocyanine green was employed as a 
marker for the intravascular space and transpulmonary transit analogous to previous 
animal experiments employing multiple indicator dilution (Linehan et al, 1985). The 
concentration of 0.5 mg/kg is known to be eliminated in an approximately linear fashion 
(Meijer et al, 1988). During the infusion (20 mins) and for the first 40 mins thereafter 
(i.e. total 1 hr) simultaneous right and left heart blood samples (5 ml) were drawn from
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the appropriate catheters after removal of the dead space volume. Sampling was 
conducted at frequent intervals during the initial accumulation phase of the infusion (30 
second intervals for 5 minutes) and during the early elimination phase after completion 
of the infusion (1 minute intervals for 5 minutes). The infusion was stopped exactly at 
20 minutes and the intravenous line disconnected but not flushed. Transpulmonary 
sampling was continued for a period of 1 hour after which the central catheters and 
peripheral infusion cannula were removed. Later phases of drug elimination were 
monitored by samples withdrawn from a separate peripheral venous cannula up to 20 
hours post commencement of the infusion. All patients remained supine for the full 
duration of the study and were monitored overnight in the cardiac investigation unit 
according to local practice.
C. Additional Biochemical methods
Indocyanine green was quantified after dilution of the plasma with 0.1% bovine 
serum albumin using standard photometric assay at 805 nm (Bjomsson et al, 1982; 
Svensson et al, 1982). The infusate formulation was shown to be stable in vitro for both 
perindoprilat and ICG at room temperature over 2 hours. There was no interference 
between the angiography dye and any of exogenous drug, ACE, plasma renin activity or 
ICG added to control plasma i n  v i t r o .
D. Pharmacokinetic analysis
To aid the interpretation of the accumulation profiles where multiple samples had 
been collected at close time intervals, and where assay variability therefore often 
exceeded the increment in drug concentration for pairs of samples, the raw data were 
subjected to mathematical smoothing before further statistical analysis. This was 
undertaken simply by substituting each concentration result with the mean of the
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reference concentration and the preceding and subsequent ones (Three point running 
mean technique, see Velleman,1980). The concentrations reflecting the start and end of 
the infusion were not adjusted.
The circulatory delay was calculated from comparison of the early, linear portions 
of the ICG accumulation data from the right heart samples with those from the left heart 
samples by applying linear regression of time upon ICG concentrations: the difference in 
Y intercept was taken to represent circulatory delay. A similar approach was used to 
assess apparent circulatory delay for the ACE inhibitor. Results are expressed as the 
mean of the individual circulatory delays for the 9 subjects with complete ICG data.
Pharmacokinetic modelling was conducted on raw concentration data. A 
hierarchy of standard multi-exponential pharmacokinetic models (1- to 3-compartment 
open, zero order input) and three modified 1-compartment open models (incorporating 
non linear tissue binding parameters, non linear plasma binding parameters or non linear 
tissue and plasma binding parameters) were fitted to the data (see Section 7.2 for further 
details). This was conducted by least squares non linear regression analysis using the 
biomedical statistics package BMD and the derivative-free option PAR (Ralston et al, 
1979) on an ICL 3980 series mainframe computer (University of Glasgow Central 
Computing Service). The derivation and application of these models had previously 
been described (Lees et al, 1989). The concentration time profiles employed were a 
combination of the right heart sampling concentrations during the transpulmonary 
catheterisation phase and the subsequent peripheral venous samples from 1 -2 0  hours. 
Where appropriate, model comparisons were based on the use of the general linear test 
(F-ratio test) (Neter and Wasserman, 1974) and the Schwarz criterion (Schwarz, 1989).
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A. Haemodynamic effects
There were no appreciable change in central or systemic cardiac pressures either 
during or up to one hour from the onset of the infusion (Figure 7.1).
B. Drug concentration and ICG profiles
The mean profile of plasma drug accumulation during transpulmonary 
catheterisation is illustrated in Figure 7.2. The ACE inhibitor did not approach steady 
state during the infusion. The small early gradient in perindoprilat concentrations 
between right and left heart samples is equivalent to a mean circulatory delay of 25 
seconds, and is exactly mirrored by the control substance ICG (Figure 7.3) from which a 
mean circulatory delay of 25 seconds was calculated. Thereafter, ICG shows rapid 
accumulation towards steady state and then rapidly declines on cessation of the infusion, 
reflecting the known short half-life of this compound. The full pattern of drug 
elimination employing right heart samples followed by peripheral venous samples is 
shown in Figure 7.4. There was no evidence during the early post-infusion period of 
any relative increase in left heart concentrations compared with those from the right 
heart, to reflect dissociation of drug from pulmonary binding sites.
C. Plasma ACE activity
ACE activity in circulating plasma from both pre-pulmonary and post-pulmonary 
sampling shows virtually complete inhibition of ACE within 90 seconds of starting 
infusion (Figure 7.5). There was little evidence for either a transpulmonary gradient in 
ACE activity or reduction in post-pulmonary ACE after discontinuation of infusion. 
Marked and persistent ACE inhibition was noted during the later period of monitoring 
with substantial inhibition of ACE activity remaining at 20 hours after the start of the 
infusion.
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Figure 7.2 Accumulation concentration time profile (mean±l SD, n=10) of perindoprilat 
in simultaneous plasma samples from right (O ) and left ( • )  heart catheters during 
constant rate infusion (1 mg, 20 mins).
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Figure 7.5: Mean ACE activity (±1 SD,n=10) in right (O) and left ( • )  heart plasma and 
peripheral venous plasma (■) during and following perindoprilat infusion.
D. Plasma Renin activity
Plasma renin activity determined from samples from the post-pulmonary 
circulation during transpulmonary catheterisation and subsequent peripheral venous 
sampling showed low basal levels prior to infusion and a delayed rise with a wide 
variation between individual patients (Figure 7.6).
E. Pharmacokinetic Modelling
The plasma concentration time profiles of perindoprilat were fitted 
simultaneously for all data sets. It did not prove possible to fit all data sets using a 
conventional 3 compartment linear model nor the non linear binding models which 
included terms for solely tissue binding or combined tissue and plasma binding. These 
were therefore rejected. Of the conventional models a 2 compartment zero order model 
provided a better fit for the observed data than 1 compartment as shown by the reduction 
in weighted residual sum of squares, F ratio and calculated Schwarz criterion (Table 7.2). 
This was not significantly improved by using a non linear binding model incorporating 
plasma binding terms.
It was clear from observing individual cases that the non-linear models did prove 
a much closer approximation to the observed data as had been previously observed (Lees 
et al,1989).
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Table 7.2: Characterisation of concentration time profiles of perindoprilat (right heart 
and peripheral venous plasma) by a hierarchy of pharmacokinetic models.
WEIGHTED RESIDUAL SUMS 
SQUARES MODEL
SCHWARZ CRITERION 
MODEL
SUBJECT A B E A B E
1 101.5 78.9 79.7 146.7 142.3 142.6
2 146.8 56.5 57.6 178.1 148.3 149.0
3 44.4 26.7 26.5 136.3 122.0 121.8
4 91.8 91.8 70.8 161.7 165.3 156.3
5 105.7 35.3 34.7 166.6 131.8 131.3
6 111.1 50.9 51.1 168.4 144.7 144.8
7 71.6 31.7 31.7 153.0 128.0 128.1
8 53.0 41.9 41.9 142.5 137.9 137.9
9 56.5 23.0 22.7 144.7 116.9 116.4
10 99.3 95.7 95.5 164.5 166.8 166.7
RANK SUM 27 18 15
FREIDMAN _ N S  NS___
(ANOYA)  P<0.05____
A = One compartment open, zero order input 
B = Two compartment open, zero order input
E = One compartment open, zero order input, non-linear plasma binding.
7.2 PERINDOPRILAT INFUSION STUDIES IN SALT REPLETE MAN.
The intravenous route of administration has been proposed for use of ACE 
inhibiton in the management of acute heart failure (Flynn et al, 1988; Ahmad et al,
1990), the treatment of accelerated hypertension (Rutledge et al, 1988; Savi et al, 1990) 
and after acute myocardial infarction (Taylor et al, 1989; Nabel et al, 1991). Detailed 
experience with the intravenous route of administration is limited.
In this section it was sought to further test the observation that the 
pharmacokinetic disposition of ACE inhibitors may be influenced by specific and 
saturable binding to plasma ACE (Francis et al, 1987) and/or tissue ACE (Lees et al, 
1989). From pharmacokinetic descriptions the contribution of tissue ACE to the 
haemodynamic effects of ACE inhibition in man might be achieved by indirect means. 
Specifically the lower end of the dose response relationship was of interest in keeping 
with the work in heart failure patients recieving low doses and other clinical populations 
eg peri-myocardial infarction where these might be relevant.
In the present study protracted low dose constant rate infusion schedules were 
employed in order to provide precise pharmacokinetic definition and also, despite the 
low likeliehood of significant response, from the standpoint of a basis for controlled dose 
titration and response (see section 6.2).
7.2.1. SUBJECTS AND METHODS
A. Design
A four-way, single-blind (subjects), crossover study was conducted in 8 
normotensive male subjects. The subjects were randomised to receive a 3 hour infusion 
of saline placebo, or perindoprilat 1 mg by constant rate intravenous infusion over 1 
hour, 3 hours or 6 hours. All subjects received all four treatments on separate occasions
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at least 10 days apart.
B. Subjects
Eight healthy men (age 19-40 years; weight 65 - 89 kg) participated in a single 
blind, random treatment order study after screening by clinical history and physical 
examination, routine urinalysis, ECG, laboratory biochemistry and haematology 
(including serum ferritin).
C. Procedure
All subjects were free from concomitant medication for the duration of the study 
and followed their normal diet. No smoking or alcohol consumption was allowed for 12 
hours before or during each of the four study days, which were conducted at least 10 
days apart and commenced at around 0700 hour after a light breakfast at home. A single 
(subject) blinded randomised treatment design was employed whereby subjects received 
intravenous perindoprilat (1 mg in 30 ml normal saline) over 1, 3 or 6 hour or saline 
placebo (30 ml over 3 hour) via a peripheral venous cannula on the dorsum of the hand.
A further heparinised cannula was inserted in an opposite antecubital vein for blood 
sampling purposes. The subjects were cannulated and rested supine for at least 30 
minutes prior to commencing the study. Infusions were administered using a calibrated 
constant rate infusion pump (Braun Secura E; Melsungen, Germany) which was set up 
and running for at least 5 mins prior to being attached to the subject’s cannula. At the 
end of the infusion the pump was switched off. The cannula remained attached and was 
removed at 6 hours without flushing. The subjects were unaware as to the significance 
of infusion duration and did not know that the placebo infusion would be 3 hours. A 
light snack was provided at 5 hour and 10 hour (no tea or coffee allowed). Blood 
pressure (BP) and heart rate were recorded supine and erect before and at frequent
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intervals during the infusion and subsequently. Due to the sampling frequency no erect 
BP recordings were obtained for the 1 hour infusion. All values were recorded in 
triplicate.
Peripheral venous blood samples were drawn for the determination of plasma 
concentrations of perindoprilat and ACE activity. During the 1 hour infusion these were 
drawn at 0, 5,10,20, 30,40,50, 60, 65,70, 80,90,100,110 min and 2,4, 6, 8,10,24,
32,48 and 56 hour; during the 3 hour infusions (including placebo) at 0,0.25,0.5,1,
1.5,2,2.5, 3, 3.25, 3.5,4,4.5,5,5.5, 6, 8 ,10 ,24 ,32 ,48  and 56 hour, during the 6 hour 
infusions at 0 ,0 .5 ,1 ,2 , 3,4, 5, 6,6 .5 ,7 , 8 ,9 ,10 ,11 ,12 ,13 ,16 ,24 ,32 ,48  and 56 hour. 
On each study day supine plasma renin activity was determined at 0 hour, at the end of 
the infusion, at the end of the study day and at 24 hours post study.
7.2.2. SPECIFIC DATA ANALYSIS
A. Blood pressure data
The timing of blood samples and blood pressure measurements was related to the 
duration of the infusion for each study day. For the purposes of comparison of blood 
pressure responses, only the common times of blood pressure recording were used.
These were 0 ,0 .5 ,1 ,2 , 3 ,4 ,6, 8,10 and 24 hours from the commencement of the 
infusions. Mean data of triplicate values for these time points were compared using 
repeated measures analysis of variance (ANOVA) with Bonferroni correction (see 
Chapter 5). In an effort to generate a response record employing all available blood 
pressure time points each individual blood pressure record was subjected to a simple 
non-linear data smoothing technique (Velleman, 1980). Each subject then provided 
"smoothed" common time point blood pressure values which were again compared using 
repeated measures ANOVA for each phase as above. The blood pressure responses 
were further described by baseline corrected responses and by deriving the maximum fall
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in systolic pressures for each individual during each phase. These were also compared 
using ANOVA.
B. Pharmacokinetic modelling
The concentration time profiles of perindoprilat using the different duration of 
infusions were characterised using a hierarchy of standard compartmental models and 
non-linear saturable binding models similar to those used in previous work whose 
derivation and validation has been described in detail (Lees et al, 1989). Briefly a range 
of multiexponential compartmental models (1 compartment (A), 2 compartment (B) and 
3 compartment (C)) were fitted to the data using derivative-free, least squares, non-linear 
regression with the statistics package BMD-PAR on an ICL 3980 mainframe computer. 
Similarly, simple kinetic models (ie. one compartment, zero order input) with extra 
parameters to describe non linear, saturable tissue binding (D), plasma binding (E) or 
combined tissue and plasma binding (F), all with one compartment zero order input 
assumed, were fitted to the observed data. If a given model was unable to fit all data 
sets simultaneously then this led to rejection of that model. The "goodness of fit" of 
models for the observed data was compared using the general linear test and calculated 
Schwarz criterion where appropriate. This assess the statistical fit of the observed to 
predicted data for a range of model systems in the form of a comparative summary 
statistic. The calculation of the parameters derived from these models has been discussed 
elsewhere (Lees et al, 1989).
7.2.3. RESULTS 
A: Haemodynamic Effects
The blood pressure response to intravenous infusion of perindoprilat is illustrated 
in Figure 7.7. During all treatments a rise in both supine and erect BP was seen between
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5 and 7 hours after starting infusions which corresponded to the subjects’ meal time. 
Supine systolic blood pressure fell with active infusions compared to the placebo control 
(Figure 7.7a). A similar pattern was observed with diastolic pressure. Similar changes 
were observed with erect blood pressures during the placebo, 3 hour and 6 hour active 
infusions (see Figure 7.7b). Statistically significant changes were seen between placebo 
and 6 hour infusion at the 6 and 10 hour time points. Smoothed erect systolic blood 
pressure falls with 6 hour infusions of perindoprilat were significantly greater than 
control between 3 and 6 hour after starting the infusion (see Figure 7.7c). There was no 
significant change in supine or erect heart rate compared to placebo.
B. Drug concentration profile
The observed drug accumulation and elimination profiles are illustrated in Figure 
7.8. All three rates of infusion, but 3 and 6 hour infusions in particular, show a sigmoid 
accumulation profile with delay in the early accumulation of the measured drug in 
plasma. The observed mean maximal plasma concentrations of perindoprilat reflected 
the rate of infusion (1 hour 51.5±11.4 ng/ml; 3 hour 30.4±8.4 ng/ml; 6 hour 19.0±4.0 
ng/ml) and were all significantly different from each other (p = 0.013, ANOVA).
C. Plasma ACE inhibition
Plasma ACE activity was rapidly inhibited by a 1 hour infusion of perindoprilat 
but less rapidly by a 3 or 6 hour infusion (Figure 7.9). The mean maximal observed 
inhibition was less with the slower rates of infusion (1 hour, 95.7±0.5% versus 3 hour, 
92.3±2.7% and 6 hour, 87.4±5.1%; p = 0.013). After 48 hours there was no significant 
difference in ACE activity from placebo with any active infusion.
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Figure 7.8: Concentration time profiles (mean±lSD, n=8) following constant rate 
intravenous infusion of perindoprilat (1 mg) over 1 (■), 3 (a ) or 
6 hours (•).
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Figure 7.9: Plasma ACE activity (mean±lSD, n=8) following placebo (A ) or 
perindoprilat (1 mg) by intravenous infusion over 1 hour (■), 3 hours (a ) or 
6 hours (•).
D. Plasma renin activity
There appeared to be a greater reactive rise in plasma renin with the 6 hour 
infusion protocol (mean change in PRA, 2.4 ng Al/ml/hr) than that seen in response to 1 
hour (0.5 ng Al/ml/hr) or 3 hour (1.8 ng Al/ml/hr) infusions of perindoprilat (see Figure 
7.10), but these changes were not statistically significant (p = 0.14). Due to the small 
number of samples and different time points studied it is not possible to interpret the 
different profiles formally in greater detail.
E. Pharmacokinetic analysis
The pharmacokinetic data from the 1 hour infusion studies supported only a 
simple one compartment model. In contrast the 3 and 6 hour infusion studies were 
clearly better described by the models employing saturable non linear binding (p < 
0.0001).
The best description of observed data was given by a model (F) incorporating 
elements to describe both tissue and plasma binding of the drug. The derived parameter 
estimates had acceptable coefficients of variation in most cases (Table 7.3). The mean 
(SD) volume of distribution for free drug was 12.1 (7.0) litres, with kej for free drug of 
1.24 h"l (1.18). The mean estimated capacity of total binding sites for perindoprilat was 
313 ng (211). Only 7.1 ng (3.9) of free drug (i.e. 163 ng in total) were estimated to 
produce 50% saturation of all binding sites. Ninety-one percent (7) of all binding sites 
appeared to be located in tissue compared to plasma.
130
PL
AS
M
A 
RE
NI
N 
AC
TI
VI
TY
 
(n
gA
I/m
l/h
r)
10 1 
9 -
8-
7 -
6 -
5 -
4 -
3 -
2 -
1 -
0-
i--------------------------1---------------------------1-------------------------- 1-------------------------- 1-------------------------- 1-------------------------- 1
0 4 8 12 16 20 24
TIME (HOURS)
Figure 7.10: The effect of constant rate perindoprilat infusion (1 mg) over 1 (■),
3 (a ) or 6 (•) or placebo (a) over 3 hours on plasma renin activity (mean + 1SD, n=8).
Table 7.3: Parameter estimates with coefficients of variation for model F, one 
compartment, open, zero order input non linear tissue and plasma binding, applied to 6 
hour infusion profiles.
Subject kel CV(%) v d CV<%) Bmax CV(%)Au5o CV(%) F CV(%)
1 0.66 10 12.2 9 179 12 4.3 38 0.87 3
2 4.09 123 2.7 100 789 7 2.5 90 1.00 1
3 1.3 37 5.8 39 381 16 13.6 26 0.99 1
4 0.82 8 9.9 8 147 9 4.9 28 0.89 2
5 0.92 16 10.5 16 241 13 9.5 27 0.94 2
6 0.50 13 23.6 13 201 17 4.5 68 0.89 4
7 ' 1.1 30 11.4 30 371 14 11.1 26 0.95 2
8 0.6 16 21.0 14 191 20 6.4 49 0.78 7
Mean
SD
1.24
1.18
12.1
7.0
313
211
7.1
3.9
0.91
0.07
k j = elimination rafe constant
Vd = volume of distribution "plasma" compartment (1) 
Bmax = Tota  ^binding capacity (pg)
Au5o = Amount of free drug that produces 50% binding (pg) 
F = Fraction of total binding sites in tissue.
7.3 ACE INHIBITION IN SALT DEPLETE MAN: ORAL ENALAPRIL IN A 
MODEL OF THE ACTIVATED RENIN ANGIOTENSIN SYSTEM.
To undertake the appropriately controlled and detailed studies of the response to 
blockade of the renin angiotensin system in patients with heart failure presents practical 
problems with concomitant medication, drug withdrawal, crossover designs and a variety 
of uncontrolled disease based factors which might influence response. The principal aim 
of this section was to establish a simple and reproducible human model suitable for 
detailed assessment of the responses to blockade of the renin angiotensin system and for 
differentiating drug effects. In the first instance the blood pressure and neurohormonal 
responses to low oral doses of enalapril were studied in young normotensive males in 
whom the renin angiotensin system had been acutely activated by a short programme of 
sodium depletion based on moderate dietary restriction and diuretic treatment.
7.3.1. SUBJECTS AND METHODS
Eight normotensive male volunteers (25.6±4.6 yrs; 70.5±6.1 kg) gave written 
consent for their participation in the study following confirmation of health by clinical 
history, physical examination, biochemical and haematological screen, 24 hour urinary 
sodium excretion (100-200 mmol) and electrocardiogram.
Salt depletion was implemented for three days prior to each of two study days. 
Volunteers were provided with all meals for a diet containing 40 mmol sodium per day. 
Dietary instruction by a qualified dietitian, and an accompanying diet sheet, defined 
allowed or disallowed supplemental foods. Fluid intake was encouraged but alcohol 
prohibited. Subjects continued on the dietary sodium restriction during the study day and 
until the return visit at 24 hrs following drug administration. During the three day 
pretreatment schedule the subjects took frusemide 40 mg (Antigen Pharmaceuticals,
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UK), twice daily at 0800 hr and 1200 hrs. The last dose of diuretic was therefore 
administered approximately 20 hours before drug administration. Following instructions 
on technique, 24 hour urinary collections were performed at the screening visit, for the 
24 hours preceding each of the two study days (day 3) and the 24 hours of each study 
day (day 4).
Volunteers attended the Clinical Pharmacology Research Unit (CPRU) after an 
overnight fast (10 hrs) on two separate occasions, 14 days apart, to receive enalapril 5 
mg (Innovace, MSD, Hoddeson, UK) or placebo (vitamin C 50 mg, APS Pharma UK in 
an opaque gelatin capsule). Treatments were administered in a randomised, double 
blind, crossover design prepared by the Department of Pharmacy.
On attendance (0800 hr) subjects rested supine for at least 30 minutes following 
placement of a heparinised venous cannula in an antecubital vein for the purposes of 
blood sampling. Basal blood samples and blood pressure readings were collected supine 
prior to measurement of erect blood pressure and heart rate and bladder voiding. Blood 
pressure and heart rate were determined in triplicate using a semiautomatic device 
(Datascope Acutorr 3A, Paramus, New Jersey) at frequent intervals during the study day. 
Blood samples were drawn at intervals for the determination of serum drug 
concentration, semm electrolytes, plasma ACE activity and plasma renin activity. All 
subjects had been supine for at least 50 minutes prior to blood sampling for renin 
activity. Drugs were administered with 200 ml of fluid (0 hr), a further 200 ml was 
given with a light breakfast (2 hr), 400 ml with lunch (4 hr) and 200 ml with an evening 
snack (9 hr).
Serum and urinary electrolytes were determined using a routine autoanalyser by 
the hospital biochemistry laboratory.
132
7.3.2. RESULTS
A. Salt depletion
In general, the salt depletion regimen was well tolerated and no spontaneous 
symptoms were reported. Urinary volume was significandy increased on the third day 
(pre-study day), in comparison with the screening day, and this was associated with 
significant falls in urinary sodium excretion (Table 7.4). There was a non-significant 
trend towards a rise in urinary potassium excretion but urea and creatinine excretion were 
unchanged. Urine volumes were significantly lower during the two study days with a 
significantly greater degree of sodium loss following enalapril. Potassium excretion was 
not significantly altered but showed a trend to reduction following enalapril.
Salt depletion was associated with significant reductions in serum sodium 
(142.5±1.0 at screening, 138.9±0.8 and 139.6±1.3 mmol.l"  ^ at baseline on the 2 study 
days) and in serum potassium (4.2±0.3 on screening, 3.810.2 and 3.710.2 mmol.l"  ^ at 
baseline on the 2 study days). Changes in serum electrolytes during the study day are 
illustrated in Figure 7.11.
Screening blood pressure was reduced from 124/6918/7 supine and 125/77112/6 
mmHg to 115/6918/7 and 108/6519/6 supine and 113/6715/9 and 113/67112/9 mmHg at 
baseline on the 2 study days.
B. Enalapril v placebo
Because supine blood pressure was slightly higher at baseline on the enalapril 
study day responses were individually corrected to the pretreatment (baseline) values on 
each study day. Baseline corrected changes in blood pressure are illustrated in Figure 
7.12. Enalapril caused a mean maximal fall in supine systolic blood pressure of 18.9±7.6 
mmHg at about 5 hours post dose, compared to 6.5±6.8 mmHg following placebo.
Similarly, enalapril caused a significantly greater fall in erect systolic blood
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Figure 7.12: Baseline corrected changes (mean ± 1SD) in (a) supine and (b) erect blood 
pressures and heart rate following oral placebo (O) or enalapril (• ) .
rate was not significantly altered by either therapy but showed a tendency to rise during 
the latter part of the study day (following lunch).
C. Drug concentrations, ACE inhibition and plasma renin activity
Drug concentrations of enalapril and enalaprilat and plasma ACE inhibition are 
sh'own in Figure 7.13. The peak plasma enalapril concentration of 50±20.8 ng/ml was 
observed at 1.25+0.25 hours but the maximum concentrations of enalaprilat were not 
attained until 4-6 hours post dose. Near maximal plasma ACE inhibition was observed 
after about 2 hours and maximum inhibition of 78±5.7% occurred at 5.2±1.2 hrs.
Supine plasma renin activity was significandy elevated at baseline on each study 
day (6.0±3.2 on the placebo day and 5.2±2.1 ngAI.ml.hr"* on the enalapril day) 
compared to salt replete pretreatment screening values (0.9±0.5 ngAI.ml.hr"*). The 
profile of plasma renin activity showed a rise following enalapril but also during placebo 
therapy following food (Figure 7.14).
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7.4 DISCUSSION
7.4.1 TRANSPULMONARY ACE INHIBITOR INFUSION
This study represents the first description of the transpulmonary 
pharmacokinetics of an ACE inhibitor in man.
Pulmonary ACE activity and the effects of ACE inhibitors on the enzyme at this 
site have been studied i n  v i t r o ,  e x  v i v o  and in a limited number of i n  v i v o  animal 
experiments. The structure of the enzyme in pulmonary homogenates is suggested to be 
only marginally different from the circulating "soluble" enzyme and it has been 
suggested that the pulmonary circulation may be the source of circulating ACE activity 
(Das and Soffer, 1988). The enzyme has been localised on the vascular endothelium of 
the lung, in common with that found in a range of organs (Ryan et al, 1980,1985), and 
has particular functions in the response to pulmonary hypoxia (Pitt et al, 1987; Oliver et 
al, 1989) or to chemical injury (Hollinger et al, 1980; Kelley, 1988). It is known to be 
present in association with alveolar macrophages (Friedland et al, 1977). In addition to 
its role as an exopeptidase contributing to localised All generation, ACE has less clearly 
defined endopeptidase functions (Re and Rovigatti, 1988).
Studies in animals have shown temporal dissociation of plasma and pulmonary 
tissue ACE inhibition from the hypotensive response to ACE inhibition. It has been 
suggested that tissue ACE inhibition better describes the pattern of this response than the 
inhibition of ACE from a plasma sample (Cohen and Kurz, 1982; Chevillard et al, 1989; 
Kamei et al, 1989).
Previous animal work by Gillis and colleagues in rabbits had successfully defined 
pulmonary tissue ACE and its inhibition by captopril by employing single pass 
pharmacokinetic studies of the bolus injection of the synthetic ACE substrate, benzoyl- 
phenylalanyl-alanyl proline (BPAP) with the co-infusion of the intravascular marker dye 
ICG (Howell et al, 1984; Chen et al, 1984; Moalli et al, 1985; Linehan et al, 1985).
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As the structure and function of ACE is likely to differ between species (Takada 
et al, 1982; Ibarra-Rubio et al, 1989) there has been difficulty defining the qualitative or 
quantitative aspects of tissue ACE inhibition in man. The relative importance of tissue 
ACE in generating the pharmacodynamic responses to ACE inhibitors in normal 
volunteers or patients remains difficult to assess. The use of a pharmacokinetic model to 
describe the concentration time profile of an ACE inhibitor may be a viable technique 
and this was studied in this and the subsequent section. This model incorporates 
elements describing a saturable competitive binding process to both plasma and tissue 
ACE (Lees et al, 1989)
Along similar lines to the studies of Gillis and colleagues in rabbits, this study 
whs designed to use the pharmacokinetic profile of an ACE inhibitor in an attempt to 
mark tissue uptake, with the co-infusion of ICG to standardise for transpulmonary flow.
This study was conducted in a patient population who required central cardiac 
catheterisation as part of their on-going medical investigation. Both the dose and rate of 
infusion were chosen on the basis of previous studies in normal volunteers (Lees and 
Reid, 1987). The regimen was chosen to minimise the risk of adverse effects in a 
population with stable ischaemic heart disease and, as expected, the haemodynamic 
effects of infusion were minimal despite the presence of concomitant therapy in the 
population studied. Blood pressure data were collected primarily for reasons of safety 
and to exclude flow changes as a confounding variable in pharmacokinetic profile.
Care was taken in the study to eliminate errors due to inadequate pump priming 
by ensuring infusion prior to attachment to the peripheral venous cannulae.
Furthermore, as ICG is known to aggregate in concentrated solution (Bjomsson et al, 
1982) the infusate was prepared containing plasma protein solution to distribute the dye 
which was prepared along with the drug 5 -10 minutes prior to commencing the study. 
Previous studies using this dose and rate of infusion and peripheral venous
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sampling had suggested that the early periods of accumulation were characterised by 
lower drug concentrations in peripheral venous blood suggestive of a sigmoid 
accumulation profile presumably due to the uptake of drug into the tissues during the 
process of arteriovenous passage (Lees et al, 1989). Despite a marked increase in the 
density of the sampling protocol the present study failed to find such a sigmoid 
accumulation profile in central venous samples taken from a main pulmonary artery.
Given the precautions taken with infusion the inhibition of circulating ACE 
activity in the initial samples was very marked. Clearly the available drug within 30 
seconds of commencing infusion was sufficient to inhibit the majority of circulating 
ACE with a residual component available for tissue uptake. The concentrations in the 
central compartments would be subject to recirculation beyond the first 2-3 minutes.
There may be several reasons for the failure to demonstrate either a sigmoid 
pattern of accumulation or a significant early transpulmonary delay in drug concentration 
during this series of observations.
Although previous studies using this dose and rate of infusion had generated 
profiles which were suggestive of tissue binding of the drug influencing concentration 
time profiles a lower dose or rate of infusion might better define this type of profile given 
the marked ACE inhibition observed. In addition although the lungs have been regarded 
as the dominant source of ACE activity for the circulation this has had to be revised in 
the light of the widespread distribution of ACE activity at a variety of different tissue 
sites (Johnston et al, 1987). The relative proportion of accessible whole body ACE 
which is situated in the pulmonary circulation remains unknown. Previous studies 
involving peripheral venous sampling reflect exposure of the given dose to the "whole 
body" ACE pool and therefore the present study might not reflect exposure of the drug to 
a large enough pool of enzyme. In addition as an infusate containing plasma protein 
solution was employed, for reasons described above, this may have affected the
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distribution of very small quantities of drug. In effect a slowed equilibration of drug 
between plasma and tissue ACE might not have been reflected in e x  v i v o  ACE inhibition 
as a substantial time period occurred e x  v i v o  prior to assay.
An arteriovenous concentration gradient would be expected from theoretical 
grounds with any drug which interacts with a tissue in order to generate its 
pharmacodynamic effect. However, such arteriovenous concentration time profiles are 
rarely defined (Chiou, 1989). In this setting the concentration of a drug at a given 
arterial or venous site is a reflection of both the blood flow at that site and the relative 
partition coefficient for the drug into the given tissue bed (Bischoff, 1986). Accordingly 
the flow rate across the lung is several hundred times greater than that for the peripheral 
sampling site and thus flow would be expected to dominate the partition of a drug such 
as an ACE inhibitor with its tissue binding sites which in this case would be 
predominantly tissue ACE. This element of site dependency in generation of a 
concentration time profile is probably the key element in our failure to describe a marked 
transpulmonary extraction of ACE inhibitors. It would seem unlikely that our patient 
population, predominantly with ischaemic heart disease, was associated with any 
particular reduction in pulmonary ACE sufficient to mask uptake. However, this aspect 
has not previously been studied.
Thus although unable to demonstrate a clear advantage of the non-linear saturable 
binding model over conventional multi-exponential pharmacokinetic models in this study 
individual data fits were often better described by the former structure. As a sum of 
exponentials or polynomial functions can always be formed to fit a series of observed 
data, the main problem is that these have no physical meaning and give no information 
about the primary system (Rescigno and Beck, 1987). It would be incorrect to suggest 
that the simple non linear models applied here are "physiological" but they may derive 
terms which are more descriptive of tissue binding and consequently better related to
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pharmacodynamic effect. The observations in this section suggest that the most 
appropriate sampling site for such comparisons would be the traditional peripheral 
venous blood.
7.4.2 PERINDOPRILAT INFUSION STUDIES IN SALT REPLETE MAN.
An influence of protein binding on the pharmacokinetics of ACE inhibitors has 
been described by a number of groups. In particular, this binding is thought to occur to 
ACE in plasma and tissues (Francis et al, 1987; Lees et al, 1989) and for most ACE 
inhibitors this is a tight binding interaction at at least two binding sites in keeping with 
enzyme structure (Perich et al,1992). Present knowledge of the haemodynamic effects 
of ACE inhibitors stems from their use in clinical practice. The pharmacological studies 
which have been carried out offer very limited evidence of the effects which occur in 
response to low doses of these drugs. As a result, the minimum effective dose is poorly 
defined. This may be of particular importance where these drugs are given to individual 
patients who are at risk of a profound haemodynamic response.
The available information on the use of intravenous ACE inhibitors comes 
primarily from studies of pharmacokinetics and bioavailability (Reams et al, 1986; 
Nussberger et al, 1987; Evans et al, 1987; Creasey et al, 1988). A case for the clinical 
use of intravenous ACE inhibitors has been made both for accelerated hypertension 
(Rutledge et al, 1988; Savi et al, 1990) and for the management of acute heart failure 
(Flynn et al, 1988; Taylor et al, 1989) and preventing left ventricular dysfunction 
following myocardial infarction (Nabel et al, 1991; Sharpe et al, 1991; CONSENSUS II 
Study group,1992). These indications remain controversial (and indeed possibly 
detrimental) and are not approved by regulatory authorities. The available experience
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with intravenous therapy is limited to bolus injection or infusion over periods as short as 
2 to 10 minutes. In many of the studies rapid dose escalation has been employed and 
this has hampered the description of the dose-response relationship in that neither 
haemodynamic, primary or seconary hormonal equilibrium is possible or in many cases 
documented.
When the approximate oral bioavailability of the drugs and the known effects on 
inhibition of circulating plasma ACE activity are taken into account, the intravenous 
doses which have been administered are likely to have been maximal or in most instances 
supramaximal. This would make an adequate description of the concentration response 
relationship impossible and more importantly limit dose titration and control over the fall 
in blood pressure.
In this study a clear haemodynamic response was documented in young salt 
replete normal volunteers after a low dose of the diacid ACE inhibitor perindoprilat. In 
addition, by using slow constant rate infusion it is evident that the slower rates of 
infusion are at least as effective in lowering BP as faster rates with equivalent total 
dosage. This is despite a correspondingly reduced Cmax and reduced maximal plasma 
ACE inhibition. The larger doses of ACE inhibitor given acutely or in this study by 
more rapid infusion, result in a high free fraction of drug which is readily eliminated by 
the kidney. Smaller doses or slower administration result in a lower free fraction. The 
ACE inhibitors are almost unique, in that the free fraction is not the determinant of drug 
effect and it is the bound fraction which is inhibiting ACE, predominantly that present at 
tissue based sites which results in the haemodynamic response. Thus, the drug is less 
"efficient" in generating its haemodynamic response when greater concentrations are 
achieved through rapid infusion. A similar pattern of response has recently been 
documented for the calcium channel-blocking drug, felodipine (Cohen et al, 1990).
The earlier work with perindoprilat by Lees suggested that the accumulation
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phase of the pharmacokinetic profile might provide further information on the tissue 
uptake of ACE inhibitors. The pharmacokinetic profile was best described by a non­
linear saturable binding relationship and the mathematical description of this profile 
provided estimates of the maximal binding and the extent of inhibition of "tissue" ACE 
(Lees et al, 1989). This study provided more detailed confirmation of a sigmoid drug 
accumulation profile, most notably with the 6 hour infusion. It has reaffirmed the 
superiority of the non-linear saturable binding models for description of ACE inhibitor 
disposition. The parameter estimates agree closely with those previously reported (Lees 
et al, 1989).
The individual parameter estimates which can be obtained from pharmacokinetic 
analysis may reflect overall tissue binding and ACE inhibition. These estimates can be 
obtained from drug concentration data in peripheral venous blood. They now need to be 
related to the haemodynamic response. In normal subjects blood pressure changes are 
definable but limited as seen in this study. A setting of enhanced response is requred to 
relate concentration to haemodynamics.
Whilst low dose constant rate intravenous infusions of ACE inhibitors are not 
currently employed in clinical practice. These results reaffirm the findings in heart 
failure (section 6.2). If intravenous treatment is indicated, constant rate low dose infusion 
should be considered. Large falls in blood pressure with intravenous administration are 
likely to be due simply to the supramaximal doses employed. The temporal dissociation 
of blood pressure response to short infusions of perindoprilat (1 mg) and the high peak 
plasma drug concentration reaffirm this message. Slow constant rate infusion should 
allow better control over blood pressure by discontinuation of infusion where marked 
sensitivity is encountered.
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7.4.3 ACE INHIBITION IN SALT DEPLETE MAN: ORAL ENALAPRIL IN A 
MODEL OF THE ACTIVATED RENIN ANGIOTENSIN SYSTEM.
The primary aim of this study was a basic description of a human model for the 
detailed study of ACE inhibitor responses, using readily acceptable means of inducing 
activation of the renin system. Although dietary salt restriction has been widely used in 
this context, a very low sodium diet (< 10 mmol/Na) has usually been employed and 
controlled studies with modern renin analysis are rare (Hollenberg et al,1981; Navis et 
al,1987). Such low salt diets are barely palatable for unselected volunteers; difficult to 
control under outpatient circumstances; require careful preparation; and are liable to 
non-compliance. In this respect, where controlled studies involving salt repletion and 
depletion are required over prolonged or repeated periods the nature and composition of 
the diet becomes even more important to the individual volunteers. We therefore chose 
moderate sodium restriction (40 mmol) with dietary provision and instruction over the 
four day study periods. In order to produce further sodium loss and to achieve 
activation of renin angiotensin system oral frusemide (40 mg b.d.) was administered on 
each of the three pre-study days. The pharmacodynamic response to frusemide has been 
extensively characterised (Hammarlund-Udenaes&Benet,1989; Boles-Ponto & 
Schoenwald, 1990). To prevent overt fluid depletion, which might predispose to reduced 
intravascular volume, a high fluid intake was specifically encouraged during the pre­
study period and similarly, the fluid intake on the study day was carefully controlled. 
Volunteers tolerated the pretreatment well and, in particular, none spontaneously 
commented on marked diuresis at any point in the study.
Both the serum and urinary electrolyte data on the third day of baseline and the 
pretreatment values on the study day suggest moderate salt depletion and renin 
angiotensin system activation. The programme of frusemide pretreatment, with the gap
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between the last oral dose and the study day avoids any acute haemodynamic effects 
which follow frusemide treatment (Johnston et al,1984) and, as predicted, produced a 
persistent degree of hyper-reninaemia (Tuck et al,1982).
Significant reductions in pretreatment serum sodium and potassium were 
achieved without overt hyponatraemia or hypokalaemia. Similarly, urinary urea or 
creatinine values were not significantly altered from baseline values and this provides 
further reassurance that overt fluid depletion was not caused and additionally that urinary 
collections were reasonably complete. In keeping with the moderate but persisting 
activation of the renin angiotensin system during the study day, there appeared to be 
some degree of antinatriuresis although there continued to be some urinary sodium loss 
from the 40 mmol dietary provision.
Although not universally accepted, measurable falls in blood pressure have been 
demonstrated in controlled studies in salt replete volunteers (Kiowski et al,1992; Lees & 
Reid, 1991) but the magnitude of the response is small and may limit the value of such 
studies, at least with regard to blood pressure, as a means of assessing the response to 
renin angiotensin system blockade. In this study, despite the low dose of enalapril, there 
were considerable reductions in blood pressure.
The role of baseline renin angiotensin system activation in the blood pressure 
response to ACE inhibitor treatment has practical as well as theoretical importance.
Since the introduction of ACE inhibitor into the treatment of hypertension and heart 
failure there has been widespread clinical concern over the so called "first dose 
hypotensive response" which occasionally is symptomatic and rarely is associated with 
renal, cerebral and cardiac hypoperfusion damage. The precise origin of this profound 
blood pressure fall is unclear but many factors may play a role: salt and fluid balance, 
the status and setting of baroreceptor reflexes, concurrent or temporarily discontinued 
drugs such as diuretics, vasodilators or digitalis and more general factors such as drug
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dose, age, diurnal blood pressure patterns, metabolism and elimination pathways and 
individual subject sensitivity. Using a model of renin angiotensin system activation such 
as that described here it will be possible to address in controlled double blind studies the 
contribution of the particular drug, the dosage selected and the level of activation of the 
renin angiotensin system to the overall pattern of response in terms of blood pressure, 
heart rate, regional perfusion, etc. Similarly, the differential effects of alternative means 
of renin angiotensin system blockade based on orally active drugs blocking the rate 
limiting enzyme, renin or angiotensin receptor blocking drugs. The baseline level of 
circulating renin seen in our study is easily comparable with those seen in renovascular 
hypertension (Hodsman et al,1982) or heart failure (Anand et al,1989) but derived in 
more controlled circumstances.
Double blind studies can readily be performed by providing oral salt repletion in 
addition to the standard 40 mmol sodium diet using coated tablets and placebo 
frusemide. In this setting active salt depletion is produced by matched placebo salt 
tablets and active frusemide. Such controlled observations are not common in the 
assessment of ACE inhibitor responses despite 15 years of clinical study. The newer 
agents for renin angiotensin system blockade could also benefit from such assessment.
In summary, this study has described a simple and well tolerated model of the 
activated renin angiotensin system in man based on moderate dietary sodium restriction 
and acute diuretic therapy. This model is suitable for initial dose ranging and dose- 
response studies with a variety of agents which act via the renin angiotensin system, for 
studies of the role of renin angiotensin system activation in individual response and for 
more detailed concentration effect studies integrating secondary neurohormonal changes 
with treatment.
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CHAPTER 8
CONCLUDING REMARKS
The studies on angiotensin converting enzyme inhibition presented here 
demonstrate, in controlled circumstances, that the haemodynamic profile of apparently 
similar agents can be differentiated at least at low doses in heart failure patients. This is 
the first occasion that such differentiation has been noted in any clinical or experimental 
study. Regardless of the practical significance of first dose hypotension, which remains 
very much an anecdotal phenomenon, this differentiation is of considerable 
pharmacological importance and may have some clinical application in avoiding 
excessive haemodynamic effects in some circumstances.
The observations with oral prodrugs and intravenous diacids may suggest that a 
differential interaction with extravascular renin angiotensin systems as one explanation 
for this observation. Clearly this requires verification and further analysis with direct 
measurements of the tissue based system being the most logical step. This would most 
easily be achieved in animal studies but, as was explored in chapter 7, a pharmacokinetic 
approach may be one alternative and has the considerable advantage of being viable in 
intact man.
The controlled low dose infusion studies in heart failure conducted over relatively 
protracted periods were shown, albeit in a stable population of heart failure patients, to 
give good control over the extent of the blood pressure response. In practical terms this 
might lend itself to further use of this technique in more unstable patients should therapy 
with these drugs be required for example in the period around acute myocardial 
infarction or in the management of acute heart failure of an appropriate cause.
The tentative description of a transient pressor response in these subjects was an
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unexpected finding. Again it emerged largely due to the controlled setting of the 
observations and regular recordings. Although likely to be of less therapeutic 
significance it may prove, on further examination, to be a further reflection of the tissue 
based renin system and its activation in these patients. Exploration of this phenomenon 
should probably be aimed at initially confirming the effect and detailed measurements of 
the circulating concentrations of angiotensin I and angiotensin II peptides. This could test 
the possibility of a peptide distribution phenomenon based on transient intravascular 
ACE inhibition by the poorly lipid soluble diacid drugs at the low concentrations seen 
during the early stages of constant rate infusion.
The studies in normal and patient volunteers summarised in chapter 7 focus on 
the pharmacokinetic description of tissue distribution of diacid ACE inhibitor drugs in 
the first two sections. This is the essential first stage to any attempt to link drug 
concentration and effect (eg haemodynamic effect) in individual subjects using a 
concentration effect modelling technique.
The transpulmonary studies were entirely novel in man but unfortunately failed to 
reveal the first pass extraction of drug across the pulmonary circulation that was 
expected. The possible reasons for this relate most probably to the dose of drug and rate 
of infusion. It did not prove possible to repeat the study with a lower dose or rate of 
infusion or indeed to study the effect on a lipid soluble agent such as one of the prodrug 
inhibitors.
The description of diacid pharmacokinetics on protracted infusion confirmed the 
efficacy of a simple non linear binding model incorporating terms for tissue and plasma 
binding parameters as the optimal technique of the range considered. This was not 
adequately described in terms of drug concentration profile during the infusion stage in 
the only previous study. The non linear binding model allows parameter estimates to be 
derived for individual subjects which might be related to patterns of haemodynamic
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response through a more complex concentration effect model. Although small blood 
pressure changes were noted in this controlled study it is likely that, at the very least, 
activation of the renin system would be required to approximate the setting in heart 
failure and make the correlation of the kinetic and dynamic response feasible.
The third section in chapter 7 clearly established an outline of salt depletion based 
on a practical schedule of diuretic treatment and low salt diet which was well tolerated, 
easily administered and controlled. The responses observed with a standard ACE 
inhibitor, enalapril given orally, were clear cut and activation of the renin angiotensin 
system confirmed at a number of levels.
This series of studies can now progress to define the pharmacokinetic and 
pharmacodynamic responses to ACE inhibition during double blind salt repletion or salt 
depletion and relate tissue binding parameters to the observed blood pressure response in 
individual subjects.
In conclusion a variety of studies are presented directed at the investigation of 
blockade of the renin angiotensin system in the setting of common disease, heart failure, 
where this system is activated. Detailed analysis of response can pay dividends both at 
the level of pathophysiology, drug differentiation and optimisation of treatment, in this 
instance with relevance to the initiation of therapy.
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